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Aims: Lung cancer survival in Scodand appears to be inferior to that in many other countries, and it 
has been proposed that this is due to low use of treatment. To investigate if this is indeed the case 
and to understand how outcomes might be improved a series of studies were conducted 
Methods and Materials: A systematic review of data published on lung cancer treatment and 
surVival rates was performed. Then, two cohorts of patients diagnosed with lung cancer in 1995, one 
from British Columbia (BC) and a second from Scotland, were compared to investigate differences in 
patient and tumour characteristics, factors affecting treatment, and survival. To assess the impact of 
recent changes in cancer care in South-East Scotland (SCAN) comparison was made with a 2002 
cohort. FinaflN-, models were developed to investigate the gap between optimal and actual treatment. 
Results: Comparison of data from 2073 BC and 3833 Scottish patients demonstrated that fewer 
Scottish patients had pathological diagnosis, and more cases regional-stage disease. The adjusted odds 
for receiNqng anV treatment was 0.7(0.6-0.8) Scotland v BC, and 0.4 (0.3-0.5) for potential-ly curative 
therapy. Five-year relative survival rate was 12% in BC and 6% Scotland (p<0.001). The adjusted 
hazard of death Scotland v BC following surgery was 1.3(l. 1-1.6), radiotherapy 1.5(l. 4-1.6) and 
chemotherapy 1.5(l. 3-1.5). Data of 927 patients from SCAN diagnosed in 1995 were compared with 
that from 971 diagnosed in 2002. The surgical rate was unchanged at 11 %, but the use of radical 
radiotherapy trebled, and chemotherapy for non-small cell lung cancer doubled. Overall survival at 
two-years increased from 11% to 15% ýog rank p= 0.003) with hazard of death 0.7 (0.6-0.8) 2002 
1995. The models suggested that based on stage distribution, performance status and co-morbidity 
the use of surgery was close to optimal, but radiotherapy and chemotherapy were possiblv under 
utihsed. Optimal use of treatment would increase long term surVival slightly, but not sufficiently to 
bring survival rates in-line with that observed in Canada. 
Conclusions: Survival of Scottish lung cancer patients was inferior to in BC, but the reasons are 
more complex than)ust under-treatment. 
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Glossary of terms and abbreviations 
ANOVA - analysis of variance 
BC - British Columbia 
BCCA - British Columbia Cancer Agency 
CD'NS - Canadian doUars (, Cl approximately = CDN$ 1.3) 
Cherno - chemotherapy 
E-SCLC - extensive stage small cell lung cancer 
EUROCARE -a coNaboration of European Cancer Registries 
L-SCLC - limited stage small cell lung cancer 
Mets - metastases 
, NISP - -Nfedical Services Plan - the Canadian healthcare scheme 
NHS - National Health Service - the British healthcare scheme 
NOSCAN - -North of Scotland Cancer Network 
NSCLC-NOS - non small cell lung cancer not otherwise specified 
PCT - potentially curative therapy 
PORT - post-operatiVe radiotherapy 
RT - radiotherapy 
SCAN - South East Scotland Cancer Network 
TNM - tumour, node, metastases staging system for cancer 
WOSCAN - West of Scotland Cancer Network 
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Chapter 1 
Introduction: History, aetiology and 
treatment of lung cancer 
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1) Histoty and aetiology of lung cancer 
Th' * the onl /Sis y case oj'cancer of the lulý ,g ipbich 
I have el, er met witb; so that Ipresume that the disease 
rareil, attacks this organ' 
1849. John Hughes Bennett, Professor of Pathology, University of Edinburgh. 
Lung cancer is a modern disease. In 1881, Fraser was unable to present more than a single 
case to the Nfedico-Chircurgical Society of Edinburgh [145]. The number of cases of lung 
cancer in Scotland rose dramatically throughout the first half of the 20th century and by the 
end of the 1950s, when the first national figures became available, there was an average of 
2078 cases per annum in men and 350 in women [175]. The incidence continued to rise, 
peaking in the mid-1980s, with around 3300 cases per annurn in men and 1300 in women. 
RecentIv, the number of cases occurring in men has dechned, but the incidence in women is 
still rising. In 2002, there were 2600 men and 2000 women with lung cancer in Scotland [98]. 
Currently the lifetime risk of lung cancer in Scottish men is 1 in 11, and 1 in 17 for women 
[98]. 
What is the cause of this epidemic? In the early days many causes were suggested including 
syphilis, tuberculosis, cobalt, tar, and car exhaust fumes, but the potential link to tobacco was 
not confirmed till the mid 20"' century. In 1950, Wilder and Graham published their paper in 
Journal of American Medical Association 'Tobacco as a possible etiolo . cal factor in 91 
bronchogeruc carcinoma' [210]. Then, in the same year Doll and Hill published their 
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landmark stud), in \N, -hich they found that in a case-series of over 1300 men with lung cancer, 
99.5(), /, ) were smokers [54]. 
Tobacco was first imported to Europe from the Americas in the mid 16" century and was 
soon promoted by the medical profession as a 'cure-al-l'. John Gerard the Engfish herbalist 
thought it cured 'mý:, uraine, toothachegout, ulcers, asthma wid deaj; iess'. [45] However, even at this 
time tobacco had its critics including 1,,, '-ing James VI of Scotland who in 1604, described 
tobacco as 'a custolve loathsome to the ge, hateful to the nose, harmfful to the brain, dagerous to the 
kings'. However, it was not until 1761 that the possible fink with turnours was noted by Sir 
John Hill in his 'Cautions against tl), e immoderate use of snuf. 
Despite these observations smoking became increasingly popular, but did not become 
widespread until the 1880s with the invention of machinery to mass-produce cigarettes. In 
the First W'orld W'ar free cigarettes were distributed to the troops in the trenches, and by the 
1920's more than half the male population in the UMted Kingdom smoked. This rose 
further during the Depression and the Second World War and by the 1940's it is estimated 
that more than 80% of men smoked. Smoking did not become socially acceptable for 
women until the Second World War, and therefore the peak rate of female smoking was 
much later; around the early 1960's. This accounts for the temporal differences in the 
incidence of lung cancer between men and women over the last century [175]. The generation 
of men born around 1904 and women born around 1920 had the highest life-time risk of 
lung cancer. 
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SI ince the publication of the results of the work by Doll et al in 1950 and the publicity 
associated with these findings, the rate of smoking in Scofland has slowly declined. At 
present it is estimated that around 30% of Scots smoke [141]. It is hoped that this figure will 
decrease further with the ban of smoking in pubfic places, as stopping smoking can reduce 
the risk of developing lung cancer. In a recent re-analysis of the 1950's cohort of doctors, 
'although lifelong smokers were 15 times more likely to develop lung cancer than non- 
smokers, those that gave up by age 64 were 7.5 times more likely to develop lung cancer than 
non-smokers, those that gave up at age 54 were 3.8 times, and age 44 were 2.0 times more 
hkely [55]. 
Though the public health message about smoking seems to be increasingly effective in 
Northern Europe and North America, smoking is becoming more prevalent in Eastern 
Europe and many other developing countries. Currently the highest incidence of lung cancer 
in the world is in the new European Union countries, notably Poland, the Czech Republic 
and Hungary [196]. 
Other aetiological factors in the development of lung cancer 
It is estimated that smoking (either personal or passive) accounts for around 90-95% of lung 
cancer but there are other aetiological factors[2]. 
1) Occupational exposures - These include tar and coal (contains carcinogenic 
benzo(a)pyrene) and heavy metals, such as arsenic, cadmium and nickel. Whether or not 
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diesel fumes and exposure to sifica are associated with an increased the risk of lung cancer 
remains controversial [3] 
2) Asbestos - Asbestos, either alone or syner istically with cigarette exposure, has been 1 91 
shown to be associated with a higher incidence of lung cancer [86] 
3) Radiation - Either come from 1) naturafly occurring sources such as radon, or 11) 
exposure medical X-rays and gamma rays either for diagnosis or treatment. 
i) Radon gas is released from the rocks in certain parts of the world, for example 
Aberdeenshire in Scotland. The association of radon gas and lung cancer was first noticed in 
miners [157]. W'hether or not exposure to radon in homes is linked to increased risk of lung 
cancer remained controversial, but in 2006 an analysis that included data on over 9000 
people Nvas published and concluded that there was an excess risk of 0.1 per Bq/m' radon 
levels in houses [109]. 
ii) The risk of exposure to diagnostic medical X-rays remains controversial; studies from 
patients screened for tuberculosis suggested there was an increased risk of lung cancer [47]. 
However, recently the level of risk of medical radiation has been questioned and a 
hypothesis that low doses of radiation may in fact be protective against cancer has been 
proposed, but this remains controversial [204]. Exposure to therapeutic radiation to the 
chest is undoubtedly associated with an increased risk of lung cancer, for example 
mediastinal radiotherapy for Hodgkin's lymphoma, especiaflv if the patient continues to 
smoke [200]. 
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4) Air poflution - the role of air pollution in the development of lung cancer is difficult to 
establish due to the close linkage of other factors, such as smoking, which are also associated 
Nvith urban areas. A recent analysis from six US cities suggested there maybe a fink between 
increased levels of particles in the air and lung cancer [110]. 
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The histoty of the treatment of lung cancer 
1) Surgery 
In 1912 the first lung cancer resection, a lobectomN,, was performed in London by Davies, 
but the patient died a few days later of post-operative complications [131]. The main 
difficulty v-as anaesthesia; in order to maintain adequate oxygenation during the operation 
the lung had to be kept inflated during the procedure, which impaired surgical access. 
However, developments in anaesthetic techniques during the 1920's enabled the first 
pneumonectomy to be successfully performed in 1933 by Ewart Graham in New York [80]. 
In the early years of lung cancer surgery the post-operative mortality was around 50%. 
However, new trauma surgery techniques developed during the Second World War led to a 
significant reduction in the post-operative mortality, such that by the mid 1950's lung cancer 
resections had become commonplace. Further improvements in surgical techniques, 
anaesthesia and post-operative care mean that today the overafl post-operative mortality rate 
is between 2 and 4% [4,17,46]. 
The first two publications reporting long term surviVal following lung cancer surgery 
performed in the late 1940s and early 1950's demonstrated a 20% five-year survival rate [144, 
184]. 
Today most sur ical series quote five year survival rates of around 40-45% [19,69], and up 1 91 
to 60% for patients with stage 1 disease [207]. 
2) Radiotherapy 
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Radiotherapy was first used in the treatment of inoperable lung cancer in the 19. "Os when 
radium seeds were inserted into the tumour using a bronchoscope [137]. In the years 
following the Second World \Var the development of radiotherapy machines that could 
deliver high-energy X-rays beams enabled much higher doses to be delivered to the lung 
without excessive toxicity. The first case reports of patients cured of lung cancer v-1th 
radiotherapy were pubhshed in the early 1950s. One series of 624 patients, referred between 
1944 and 1948 to the Brompton Hospital in London, included 109 N-, -ho received 
radiotherapy to a dose of 4000rads (40Gy) [28]. For this group of patients the two-year 
survival rate was 15.5%, and at five vears 5.9% were still alive. 
The first Scottish case-series of lung cancer patients treated with radical radiotherapy , vas 
published in 1989 from the Edinburgh Cancer Centre [143]. It included data on 446 patients 
treated between 1974 and 1981. All received 20 fractions of radiotherapy which was planned 
using chest radiographs and a barium swallow to identify involved lymph nodes. The five- 
year survival for the group as a whole was 10.6%. Those patients without obvious nodal 
involvement had a five-year survival of 18.6%, compared with 7.4% for those with nodal 
enlargement. 
Since the publication of this series there ha: ve been many changes in the management of lung 
cancer. One major change has been the introduction of CT scanning during the 1980s and 
1990s. This diagnostic tool is more accurately able to identifV metastatic spread to lymph 
nodes and distant sites. Therefore, some of the improvement in the sunival of patients -'x-ith 
early stage disease observed during this period can simply be attributed to the use of more 
accurate staging, the so called 'Will Rogers' effect [63]. 
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CT scanning is now also used in the planrung of radiotherapy; enhancing the accuracy of 
tumour locahsation and dose calculations. Todav, 3-D conformal radiotherapy, where the 
treatment volume is shaped to encompass the tumour and minimise the dose to normal 
fissues, is the standard of care. However, even with these advances the results remain 
disappointing with three-year progres sion- free survival below 30% [1111. 
3) Chemotherapy 
The first reports of the response of lung cancer to nitrogen mustard chemotherapy were 
published in the early 1950s [28]. In the Brompton Hospital case series published in 1951,54 
patients were treated with chemotherapy alone, using mainly nitrogen mustard. Ahout half bI 
had symptomatic benefit, but almost all suffered chemotherapy induced vomiting, and many 
refused to have further treatment. Complete responses were observed in a number of 
patients with small-cell lung cancer (SCLC), which sparked great interest [28]. 
Over the next two decades, with the introduction of new chemotherapy drugs, such as 
cyclophosphomide and cisplatin, and better anti-sickness agents, the use of chemotherapy in 
the treatment of SCLC became commonplace. By the late 1970s and early 1980s case-series 
and clinical trials confirmed that patients could experience long term survival With 
chemotherapy for SCLC [87]. 
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Howevcr, it Nvas not until the mid-1990s that the use of chemotherapy for patients with non- 
small cell lung cancer (NSCLC) became widely accepted. With a much lower response rate, 
critics felt that the toxicity was not worth the small sur\-1val benefit. However, in 1995 a 
meta-analysis of chemotherapy for NSCLC was published in the British Nledical journal [6] 
and demonstrated in the palliative setting a 10% absolute improvement in survival at one- 
year, and when combined with radical radiotherapy there was an additional 4% improvement 
in sun-A-al at two vears. 
'Nfore recentlv, trials have been published which demonstrate that there is also a survival 
benefit when chemotherapy is used in the adjuvant setting after surgery for early stage 
NSCLC [56,207]. 
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2) Current recommended management of lung cancer 
Lung cancer is not one disease, but a number of different pathological entities. For simplicity 
these are grouped into 'small-cell lung cancer' (SCLC), which is managed primarily with 
chemotherapy and 'non-small cell lung cancer' (NSCLC) a collection of different 
patholo ical ty es (mainly squarnous cell, adenocarcinorna and large cell) that tradifionallý 91 ,pI 
were managed mainly With surgery and radiotherapy. 
Currently lung cancer is only curable when it is confined to the thorax, so the stage of the 
lung cancer at presentation is the primary determinant of treatment and prognosis. The 
current staging systern for NSCLC is shown in Table 1.2a and 1.2b and SCLC in Table 1.3 
[133,138] 
Table 1.2a TNM system for NSCLC (1997) 
T1 3 cm surrounded by lung or visceral pleura, no evidence of invasion of proximal bronchus 
T2 >3 cm, or invading visceral pleura or causing atelectasis of the lobe, or invol\-Ing 
proximal bronchus but >2cm from carina. 
T3 Invading chest wall, 
dia 
. 
phragm, mediastinal pleura, or pericardium, or lesion <2 
cm from carina or causing atelectasis of whole lung 
Invading mediastinum or involving heart, great vessels, trachea, oesophagus, ZD 
T4 vertebral body, or satellite nodules Within same lobe or malignant pleural or 
pe ardial effusion 
Nl metastases in peribronchial or hilar lymph nodes. 
N2 metastases in subcarinal or ipsi-lateral mediastinal lymph nodes. 
metastases in contra-lateral mediastinal or hilar lymph nodes, any supraclavicular N3 lymph nodes. 
Mi distant metastases. 
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Table 1.2b Staging system for NSCLC (1997) 
Stage I TlNO', \I(), T2NOMO 
Stage 11 T1N1 MO, T2N 1 MO, T3NOMO 
Stage III TIN2-3NIO, T2 N2-3MO, T3NI-3NIO, T4NO-3NIO 
Stage IV TI-4 NNO-3 Nll 
Table 1.3 Staging for SCLC (Veterans Administration Lung Cancer Study Group) 
Limited Disease can be encompassed in a 'tolerable' radiotherapy field* (L-SCLC) 
Extensive Disease that cannot be included in the above definition (E-SCLC) 
*Debate remains about patients with contra-lateral supra-clavicular iympti nocies or picurat errusions; mese wcrc mcmucu 
within the original definition of 'limited', but are frcqucntl), excluded from clinical trials. 
A patient's general fitness is also a major determinant of treatment selection and prognosis. 
The WHO (Zubrod) performance status scale is probably the most widely used in lung 
cancer and is shown in Table 1.4. 
Table 1.4 Performance status 
\X, 'HO performance status 
0 Able to carry on normal activities without restriction 
1 Symptoms but able to do light work 
2 Marked restriction of activity but spends <50% time in 
chair/bed 
_ 3 _ Marked restriction of activity but spends more than 50% time 
in chair/bed 
4 Unable to get out of bed 
17 
Current recommended treatment of lung cancer 
In 2005, two systematic reviews of the literature relating to diagnosis, sta ing and 91 
management of lung cancer were published in the UK; one performed by the Scottish 
Intercolle 'ate Guidelines Network (SIGN) and the second bv National Institute for Health 91 
and Clinical Excellence (NICE). The recommenclafions are summansed below: 
Diagnosis and staging 
0 All patients with known or suspected lung cancer should undergo a contrast 
enhanced CT scan of thorax, fiver and adrenal glands 
e Bronchoscopy should be performed in patients with central lesions to obtain 
pathological specimen 
Percutancous biopsy should be performed in patients with peripheral lesions 
0A positron emission tomography (PET) scan should be performed in patients with a 
solitary pulmonary nodule where a biopsy is not possible 
e PET scan should be performed in patients with NSCLC who are being considered 
for surgery or radical radiotherapy 
Treatment of NSCLC 
AU patients with Stage I and II, who are medicaUN, fit and who have adequate 
pulmonaný function, should be offered surgery 
0 Adjuvant post-operative chemotherapy should be discussed with patients with 
pathological T2NOMO or more advanced stage disease 
9 Post-operative radiotherapy should be considered after an incomplete excision 
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0 Patients with Stage I or 11 with reasonable performance status who are not fit for 
surgery, or who decline it, should be offered radical radiotherapy 
0 Patients with Stage III with a good performance status should be offered radical 
radiotherapy with chemotherapy, provided the disease can be encompassed safely 
within a radical radiotherapy volume. 
0 Chemotherapy should he offered to patients with Stage III and IV disease with good 
performance status. 
0 Palliative thoracic radiotherapy should be offered to patients with advanced disease 
who have cough, haemoptysis or chest pain 
* Palliative radiotherapy should be considered for patients with symptomatic brain 
metastases 
0 Palliative radiotherapy should be offered to patients with symptomatic bone 
metastases 
Treatment of SCLC 
0 All patients should be offered platinum based multi-drug chemotherapy 
* All patients with limited stage disease should be offered thoracic radiotherapy and, if 
there is a response to chemotherapy, prophylactic cranial irradiation 
0 Patients with e-xtensive stage disease who have had a complete response at distant 
sites should undergo consolidation thoracic radiotherapy 
0 Palliative thoracic radiotherapy should be offered to patients with advanced disease 
who have cough, haemopqsis or chest pain 
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0 Palliative radiotherapy should be considered for patients with sý, mptornatic brain 
metastases 
9 Palbative radiotherapy should be offered to patients with symptomatic bone 
metastases 
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3) Previous research on lung cancer treatment and outcomes in 
Scotland 
()-, -cr the past 25 years a number of studies have been pubbshed which examine the 
treatment and survival of lung cancer in Scotland. The Scottish Cancer Registry which has 
complete coverage of the country and high case ascertainment has aided this research. 
The first prospective regional audit included data on patients resident in South East Scotland 
who were diagnosed with lung cancer in 1991 [64]. The records of 662 of the 1073 patients 
(630"o) in the Scottish Cancer Registry were examined. 510 (82% of identified cases / 48% all 
cases in Scottish Cancer Registry from the region) had pathological confirmation, 441 
(71%/41%) underwent bronchoscopy, and 112 (18%/10%) a CT scan. 130 (21%/12",, "o) 
patients underwent surgery, 168 (27%/16%) radiotherapy (10 radical radiotherapy) and 69 
(11%/6.5%) chemotherapy, including 61 of 125 (49%) patients with SCLC. The median 
survival for the whole cohort was 6 months, with 15% alive at 24 months. Of those treated 
with curative intent the median survival was 18 months, With 40% alive at two years. 
In another study, a random sample of 262 of 1142 cases diagnosed in 
Glasgow in 1991-92 
was examined to look at patterns of care [106]. Of this selected cohort, 
78% underwent 
bronchoscopy and 36% a CT scan. Pathological confirmation was obtained in 69% of cases. 
Surgery was used in 5% of patients, radical radiotherapy 2.5% and 
10.2% chemotherapy. 9% 
of the cases were alive at 3-years. 
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In a study conducted in Northern Scotland, Campbell el a/ identified a cohort of 661 patients 
diagnosed with lung cancer in 1995-1996, of whom 13% underwent surgery, 63", o 
radiotherapy and 19% chemotherapy within the first year of diagnosis [31,32]. 
Chemotherapy was less likely to be delivered to patients from socially deprived areas. 
In 1998, a national retrospective audit of Scottisb lung cancer patients diagnosed in 1995 was 
performed. The medical records of 3855 of the eligible 4225 cases (91%) were examined. 
The general results were published in 2001 [83] and showed a resection rate of 10.6%, a 
radiotherapy utilisation rate of 35.8% and chemotherapy of 16.2%, within six months of 
diagnosis. The median survival was 3.6 months, with 10% alive at two years. Patients who 
saw a respiratory physician had reduced hazard of death even when age, gender, deprivation, 
stage and pathology were taken into account [651. A more detailed analysis of factors 
affecting the use of thoracic radiotherapy was published in 2002 [62] and showed age, extent 
of disease, involvement of a lung cancer specialist, pathological confirmation, and 
healthboard area all affected whether or not a patient received radiotherapy. However, 
detailed analyses of the factors affecting the use of surgery and chemotherapy have never 
been published. 
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Comparison of Scotland with other countries 
EUROCARE is a coUaborative effort of the European Cancer Registries and has pubbshed 
three reports (EUROCARE 1 1972-1984, EUROCARE 11 1985-1989 AND EUROCARE 
111 1990-1994) [100,1671 comparing the sunival for various cancers across Europe. In each 
of the three reports the survival rates for lung cancer patients in Scotland were below the 
European average. Therefore, to determine whv Scottish lung cancer patients have inferior I 
sunival, and to ascertain if this is due to differences in patient and tumour characteristics 
and/or in treatment, a detailed comparison to a country with good lung cancer outcomes is 
reqwred. 
To date, there has been only one population-based international comparison examining 
factors that might explain the differences in lung cancer survival between countries [187]. 
This study examined impact of patholo ical ty e and stage distribution between Denmark, 91 ýp 
Norwav and Finland to see if these factors could explain the lower lung cancer survival in 
Den-mark. There were more patients with non-localised disease were found in Denmark, 
which was given as a possible explanation. However, the stu& did not include data on the 
treatment utilisation in the three countries, which obviously could have had an impact on 
outcome. 
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4) Rationale of this thesis 
British Columbia (BC) is a province in Western Canada with a population of 4 million, half 
of whom live in the metropolitan area of Greater Vancouver, with the remaining population 
widely dispersed over nearly 1,000,000 square Hometers. AU indi iduals resident in BC have Ivi 
access to free health-care through the Medical Services Plan. The British Columbia Cancer 
Agency (BCCA) provides cancer care to all patients in BC through its centres in Vancouver, 
NT ictoria, Kelowna and Fraser Valley. AN the patients are treated with the assistance of 
unified management guidelines, which are available to all hospital and community doctors in 
BC. Linked with the BCCA is the British Columbia Cancer Re istry, which has an estimated 91 1 
93.5% case ascertainment, for A cancers combined. However, it is hkelv that the case 
ascertainment for lung cancer exceeds this, as lung cancer cases can be identified from 
surgical pathology reports, BCCA database or death certificates. The computerized records 
of BCCA detailing all cancer treatments are directly linked to the Cancer Registry. 
Scotland has a similar population and healthcare system. The population is 5.5 million, the 
majority of whom live in the urban areas around Glasgow and Edinburgh and like BC, all 
patients have access to free healthcare through the National Health Service. There are five 
Cancer Centres, which function independently, in Glasgow, Edinburgh, Dundee, Aberdeen 
and Inverness. The Scottish Cancer Registry has a long association with these Cancer 
Centres and achieves nearly 97% case ascertainment for all cancer sites [26], but as in BC, 
the case ascertainment for lung cancer is likely to be higher than this. 
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Past 
For patients diagnosed with lung cancer in British Columbia in 1992 the five-vear relative 
survival rate for men with lung cancer was 12"/0, and 15% for women [34]. This compares 
with 6% for men and for women in Scotland for the period 1992-1996 [97]. ConsequentIv, a 
comparison of lung cancer cases diagnosed in British Columbia and Scotland in 1995 has the 
potential to provide valuable information that could assist our understanding of whý T the 
survival in Scotland is inferior, and to inform on methods in which lung cancer management 
could be altered to improve the outcome of Scottish patients. 
Pr, F-Ql-nt 
Since the 1995 audit, in an effort to improve the survival, many changes have been made to 
the organisation of cancer services in Scotland. These changes have included the 
development of the Scottish National Guidelines [SIGN], the introduction of regional 
cancer networks and multi-discipfinar-v meetings, and the appointment of more lung cancer 
specialists. Therefore if recommendations on future changes to lung cancer services are to be 
made, it is important that data on more recent patient management and outcomes are also 
examined. 
Future 
Finally, though changes have been made to healthcare organisation, it is important to 
examine the gap between optimal and actual patient management. If patients are to receive 
the appropriate treatment it is important that the resources are In place to meet this demand. 
As noted above, the tumour type, stage at presentation, and the patient's performance status 
25 
are the priman- determinants of the most appropriate treatment. If these factors are known 
within a population then the resources required for optimal cancer management can be 
estimated and future healthcare provision planned to meet the predicted demand. 
Therefore, the aim of this thesis is to test the hypothesis that 'the outcome of lung 
cancer in Scotland is poor and that this could be improved by optimal use of 
treatment'. 
To investigate this, a series of studies were performed 
1. In order to contextuahse the situation in Scotland, a systematic review was 
conducted to estabhsh how treatment utihsation and sur-viNTal rates vaty around the 
world. 
2. The characteristics of a population of Scottish lung cancer patients from 1995 were 
examined to establish whether the levels of treatment were sub-optimal and surviVal 
was poor 
3. Comparison was made with a similar population from British Columbia diagnosed 
with lung cancer in the same year, to understand the differences in patient, tumour 
and management characteristics that might account for any differences in outcome. 
4. A cohort of lung cancer patients diagnosed in 2002 from South-East Scotland was 
then compared with the patients from the same area diagnosed in 1995, to establish 
whether the changes in health service organisation have had any impact on use of 
treatment and sunlVal 




Comparison of international series 
00 
examining treatment and survival of lung 
cancer patients 
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Factors affecting population-based cancer survival rates 
The outcome of any population of cancer patients depends on three factors: 
i) the proportion presenting with disease at a stage where it is treatable, and idealIv curable 
ii) the frequency of use and efficacy of treatment 
hi) the prevalence of co-morbid diseases. 
a) Stage at presentation (see also Chapter 8) 
The clinical stage at which cancer is diagnosed is dependant on the biological behaviour of 
the tumour and the presenting symptoms. In order to make a diagnosis early it is critical that 
the patient is aware of the potential significance of any symptoms and that these are 
recogn'sed as important by healthcare professionals. Some cancers, such as breast or skin, 
present with an obvious problem that is readily recognised and which instigates an urgent 
referral to a specialist. Other malignancies, such as ovarian and lung cancers, often present 
with a wide-range of non-specific symptoms, for example, fatigue, weight loss or shortness 
of breath, which can easily be attributed to other co-morbid diseases. This can result in a 
delay in diagnosis. However, for manN, cancers the propensity for early metastases means that 
by the time symptoms have developed, the disease has already spread to lymph nodes or 
other organs thereby reducing the chances of cure [152]. 
Cancer screening is potentially the most effective method to improve sur-,, ival, by detecting 
cancers at an asý T mptomatic, often pre-invasive stage. Screening has proven particularly, 
beneficial in cervical cancer where it is estimated that up to 91% of cervical cancer deaths, 
and around 18% of breast and colorectal cancer deaths, could be avolded [93]. For lung 
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cancer there is at present no effective method of screening, though large trials of CT 
scanning (with or , x-ithout biological markers) are underway. In a large US trial, 484 turnours 
were detected in the 31,567 patients who underwent screening [90]. Of those lesions which 
were more than 36mm in size, 55% had already metastasised to lymph nodes or distant sites 
I ]. 
Screening with CT scans is heavily resource dependant in terms of both equ* 11 ipment and staff. 
In addition, the procedures required to confirm or refute the suspicion of cancer, are 
invasiVe, for example a thoroscopic blopsy. Consequently, the cost-benefit balance of CT 
screerling is likely to be marginal 
b) Treatment 
Over the past half-century most cancer research has concentrated on understanding the 
biology of cancer, searching for new types of therapeutic agents and investigating these 
agents in clinical trials. But, however successful these agents are in clinical trials, all the 
money and effort are wasted, if these new therapeutic options are not available to the wider 
cancer population, and bring about an improvement in survival of the whole population. 
Factors (other than stage at presentation) which have been shown to affect whether or not 
treatment is given, include patient's age, gender, race, performance status, co-morbid 
diseases, social deprivation, education, ability to pay for healthcare, and the proximity of 
cancer specialists. In some countries, organisation of health care is also a factor. 
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Although improvements in survival have occurred in the majority of other cancers, UK lung 
cancer survival rates have remained remarkably unchanged over the last 15' years [40]. 
Surgery and radical radiotherapy are effective treatments for lung cancer, but only a minorlt\T 
of patients are suitable for these treatments. Other therapeutic options, such as 
chemotherapy, have low efficacy in advanced disease and hence httle impact on population- 
based survival. Consequently, if survival rates are to improve, the proportion of patients 
presenting with early stage disease receiving potentially curative treatment must be 
maximised, and more effective treatments need to be found. 
c) Co-morbid diseases 
Many of the older, population-based, series report only overall or crude survival. Adthough 
this is a useful measure, no account is taken of other causes of death, such as infectious 
diseases or ischaernic heart disease. This could have a sign1ficant impact on reported 
outcomes, particularly when comparing countries with very different disease profiles, such as 
developed and developing nations, or one with a much older population. 
There are two principal methods of overcoming this problem: 
1) Cause specific survival 
Cause specific and progression free survival rates are frequently used in chnical trials when 
detailed medical record review can be performed to confirm the accuracy of the cause of 
death. However, in the population setting this is not practicable and the accuracy of death 
certification is variable. In lung cancer, where the disease has such a high mortality rate, it is 
often simpler for the medical practitioner to attribute death to the cancer, rather than seek 
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out other potential causes. ConsequentIv, cause specific sun-IN-al data will over-estimate the 
number of deaths due to lung cancer and therefore should be interpreted with caution. 
2) Relative survival 
Relative sut-vival compares the obsened survival with the expected surviVal for a cohort of 
the general population with the same age and sex profile. It is therefore an estimation of the 
excess deaths due to cancer. When populations from two countries are compared and thcý 
have very different age profiles, then an age-adjusted relative survival, xhich weights the 
population to a standardised population, should be calculated. 
However, it should be noted that the life-tables used to calculate the expected survival are 
for an average population and do not take account of different disease profiles within a 
population. This is a potential source of error when examinIng relative survival rates for lung 
cancer patients, as this group has a much higher rate of other diseases, than the general 
population. 
Figure 2.1 demonstrates, using a hypothetical example, the impact of deprivation on fife 
expectancy. Relative survival based on the general population will under-estimate the survival 
for the least deprived and over-estimate it for the most deprived. However, it has been 
estimated that using deprivation-adjusted life tables would only have an impact of less than 
1% on the five-year survival rate of lung cancer in Scotland [186] 
31 
Fiaure 21 Difference in relative surv4val estimates when using deptivation-specific compared 
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When comparing survival outcomes from population-based series, it is important to note the 
following: 
1) the distribution of clinical stages at initial presentation 
fi) the rates of treatment use 
i-ii) the methods of survival. reporting 
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International rates of treatment and survival for lung cancer 
Over the Iast two decades, a vast amount of literature has been published reporting rates of 
treatment and lung cancer survival from various regions around the world. However, a direct 
comparison between countries is diff 1ý icult, because of the wide varietý of approaches to data 
collection and analysis used. Five-year survival rates vary from 16% in France and the USA, 
to 7, o in the UK, Denmark and Poland [167]. These differences may represent genuinely 
inferior survival, but could also be demonstrative of differences in data collection and 
analysis. 
EUROCARE is a coilaboration of Cancer Registries in Europe and was set-up in the 1980's 
to evaluate cancer survival rates across Europe. The results of the most recent analysis 
pertaining to lung cancer are shown in Table 2.1 and demonstrate the wide range of sunival 
figures reported, including neighbouring countries. 
In an Editorial in Annals of Oncology, published to coincide with the release of the 
EUROCARE III data, Berrino [16] describes the potential difficulties of comparing 
population-based outcomes. The potential hazards are not only applicable to EUROCARE, 
but to the literature as a whole. 
1) Population coverage: 
There are wide differences in the proportion of the population covered 
by the different 
cancer registries. Table 2.1 includes the proportion of each nation's population covered 
bv 
the European cancer registries. Only half of the EUROCARE countries collect 
data from all 
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re ions, the others only fund data collection in selected areas. In general, those registries with 91 
wider coverage report inferior survival. This is demonstrated in Figure 2.1 as a scatter 
diagram. In countrics where the cancer registry is not centrally funded, there may be a bias 
towards collecting data in the more motivated re ions, which are not necessarlIN- 91 
representative of the treatment and outcomes of the wider population. 











Austria 8 41 19 16 
Czech Republic 8 32 12 8 
Denmark 100 25 9 7 
England 63 22 9 7 
Estonia 100 27 10 8 
Finland 100 34 13 9 
France 3 44 20 14 
Germany 2 33 15 12 
Iceland 100 33 15 11 
Italv 15 36 14 11 
Netherlands 24 38 16 13 
Norwaý, 100 30 12 9 
Poland 6 28 10 7 
Scotland 100 23 9 7 
Slovakia 100 31 11 8 
Slovetua 100 33 12 10 
Spain 15 33 15 13 
Sweden 100 32 13 10 
Switzerland 12 38 18 13 
Wales 100 18 9 8 
I age-adjustcd relative survival to account for different age distribution in each country 
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2) Catchment area: 
Many studies which purport to be 'population-bascd', are in fact based on referral to a single 
institution or collection of hospitals[95,1911. Although this might be reasonable in an iflness 
with a high rate of pathological confirmation, it is not appropriate for lung cancer where up 11 
to a quarter of patients have a radiolo ical diagnosis. Conscqucntly, there may be gross 91 Z-) 
undcr-rcporting of commufflty-diagnoscd cases. These latter cases are not referred to 
hospital, either because of their poor performance status, or inability to pay for healthcare. 
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3) Case ascertainment: 
The method of identifying cases varies greatly between cancer registries. In some countries, ý7) 
such as Denmark, afl doctors are legafly obfiged to inform the cancer registn- and therefore 
case ascertainment should be complete. At the other extreme, some registries do not record 
non-patholo ically confirmed cases or 'death-certificate-only' cases, and therefore these 91 
registries will have much lower case ascertainment, particularly for lung cancer. As patients 
without a tissue diagnosis would be expected to have an inferior prognosis, primarily due to 
older age, exclu(: bng such cases will enhance the survival figures. In some countries, such as 
France, data protection regulations prohibit access to death certificate data [355,132]. The 
omission of non-patholo ically confirmed and death certificate only cases (which can 91 
represent up to 20-30% of lung cancer cases) could have a marked impact on survival 
figures. 
4) Follow-up: 
In-order to accurately quote survival figures, it is important to follow-Up patients with 
records which are linked to cancer centres, hospitals and the re istry of deaths. Many 91 , 
registries have active computerised links with the latter. This increased accuracy in 
identifýTing deaths and may make survival figures appear inferior if the f6flow-up of suniving 
patients is less assiduous[132]. Other registries do not have finks to death registries outside 
their re ion and therefore they could potentially under-identify deaths [841. This is a 91 
particular problem where there is a highly mobile population or cross-regional hospital 
referral. 
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5) Method of calculating survival: 
As discussed earlier, in order to trv and account for differences between populations, relative 
survival rates should be calculated. Relative survival takes into account the He expectancv, 
by age and gender for each specific population and therefore estimates the excess deaths due 
to cancer. If populations with very different age profiles are compared then age-adjusted 
relative survival should be calculated to standardise the population. 
Though 'cause specific surviVal' can be used, it is well recognIsed (probably due to the 
lethality of the disease) that in lung cancer doctors readilv attribute death to this disease and 
therefore other causes may be under-reported. Consequently, relative survival, rather than 
cause-specific survival, is a more appropriate measure for lung cancer. 
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Summary ofpubhshed lung cancer series 
A search of 'Pubmed' and 'Medhne' was performed using the terms 'lung cancer and 
population' for -all papers, written in English, published between 1995 and 2005. A total of 
2/ 96 potential papers were identified on 'Pubmed' and 2965 by 'Medline'. These lists were 
searched to identiý, those which reported data on population-based lung cancer treatment 
and survival. Next, reference lists in each publication were searched, to ldentifV any 
previously urlidentified papers. 
Publications were excluded if they either 
i) related to a hospital only registry 
ii) analysed only a sub-group of patients, for example sur ical cases only, or a minor 91 1 
patholo ical entity 91 
iii) used patterns of care studies, where only the data on a sample of patients whose medical 
records were available, were selected. 
A total of 45 publications were identified and the Tables below summarise the data (Table 
2.2a = England and Wales, Table 2.2b = Rest of Europe, Table 2.2c North America, and 
Table 2.2d Australia). 
When a research group published revised data on the same population, the most up-to-date 
information has been included in the tables. The publications underlined and in bold, 
represent those that most closely reflect the methodology used in this thesis. 
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England and Wales 
Cancer care in England and Wales is almost entirelý- delivered by the National Heath Service 
(NHS), financed by taxes and free at the point of defivery. All patients should havc equal 
access to healthcare. 
Three cancer registry pubfications were identified, two examining treatment and surviVal of 
lung cancer patients and one general paper that reported data on the changes in lung cancer 
sun-lVal [37,40,99]. The papers from Yorkshire [37] and Thames [991 Cancer Registries 
both demonstrated low use of treatment, with between 44 and 86% of patients not receiving 
any. Reduced use of treatment appeared to be associated with increasing age, more advanced 
disease, depriVation (in Yorkshire), and area of residence. The rates of treatment, particularIv 
surgery (7%) and radiotherapy (17%) were ven- low in South-East England. The surVival 
rates reported were also low, With only 8% of patients alive at three years In South-East 
England, and 4% alive at five years in Yorkshire. 
In a study reporting data from all England and Wales registries for the period 1996-99, 
Coleman et al [40] demonstrated the five-year relative survival rate of 6%, which was 
unchanged from the previous decade. Inferior survival rates were was observed in men who 
lived in deprived areas, but the impact of deprivation was less marked for women. 
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Rest of Europe 
All member states of the European Union have some form of publicly funded healthcare 
, \N,, ith var\, ing amounts of involvement of private facilities [132]. For example, in France 
employers pay 42% of gross salary and employees 21%, for healthcare that is defivered bv 
public and private hospitals which both receive identical re-imbursement. In The 
Netherlands, healthcare is funded by obligatory deductions from wages into mutual 
insurance compatues and the ma)ority of cancer care I ided by state-run regional is provi 
'Comprehensive Cancer Centres'. 
A number of studies have been published reporting data from France [68,84,114,130]. The 
French Cancer Registries, due to data access restrictions, do not use death certificates for 
registration. The publications report data only on patients who have had a pathological 
confirmation. The series from Bas Rhin [68,114] demonstrated an improvement in the 
median survival over the period 1981-1997 in SCLC patients, thought to be due to increased 
use of chemotherapy. There was also an increase in the number of patients having surgery, 
but there was no improvement in the survival of the patients with NSCLC. The reasons for 
the lack of benefit With the increase in surgery was uncertain, but the increased proportion 
undergoing resection for locabsed disease (110/180 (61%) 1982-5 to 162/202 (80%) 1994-7) 
would probably be insufficient to produce a statistically significant improvement in 
population-based survival. 
Two groups from the Netherlands have published data [48,101,102]. De M)ke and 
colleagues from A/laastricht and Limburg showed that of the patients diagnosed in 1997-8, 
24% underwent surgery, 42% radiotherapy and 13% chemotherapy. 80% of patients With 
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localised disease were treated according to guidelines, but only 50% of patients -ý, vith re ional 91 
disease. The Eindhoven Cancer Registry have pubbshed a number of studies examining 
trends in treatment over time and the prevalence of co-morbidity in cancer patients [101- 
103] 
In 2003, Mahmud et al published data [120] from the Republic of Ireland Cancer Registry. 
This series has high case ascertainment (96%). The use of treatment is simAar to that seen in 
England and Wales; the surgical rate of 12%, radiotherapy 29%, chemotherapy 17%, with 
50", 'o receiving no treatment. The five-year survival rate was 9%. 
North America 
In the USA healthcare is privately funded, with Medicare providing insurance cover for 
those over the age of 65 years, and Medicaid for those on a very low income. Medicare is a 
Federal Insurance scheme with three levels of cover; Part A covering basic health care needs, 
Part B which mcludes screening, and the Prescription Drug Program, which covers drug 
costs. In addition to the insurance pren-uums paid whilst working, all patients have to paý 
other charges including 20% of doctor's costs, $1000 per in-patient hospital stay, and dalh 
charges of $250-$500 per day for in-patient admissions exceeding 60 days. 
Medicaid is run by each US State and has fixed poverty thresholds (around $1000 per month 
income for a family of four), below which healthcare costs will be covered. Up to a quarter 
of each State's budget is spent on Medicaid. However, many employees on low income earn 
too much to be eligible for Medicaid, but are uninsured. In 2004,68% of US citizens had 
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private insurance, 16% were covered by Nfedicald and \tcdlcare, and 16% (46 mil-fion LITS 
cifizens) were uninsured (range 8",, "o Minnesota to 25% in Texas) [1]. Only 600 ) of emploN ers 
offer healthcare insurance and the average annual cost of private insurance for a family is 
$11,000. 
A number of publications report data from the Sun-1val Epidemiolop, and End Results 
(SEER) program of the National Cancer Institute. This collects data from 11 regions across 
the United States of America, representing around 14% of the US population. SEER 
captures around 97% of the incident cases in each region, collating data on turnour site, 
stage, and histology, date of diagnosis and cause and date of death. Patient related factors, 
such as age, gender, ethnic group, post-code (used to hnk with census data on income and 
education) are collected along With data on surgery and radiotherapy within four months of 
diagnosis. No chemotherapy data are coUected. SEER only publishes data on patients with 
pathologIcally confirmed cancer. 
The SEER pubhcations [24,57,58,73,78,153,160,1621 and a number of other series [71, 
127,183] have examined the impact of factors such as race, social deprivation, and 
insurance-c over, on the treatment and survival of US lung cancer patients. These 
publications all report similar results with older patients, non-Whites and un- 
insured/Medicaid patients less likely to receive treatment. The impact of deprivation appears 
to be greater in the USA than in Canada where there is a publicly funded healthcare system 
[21,77,78]. 
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The treatment rates in the USA are higher than that in ý'K. In Kentucky, for example, 30",, ýo 
receive no treatment, 24"/() undergo surgery, 37% radiotherapy and 29% chemotherapy [127]. 
In general, the sunival rates are also higher in the USA than in Europe, with a five-year 
relative sun: ival rate of between 16 and 11%, but the pubhcations onlA I report data on 
patients with pathological confirmation and often exclude 'death- ce rti fi c ate- only' cases. The 
impact of excluding these cases is difficult to quantify, but 1 excluded cases is likelv that the 
have shorter survival. 
Australia 
Australian healthcare is provided by a mix of public and private hospitals funded by the State 
run healthcare system, supplemented by private insurance schemes. In principle all 
Australian citizens should have equal access to healthcare. 
A number of comprehensive reports have been pubfished examining the treatment and 
sunival of patients with lung cancer in Australia [94,163,201,202]. In general around a 
quarter of patients do not receive any treatment, a fifth surgery, and half radiotherapy. In 
one studv, despite the universal access to healthcare, there was significantly less treatment 
delivered to patients in rural areas, though this did not impact on survival [202]. The survival 
rates appear similar to the UK, with an overall survival rate of 8% in New South Wales. 
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Conclusions 
Much of the variation in the published lung cancer sunTival rates can be attributed to 
differences in the methods of coflecting and reporting of the data. Whenever population- 
based survival rates are compared, it is important to appreciate the nature of the population 
fromm, -hich the cases are collected, the methods of data capture and follow-up, and the exact 
sun, lVal measures quoted. 
a) Stage at presentation 
Though detailed data are not available in all series (and often for a sizeable n-unority the stage 
at presentation is unknown), generally around 30% of patients appear to present with 
localised disease. A further 30% have regional and 40% distant disease. 
b) Treatment rates 
The proportion of patients not receiving any treatment varies from around 30% in USA to 
85% in parts of England. The rates of surgery ranged from 7% in Thames region to 24% in 
the Netherlands (32% in Detroit NSCLC), and use of radiotherapy from 17% in Thames to 
56% m New South Wales. The use of chemotherapy also varied greatlý-; from 8% in Thames 
to 29% in Kentucky (senes that include both SCLC and NSCLC). 
Factors which affected the use of treatment appeared to be age, social depnVation (including 




Method of reporting of survival 
Reported five-year survival varies greatly from 6% in Enghsh Registries to 16% in Detroit, 
but the series differ greatly. The publications which give whole-population data including 
both pathologically confirmed and non-confirmed cases generally report five-year relative 
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Chapter 3 
Lung Cancer in British Columbia in 
1995: treatment and survival 
55 
Methods 
The British Colurnhia Cancer Registry was set up in 1969 and is closely linked Nvith the 
Province's four cancer centres which make up the British Columbia Cancer Agency (BCCA). 
This association has enabled integrated data collection with computer linkage of cancer ZD 
registration and treatment detafls. The case ascertainment of the cancer registry in 1995 %vas 
estimated as 93.5"'o. This is not as high as in some countries such as Scotland, primarily due 
to a more mobile population. Cases are identified primarily through patholop- reports and 
death certificates. 
Ethical approval from the University of British Columbia Clinical Research Ethics Board 
was obtained for this study. 
1) Data CoRection 
i) Data available from cancer registry 
The following data are collected: 
ý. lame 
Gender 
Date of birth 
Address including postcode 
Date of diagnosis - defined as date of pathological confirmation, or if not performed 
the date of radiological or clinical diagnosis 
Method of diagnosis (pathology, cytology, autopsy, radiolo ical, clinical) 91 
Pathological type 
56 
Site of tumour 
Stage of tumour - TNNNI where available, if not, global staging J-Bý 
Date of death 
Cause of death on death certificate 
ii) Data from British Columbia Cancer Agency Database 
Referral - if seen in BCCA 
Radiotherapy 
Date of first fraction 
Site of treatment 
Intention of treatment as specified by treating physician 
Dose dehvered 
Fractions 
Chemotherapy -A chemotherapy direcdy supervised by a BCCA Oncologist. 
Chemotherapy agents delivered 
Date of first cycle 
Date of last cycle 
FoHow up 
Date last seen 
57 
iii) Data from BCCA pharmacy database 
In British Columbia, commurim, oncologists, internal medicine specialists who have spent 
time training in oncology, deliver some chemotherapy. In remote commun-ities general 
practitioners, under the supen7ision of an oncolog'st, also give some oral chemotherapy. 
However, all chemotherapy is dispensed by a BCCA pharmacy; therefore it was possible to 
identify all patients recei-\Tlng chemotherapy in the community using the pharmacy database. 
Chemotherapy 
Type of agents used 
Date of first cycle 
Date of last cycle 
iv) Data from Medical Services Plan 
Surgery is an important treatment modality used in lung cancer. In British Columbia (BC) 
the surgeons who perform lung cancer resections work in a variety of teaching and 
community hospitals that do no have direct links to the BCCA. Therefore, in order to 
identiý- the patients that underwent a resection an alternative approach was required. 
Though the members of the staff of the BCCA are salaried, other doctors in BC work on a 
'fee-for-service' basis, billing the Medical Services Plan. This is a comprehensive insurance 
scheme run by the Provincial Government. Therefore, details on all hospital admissions, 
investigations, and operations are available from this source. 
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A hst of the patients diagnosed vvith lung cancer in 1995 identified by the Cancer Registry 
was supplied to the -NISP who then conducted a match with their database, and provided 
details on the following. 
Diagnostic procedures - CT scans, bronchoscopy, CT guided blopsy, and the 
speciaht-v of the doctor who conducted this I 
Staging procedures e. g. mediastinoscopy 
Surgery - nature of operation performed e. g. pneumonectomv, lobectomv etc. 
v) Data from General Practitioners (see Appendix 1 for questionnaire) 
Some patients had not been referred to BCCA, nor had received any cancer therapy 
therefore, in an attempt to try and obtain further information on these patients; letters were 
sent to the patients' general practitioners. 
Unfortunately, though letters were sent to more than 500 GPs, only 290 replies were 
received, of wl-Lich only 127 (25%) could provide useful information. In BC, the GPs are 
only required to keep their records for five years after death; so manv sets of files had been 
destroyed. 
The following information was requested: 
2 Method of diagnosis 
Stage of disease Oocalised, regional or metastatic) 
Any treatments received and where 
If the patient was not referred for treatment, why not (refused, dying, felt not to be 
appropriate etc) 
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2) CoRation of information 
From the Cancer Registry, all patients diagnosed with lung cancer JCD-9 162; ICD-10 C33- 
C34) in British Columbia between 01 January 1995 and 31 December 1995 were identified 
and an SPSS database created. Using the patient's unique Canada Care identification number 
and file merge techniques, the data from the -NfSP, pharmacy and the GPs were added to the 
database. 
Then, in order to enable comparison with the previously collected Scottish data the time 
from diagnosis to each procedure or treatment was calculated, and anv treatments that 
commenced more than six months after diagnosis were excluded. An exception was made 
for consolidation radiotherapy for linUted stage small cell lung cancer (SCLC), when the 
radiotherapy is part of the 'initial treatment package', but can start seven months after 
commencing chemotherapy. 
Then new variables were derived 
1) Age at diagnosis - this was grouped into four categories aged under 60,60-69,70-79 and 
over 80 years. 
2) Distance to cancer centre - in previous studies in BC a traveffing distance of more than 
two hours to a cancer centre was defined as 'long' [92]. Travel times have previously been 
calculated for each post-code. 
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3) Income - The average household income for each post-code can be derived from census 
data. In 1998, the mechan household Income In BC was $CDN48,800. This the on1v data 
on the distribution of household income in the population that could be obtained from the 
Canadian Census website. There was little change in income over the period 1995 to 1998 
so this N-alue was used to divide the population into two groups. The income was also 
divided into fi,, -c groups <CDN$40,000 per annum, 40-49K, 50-59K, 60-69K and 70+K. 
4) Summary pathology - the following groups were formed: small cell, squarnous cell, large 
cell, adenocarcinorna (including bronchoalveolar), non-small cell lung cancer not otherwise 
specified (NSCLC-NOS) and other (included types such as acinar, or spindle cell). 
Clinical summary stage - in order to match the Scottish data the stage was also 
classified as either 'local', 'regional' or 'metastatic', corresponding to node negative, involved 
lyMph nodes, and presence of metastasis, respectively. This does not correspond exactly With 
the more conventional Stage I-IV staging system as T1-T4NO = localised and TxNl-3= 
re ional, but is easier to apply when data for staging investigations is limited. Cases with 91 
limited stage SCLC were defined as 'regional' and extensiVe 'metastatic'. Some unstaged 
patients had a date of diagnosis the same as the date of death. There was obviously no time 
to perform staging investigations so these patients were defined as 'autopsy' stage. 
6) Potentiafly curative therapy - this was defined for NSCLC as either a resection 
(segmentectomy (including wedge resection), lobectomy or pneurnonectomy) or radical 
radiotherapy with a dose of at least 50Gy. A number of patients received radiotherapy with 
an intent described as 'radical' by the treating physician, but to a dose of less than 50Gy. A 
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similar discrepancy occurred 11' in the original analysis of the Scottish data [62]. Therefore, i 
order to ensure a uniform approach with the various fractionation schedules, and as it is 
exceedingly unhkely that a dose of less than 50Gy would be curative; this approach , vas also 
adopted for the BC patients. 
For those patients with limited stage SCLC potentially curative treatment was defined as 
chemotherapy combined with either thoracic radiotherapy with a dose of at least 30G\- 
(chernoradiation), or with surgery. 
7) Palliative treatment was defined as anv treatment delivered out-With the definitions 
defined above. 
8) Chemotherapy - the regimens were combined to form two groups; multiple agents or 
single agent /unknown regimen. Z: ) 
9) Survival time - calculated as the time from date of diagnosis to date of death or date last 
seen. Patients who died the same day as an operation had their date of diagnosis moved one 
day forward to ensure their inclusion in the analysis of treatment delivered. 
10) Cause of death - the primary and secondary causes of death were available. Those 
patients with lung cancer as primary cause of death, or with lung cancer as secondary cause 
of death, but an obvious linkage with lung cancer, for example pneumonia, were defined as 
ha,,, qng had died of lung cancer. Other causes of death were combined to form a single group 
of patients with 'other cause of death'. However, in lung cancer it is well recogmsed that 
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maný, patients are certified as dying of lung cancer when this may not represent the genuine 
cause of death, so any cause-specific survival analysis should be interpreted with caution. 
3) Statistical Analysis 
The majority of the data were analysed using descriptive statistics. Associations between 
variables were assessed using chi-squared for grouped data and Analysis of Variance 
(ANOVA) for continuous data. To examine the factors that affected treatment delivery chi- 
squared analyses and multivariate lo istic regression analyses were conducted. The latter was 91 
performed using dichotomous and categorical variahles to calculate the odds of receiving 
treatment. Kaplan Meier survival analyses were conducted to plot survival cur-, Tes and to 
estimate the median, one, two and five-year sunTiVal. Factors affecting survival were 
examined using log rank tests and Cox's proportional hazard regression analyses. 
All p values of less than 0.05 were deemed statistically significant, though those greater than 
0.01 should be interpreted with caution due the large number of statistical tests performed. 
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Results 
1) Demographics and tumour factors 
2256 patients -\vere identified, with a median age of 70 (range 22-100). There were 1323 men 
(58.6(', )) and 933 women. 647 (28.7%) patients hved more than a t\-, -o-hour drive from a 
Cancer Centre. The median income was lower than the BC avcragc at $CDN 46,670 (mean 
48,206 sd 9615) and 556.3% of the population lived in an area with below the median 
household income for British Columbia. 
The diagnosis was confirmed with histology in 55.5%, cytology 25.2% (ante-mortem 
pathological confirmation rate of 80.7%). A radiological/ ch ni cal diagnosis was made in 
at autopsv in 1.4%, and the method of diagnosis was unknown in 6.3%. In 1032 
(45.7%) cases, the turnour was located in the upper lobes, 454 (20.1%) the lower lobes, 144 
(6.4", '0) main bronchi, 102 (4.5%) right middle lobe, 26 (1.2",, '()) were multi-focal and in 498 Z--) 
1.1 %) the site was unknown. 
Of the 1850 (82%) patients with pathological confirmation, 636 (34.3%) had 
adenocarcinoma, 477 (26.7%) squarnous cell, 307 (16.6%) small-cell, 222 (12.0%) large cell, 
177 (9.50,,,, o) NSCLC not otherwise specified (NSCLC-NOS), and 31 (1.7%) other 
patholo ical ty es. No patholo ical confirmation was obtained in 406 patients. 91 ,p 91 
For the purposes of analysis, three large patholo ical groups were defined; no pathology, 1 91 
small cell and NSCLC, the latter consisting of all the remalmng pathological subtypes. 
marih with chemotherapy and Historicafly this division was made as SCLC was managed pri 
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NSCLC with surgenI and radiotherapy, though this distinction applies less so now than in 
the past. There vvere no significant differences in the distribution of gender, distance to 
cancer centre between these three groups (X2 p>0.05) or income (ANOVA p>0.05), but the 
'no pathology' group was significantly older (ANOVA mean age 'No path' = /6, SCLC =67, 
NSCLC =6' years p<0.001) 
Detailed information on staging was available for 1472 (65.2%) patients (Table 3.1 a) and less 
detailed staging using the local: regional: metastatic system (LRAý for 1975 (87.5%) cases 
(Table 3.1b). This additional information came either from the GP questionnaires or was 
derived from treatment; for example, if the patient received radiotherapy for hone 
metastases soon after diagnosis they were deemed to have had stage IV disease at 
presentation. 
Table 3.1a Distdbution of staowat presentation 
IA IB IIA 1113 IIIA IIIB IV LIMIT EXTENT UNKNOWN 
NUMBER 1-55 188 20 119 173 176 38 3 104 154 784 
% 6.9 8.3 0.9 5.3 7.7 7.8 17.0 4.6 6.8 34.8 
Table 3.1bDisuibution of staee usine broaderzroups 
LOCALISED REGIONAL METASTATIC AUTOPSY UNKNOV'N' 
NU? \fBER 498 538 756 183 281 
% 22.1 23.8 33.5 8.1 12.05 
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2) Stagring and treatment 
For the following analyses, the 183 patients who died on the same day that their diagnosis 
was made were excluded as there would have been insufficient time to either conduct 
investigations or administer treatment. Thi I lan age is excluded group contained 59% men, med' 
was 78 years (mean 76.6 sd 10.4), 29% fived more than two hours from a cancer centre, the 
median income was $CDN 48,230 (mean 46,900 sd. 10500) and only 33 (18%) had had 
pathological confirmation (23 at autopsy). This group was significantly older (p<0.001), and 
obviously was less likely to have had patholo ical confirmation (p<0.001) than the main 91 
group. 
i) Staging Investigations 
Of the remaining 2073 patients, 1526 (73.6%) underwent a CT scan and 1288 (62.2%) had a 
bronchoscopy. 494 (23.8%) of patients also had a mediastinoscopy. 
ii) Any treatment 
546 (26.3%) patients were treated with potentlafly curative intent, 826 (39.8%) palliative 
treatment and 701 (33.8%) did not receive anN- treatment in the first six months following 
diagnosis. 
iii) Surgery 
489 patients (23.6%) underwent an attempted resection, for 51 (10.2%) patients (2.5% of the 
population) this was an 'open-shut' thorocotomý T, and 438 had a cancer resection. 
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The mcdian -age of the SUrgical patient was 67years (mean 65.55, range 32 to 84), which was 
significantly younger (ANOVA p<0.001) and the median income at SCDN47,7()() x-vas ý7) .I t) 
higher than those not undergoing surgen (ANOVA p=0.03). Z71 
Lobectomy , vas the most frequently performed operation with 317 (155.3% of population) 
patients undergoing this type of resection, 83 (4.0%) had a pneumonectomy and 38 (1.8ý/()) 
se(), mentectomy. Twenty-five different surgeons performed the operations (figure 3.1) with a , L-- Z7, 
median number of five operations per year (range of 99 to 1). Six. surgeons performed 62% 
of the resections. Twelve patients died within 30 days of resection and three post- 
thoracotomy; giving -a 4.8% post-operative mortality rate for pneumoncctomy, 1.9% for 
lobectomy and 6, /, ) post-thoracotomy (3.1% for A operations). This rate is in keeping with 
other pubfishcd series from this cra [511. 









The final pathological stage of the 438 resected tumours is shown in the Table 3.2. 
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Table 3.2 Distiibution ofpathological stage 
IA IB ITA 11B MIN 11113 IV LLMIT Unknown 





26.9 3.9 15.5 9.4 3.7 2.3 1.8 9.4 
The most common pathological type was adenocarcinoma, which occurred in 205 (46.8%) 
patients, 136 (31.1', ýo) had squamous cell, 40 (9.1%) large ceR, 8 SCLC, 16 (3.7%) 
NSCI, C-', 's, -OS, 28 (6.4%) other and in five cases the type was not recorded. 
Thirtý--four patients with NSCLC received high dose pre or post-operative radiotherapy 
(PORT) (one patient underwent radical radiotherapy delivered to a second lung cancer), and 
three of the SCLC patients received adjuvant treatment. Most of the NSCLC patients who 
received PORT had either Stage IIA (38.2%) or Stage IIIA (29.4%). Unfortunately the 
indication for PORT, for example positive resection margin, was not recorded. The time 
from surgery to post-operative radiotherapy ranged from 22 to 132 days. Within the first six 
months palliative radiotherapy to the chest was delivered to eight of the surgical patients, and 
eleven received radiotherapy to other sites. 
Twenty patients who had a resection received chemotherapy, only one pre-operativejýT. 
The 
time from operation to starting chemotherapy ranged from 16 to 173 days (median 
53 days). 




836 (40.3%) of patients received radiotherapy in the first six months following diagnosis. 
The first course of treatment , vas radical radiotherapy to a dose of >-50Gy for 45 patients 
(2.2'/o population), 34 (1.6". /o) pre or post-operative radiotherapy, 67 (2.9%) adjuvant thoracic 
treatment for SCLC, 533 (26%) palliative radiotherapy to the chest, and 158 (7.6"/, "(, ) palliaUve 
radiotherapy elsc\x-here. 
A second course of radiotherapy was defivered at some point during their hfetime to 275 
patients (40 patients prophylactic cranial radiotherapy (PCI) and 235 palliative treatment), 44 
patients received three courses of radiotherapy, 14 four courses, 5 five courses, 1 seven and I 
eight courses of treatment. 
Of those patients who did not receive radiotherapy during the first six months, 21 went on 
to do so later. Therefore the population lifetime use of radiotherapy was 41.3% (38% 
including 'autopsý T' cases). 
Ten patients had the radiotherapy intent defined by their oncolo ist as 'radical', but received 1 91 
a dose of <50Gy (range 10-48Gy mean 35.3Gy). For the remaining 45 patients, the dose 
ranged from 50 to 60Gy (mean 52.4Gy) with a median fractions of 20 (median 20.6, range 
15-30). The most commonly used fractionation schedule was 50Gy in 20 fractions (16 
patients). 
For the 34 patients who received post-operative radiotherapy the median dose was 50GN- 
(range 20-65Gy mean 49.7Gy) With median of 20 fractions (mean 19.7) 
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Chemoradiation Nvas delivered to 67 patients (57%) with timited-stage SCLC. The median 
dose used was 40Gy (range 30-55.2Gy). A dose of 40Gv in 15 fractions was used for 67.2"', ) 
of patients. 
For those patients -, N-ho received paltiative radiotherapy to the chest the commonest 
fractionation schedule was 20Gy in five fractions (range 5-48G), ). 43.6% of patients received 
a dose of 20Gy in 5 ftactions, 22% 30Gv in 10 fractions and only 4.8% of patients had a 
single fraction treatment using between 8 and 10Gy. Sixteen patients received brachytherapy 
as their initial palliative radiotherapy treatment. 
Similarly, the most frequently used fractionation schedule for 166 treatments debvered to 
other sites (56.3% bone, 40.5% brain) was 20Gv in 5 fractions (50.9% of treatments). The 
doses ranged from 6 to 44Gy in 1 to 16 fractions. 
During the first six months following diagnosis a total of 8409 fractions of radiotherapy 
were dehvered, 6778 (80.61/o) as part of the first treatment course and 1360 in the second. 
2821 fractions (33.5% of total) were used as part of curative therapy, either during radical, 




A total of 368 (17.3"lo) of the 2073 patients received chemotherapy, 285 of whom received a 
platinum based re ime. The three most commonly used regimes were PAVE (cisplatin, 91 
adriamycin, vincristine and etoposide) 85 cases, PNAV (cisplatin, vinorelbine) 75 cases, and 
alternaUng EP/CAV (etoposide, cisplatin / cyclophosphorrýdc, adriamycin, vincristine) 62 
cases. 
The median time between diagnosis and commencing chemotherapy was 19 days (mean 28.6 
0 to 1-5 days). The number of cycles was not recorded, but the date of the first and last cvcle 
was available and could be used as a surrogate. The median time between these two dates 
-,. v, as 558 days (mean 62 days). The majority of chemotherapy protocols used had a 21-dav 
cycle length so this approximates to an average of 4 cycles per patient. 23% of patients 
received only one cycle of chemotherapý T (<21days) and 14% two cycles (21-42 days). 37 
(10%) patients died within a month of starting chemotherapy. 
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3) Treatment combinations by,. Vathologrical groups 
i) SmaH CeH Lung Cancer 
There Nvere 306 patients vvith SCLC, 36"/o of whom had hmited stage disease. The treatment 
combinations are shown in Table 3.3. 
Table 3.3 Treatment deKvered patients uith SCLC 
Number % 
Sur,, en-* onlv 3 1.0 
Surgery and chemotherapy 2 0.7 
Surgery, chemotherapy and post operative radiotherapy 3 1.0 
Chemotherapy and adjuvant thoracic radiotherapy 64 20.9 
Chemotherapy 91 29.7 
Chemotherapy and palliative radiotherapy 71 23.2 
Palliative radiotherapy 22 7. ? 
None 50 16.3 
*= Resection 
76 patients received PAVE, 62 patients received EP/CAV, 40 oral etoposide, 26 CAV, 19 
EP, 8 other various regimes. 
Of the Ill patients with limited stage disease, 72 (64.9%) received potentiaUy curative 
treatment (chemoradiation or surgery +/- chemotherapy), 34 (30.6%) palbative treatment 
and 5 no treatment. There were 168 individuals with extensive stage disease of whom 
134 received palliative treatment (81%). Of the 27 unstaged patients, 14 received 
chemotherapy and 13 no treatment. 
Therefore, 75.5% of the SCLC patients received chemotherapy as a component of their 
initial treatment. Of these 25 (10.8%) died within a month of commencing chemotherapy, 4 
of 94 (4.2%) with limited stage disease, 17 of 123 (13.8%) with extensiVe disease and 4 of 
14 
(28.6%) the unstaged patients. 
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ii) Non-SmaH Cell Lung Cancer 
A total of 1540 patients vvere diagnosed with pathologically confirmed NSCLC. The 
distribution of management is shown in Table 3.4. 
Table 3.4 Treatment deHvered patients vf4th NSCLC 
Number % 
Surgery only 364 23.6 
Surgery and chemotherapy 8 0.5 
Surgery, chernothe 
- 
rapy and post operative raciiotlierapy 5 1.9 
Surgery, chemothe 
- 
r-apy and palliative radiotherapy 1 0.1 
Surgery and post operative radiotherapy 29 1.9 
Surgery and radical radiotherapy 1 0.1 
Surgery and palliative radiotherapy 17 1.1 
Radical radiotherapy 38 2.5 
Radical radiotherapy and chemotherapy 3 0.2 
Palliative radiotherapy 499 32.4 
Chemotherapy 60 3.9 
Chemotherapy and pathative radiotherapy 56 3.6 
None 459 29.8 
Potentially curative treatment (surgery or radical radiotherapy) was used in 30.3% of patients; 
palliative treatment in 39.9%, and 29.8% received no treatment. The management intent, 
broken down by the extent of disease, is shown in Table 3.5 and demonstrates that two- 
thirds of patients with localised disease were treated with curative intent, and one-third of 
patients with regional disease. 
TAhh- T ; Tn-Atment intent and stape at Dresentation 
x 2with p<0.001 Localised Regional Metastatic Unknown Total 
potentially curative 292 128 12 34 466 
65.6% 31.7, "0 2.3% 19.20,,, "(1 
1 
30.3 
palliative 92 192 322 9 615 
20.7% 47.5% 62.6% 5.1% 39.9% 
none 61 84 180 134 459 
13.71"', 1 20.8% 35.0% 1 29.8" , () 
Total 445 1 404 514 188 1 154() 
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113 patients died within a month of commencing treatment, 12 (2.6%) receiving potentiaHy 
curative and 101 (16.4%) with paRiative treatment. 
Of the 133 NSCLC patients who received chemotherapy, the most commonly prescribed 
regime \vas cisplatin and vinorelbine, which was delivered to 74(-')6", 'o) patients. Of the 133 
patients with NSCLC nine (6.7%) died within a month of starting chemotherapy. 
iii) Patients without pathological confirmation 
A total of 227 patients did not have a patholo ical diagnosis recorded on the BC Cancer 91 t) 
Registry database. Five of these patients underwent a resection so pathological type would 
have been available, but had not been recorded. Localised disease was present in 53 patients, 
23 had regional and 74 metastatic disease. The stage was unknown in 77 individuals. The 
management used for this group of patients is shown in Table 3.6. 
Table 3.6 Treatment deUvered patients u4thout patholoeical confirmation 
Number % 
Surgery only 4 1.8 
Surgery and chemotherapy 1 0.4 
Radical radiotherapy 3 1.3 
Chemotherapy 3 1.3 
Palliative radiotherapy 24 1.3 
None 192 84. Eýý] 
All patients receiving potentially curative treatment lived more than a month, but three 
patients given palliative chemotherapy died within this time frame. 
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4) Factors affecting use of treatment 
In order to explore the factors affecting whether or not patients received treatment, chi- 
squared and logistic regression analyses were performed (Table 3.7). There was no significant 
impact of gender or distance from cancer centre, but patients were less likely to receive 
treatment if they were older and hved in an area with an income below the median for 
British Columbia. As one would expect, treatment was also less frequently delivered to 
patients with metastatic disease and in those whom a pathological diagnosis had not been 
obtained. 
Ta ble 3.7 Fa c tors affe c tinu usc of an v trea tm en t 
ANYTREAT'MENT Yes No x2 Unadjusted Adjusted 
odds ratio of odds ratio of 
receiving receiving 
treatment treatment 
Gender Male 794(65.3%) 421 P=0.34 1 1 
Female 578(67.4%) 280 1.1 (0.9-1.3) 1.0 (0.8-1.3) 
Age <60 351 (82.8%) 73 P<0.001 1 1 
60-69 455 (72.7%) 171 0.6 (0.4-0.8) 0.6 (0.4-0.9) 
70-79 461 (62.7%) 274 0.4 (0.3-0-5) 0.4 (0.3-0.6) 
80+ 105 (36.5%) 183 0.1 (0.08-0.2) 0.2 (0.1-0.3) 
Distance to <2 hrs 996(67.4%) 481 P=0.07 1 1 
Cancer centre >2 hrs 375 (63.1%) 219 0.8 (0.7-1.0) 0.8 (0.7-1.1) 
Income < 48,800 740(63.5%) 425 P<0.01 1 1 
CDN S> 48,800 631 (69.6%) 275 1.3 (1.1-1.6) 1.3 (1.1-1.7) 
pathology NSCLC 1081 (70.2%) 459 P<0.001 1 1 
Type SCLC 256 (83.7%) 50 2.2 (1.6-3.0) 2.8 (1.9-3.9) 
No pathology 35 (15.4%) 192 0.07(0.05-0.1) 0.1 (0.1-0.2) 
Stage Locahsed 390 (78.3%) 108 P<0.001 1 1 
Regional 429(79.7%) 109 1.1 (0.8-1.5) 0.7 (0.5-1.0) 
Metastatic 490(64.8%) 266 0.5 (0.4-0.7) 0.4 (0.3-0.5) 
Unknown 63(22.4%) 218 0.08 (0.06-1.1) 0.07 (0.05-0-11) 
Figures in bold are statistically significant (p<0.05) I 
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i) Use of potentially curative treatment 
Similarly patients were also more hkely to be treated with curative intent if they Nx-erc 
younger, lived in -an area with a higher income, had NSCLC, and obvIouslv if the disease was 
locahsed (rable 3.8). 
Table 3.8 Factors affecting the use ofpotentially curative treatment 
POTENTIALLY Yes No x2 Unadjusted Adjustcd odds 
CURATIVE odds of ratio 
receiving PCT of receiving PCT 
Gender Male 313 (25.8%) 912 P=0.48 1 1 
Female 223(27.2%) 625 1.1 (0.9-1.3) 1.0 (0.8-1.3) 
A(-, -c <60 134(31.6%) 290 P<0.001 1 
60-69 189(30.2%) 437 0.9 (0.7-1.2) 0.75 (0.53-1.08) 
70-79 199(27.1%) 536 0.9 (0.6-1.0) 0.62 (0.44-0.87) 
80+ 24(8.3%) 264 0.2 (0.1-0.3) 0.16 (0.09-0.27) 
Distance to <2 hrs 377 (25.5%) 1110 P=0.19 1 1 
Cancer centre >2 hrs 169(28.5%) 42-5 1.2 (0.9-1.4) 1.1 (0.8-1.4) 
Income < 48,800 281(24.1%) 884 P<0.01 1 1 
C DN $> 48,800 264(29.2%) 641 1.3 (1.1-1.6) 1.4 (1.1-1.8) 
Pathology NSCLC 466(30.3%) 1074 P<0.001 1 1 
TyPe SCLC 72(23.5%) 234 0.7 (0.5-0.9) 2.1 (1.4-3-3.0) 
No pathology 8 (3.5%) 219 0.1 (0.04-0.2) 0.1 (0.04-0.2) 
Stage Locahsed 296(59.4%) 202 P<0.001 1 1 
Regional 202 (37.5"1"0) 336 0.4 (0.3-0.5) 0.27 (0.2-0.36) 
Metastatic 12(1.6%) 744 0.01 (0.5-0.2) 0.01 (0-0.012) 




elivery of surgery, radiotherai3v of chemothera 
\\Iicn deprivation was taken as a dichotomous variable (greater or less than Provincial 
median) then on chi-squared analysis only age, pathology type and stage affected the use of 
surgen 
T; 
with ýTounger patients with NSCLC and those with localised disease more likelv to 
undergo a resection (Table 3.9). However, the verN, nature of surgery the stage and pathology 
týype are more likely to be known so the lo istic regression multivariate analysis without these 91 1 
variables, then only age over 70 years was sigmficant. 
However, if income was divided into six bands then surgery was more likely to be performed 
in patients below the age of eighty and in those fiving in areas with the highest average 
income levels (Table 3.10). 




x2 Unadjusted odds 
of surgery 
Adjusted odds of 
surgery 
Age <60 117/424 P <0.001 1 T 
60-69 180/625 1.1(0.8-1.4) 1.1(0.8-1.4) 
70-79 175/735 0.8(0.6-1.1) 0.8 (0.6-1.1) 
80+ 17/288 0.2(0.1-0.3) 0.2(0.1-0.3) 
Income <40K 79/409 P=0.053 1 1 
40-49K 198/799 1.4(l. 03-1.8) 1.5 (1.1-2.0) 
50-59K 150/653 1.2(0.9-1.7) 1.3 (0.9-1.8) 
60-69K 43/156 1.6(l. 04-2.4) 1.9 (1.2-3.0) 
70K+ 19/54 2.3(l. 2-4.2) 2.5 (1.3-4.6) 
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On multivariate analysis, patients were more hkely to receive radiotherapy if they were 
ger, had more advanced disease, or had tissue confirmation. SimilarIN, those patients youn, --, 11. I 
who hved under two hours Journey time from a cancer centre were more Ekely to receive 
radiotherapy, probably a consequence of patients and doctors being deterred by the long 
journey for those fiving in remote areas (Table 3.9). Income had no impact whether 
examined as a dichotomous or categorical variable. 
iii) Chemotherapy 
On cl-ý-squared and multi-variate analyses younger patients, especiallv those under the age of 
60 N-ears, those with SCLC, or more advanced disease were more bkeIN- to receive 
chemotherapy, as were patients with a higher household income (Table 3.9). This was also 
observed if income was entered into the model as categorical variable (adjusted odds 
SCDNL'70+ 6.1(2.7-13.8), 60-69K 2.2 (1.1-4.2) compared to income group <401, C). 
The reason for the impact of income on the use of chemotherapy and surgery was uncertain, 
but could ha: \-e reflected more co-morbid disease in socially deprived patients, which 
precluded the safe delivery of chemotherapy or an operation. 
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6) Overaff Survival 
Exact date of diagnosis was not availablc for three patients so were removed from the 
sunival anah-sis. 
Using the Kaplan--, \Ielcr method for the analysis of sun, lval for the complete cohort of 2253 
patients the median survival was 6.2 months, with 33.7% ahve at one vear, 20.1"/o two vears 
and 9.40'() at fivc years. 
For the 207 0 patients -, -, -ho hved more than one day foHowing diao-nosis, the median survival 
was 7.4 months, with D'D'. 3', //o of patients suniving six months, 36.7% one-vear, 22.0% t-wo- 
vears and W. -')'N 
five-vears (ficure 3.2a). As one would expect patients with more advanced 
disease had reduced survival, as did those without a tissue diaonosis. Neither household (111) 
income (as dichotomous or categorical variable), nor *ourneý- time to a cancer centre, were 
associated with a difference in suf-, -l-, -al, but as has been seen in several other series, women 
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Table 3.11 Factors affecting survivalofpatients vvith king cancer in BC199.5 
N= 20 -1/ 0 'Median survival Log rank Unad)'usted Ad)*usted 
(montl-is) hazard hazard 
of death of cleath 
Gender "\I"Llc 7.1 (6.4.7.8) P<0.001 1 1 
Female 7.9 (6.8-9.0) 0.9(0.8-0.9) 0.9 (0.8-0.9) 
Age <60 9.4 (8.2-10.6) P<0.001 1 1 
60-70 8.3 (6.9-9.6) 1.1(0.9-1.2) 1.1 (1.0-1.3) 
70-80 6.6 (5.7-7.5) 1.3(l. 2-1.5) 1.4 (1.2-1.6) 
80+ 4.0 (3.1-4.9) 1.8(l. 5-2.1) 1.6 (1.4-1.9) 
Income <48,800 7.2 (6.5-8.0) P=0.28 I I 
CDN S >48,800 7.6 (6.7-8.5) 0.95(0.9-1.0) (0.9-1.1) 
journev <2 hr 7.1 (6.4-7.8) P=(-). 26 1 1 
>2 hr 7.8 (6.8-8.9) 0.9 (0.8-1-0) 1.0(0.9-1.1) 
Pathology NSCLC 8.2 (7.4-9.0) P<0.001 
SCLC 7.6 (6.6-8.7) 1.4(l. 2-1.6) 1.0 (0.8-1.1) 
No pathology 2.7 (1.9-3-5) 2.1(1.8-2.4) 1.7 (1.5-2.0) 
Stage Localised 22.9 (19.2-26.6) P<0.001 I 
Regional 10.9 (17.5-21.3) 1.8(l. 6-2.0) 1.9 (1.7-2.2) 
Metastatic 3.7 (3.3-4.1) 4.1(3.6-4.7) 4.3 (3.8-4.9) 
Unknoxvn 2.8 (2.1-3.6) 3.0(2.6-3.6) 2.7 (2.3-3.2) 
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5546 patients in the cohort received potentially curative treatment and had a median sun-1val 
of 34 months (95"/oCl 29.4-38.5), 825 received palfiative treatment only and had a median 
survival of 6.3 months (5.8-6.8) and 698 no treatment -,, vith a median survival of 2.3 months 
(2.1-2.8). The survival statistics for 1) the different types of potentiafly curative therapy are 
shown in Table 3.12,11) the factors affecting sunival according to treatment intent are 
shown in Tablc 3.13, and iu) by trcatment modafin- in Tablc 3.14. This analý-sis shows that 
regardless of treatment intent women had improved survival, as did younger patients, those 
with pathological confirmation, and with less advanced disease. 
Ta ble 3.12 0 verall s unival follo u4ng po ten tial c ura tive th erapy by tre a tm en tmo dality 
MccEan I year 2 ycar 5 year 
(months) 
Resection 40.8 81.0% 65.7% 38.6ý 
n=438 
Radical radiotherapy 17.6 6 8.2 38.6", ) 10.606 
(n=45) 
Limited SCLC cherno + 15.4 -). 3' 6 )5.9", ) 
1-7.20 
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ii) Cause specific survival 
As discussed in Chapter 2 for patients with a diagnosis of lung cancer cause specific analysis 
should be taken with caution. 
By five years, of the original 2073 patients, 1651 (80%) had died of lung cancer, 183 died of 
other causes and 239 were allve. SurVival rates, as calculated by the Kaplan Meier method are 
shown in Table 3.15. (For data on relative survival see Chapter 5) 
Table 3.19 Cause specific surpival and treatment intent andpathological type 
Median (months) 1 year 2 year 5 year 
Whole group 
(n=2070) 8.2 (7.5-8.8) 39.9% 25.0% 13.9% 
Potentially curative treatment 
(n=546) 40.6 (32.9-48.3) 80% 63.9% 42.7% 
Palliative treatment 
(n=826) 6.6 (6.1-7.1) 24.4% 8.7% 2.6% 
No treatment 
(n=698) 2.0 (2.5-3.6) 26.1% 12.8% 3.0% 
NSCLC 
(n=1540) 9.0 (8.1-9.9) 43.4% 28.2% 17.1% 
SCLC 
(n=306) 7.9 (6.9-8.8) 30.5% 12.9% 6.1% 
No pathology 
(n=224) 3.7 (2.7-4.6) 28.0% 11.3% 2.0% 
In the Cox's regression model gender, age over 70, no pathology, and more advanced disease 
all predicted for increased hazard of dying of lung cancer (Table 3.15). 
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Table 119 Factors affecting cause specir ic survival 
ed' M lan (months) rank L'nad'Listcd ha/ard 4 1 A&Listcd hýizard ()f 1 
13 valLIC lung canccr dcath ILL1111 CaIICCF dCath 
Gcnder Malc 7.9 (7.2- 8.6) 0.009 1 1 
Fcrn, alc 8.8 (7. _5 )- 10.0) 0.9(0.8-0.96) 0.9 (0.8-0.96) Age <60 9.7 (8.2-11.2) 0.001 
60-69 9.8 (8.2-11.4) 1. (-) (o. 9-1.1) 1 (0.9-1.2) 
70-79 7.6 (6.6-8.6) 1.2(l. 1-1.4) 1.4 (1.2-1.6) 
80+ 4.8(3.8-5.9) 1.6(l. 4-1.9) 1.5 (1.3-1.8) 
Distance <2 hours 8.0 (7.3-8.7) 0.23 1 1 
>2 hours 8.4 (7.2-9.7) 0.9(0.8-1.0) 1. ()(0.9-1.1) 
InCOMC < 48,800 7.9 (7.2-8.7) 0.25 1 1 
C DN' > 48,000 8.5 (7.3-9.7) (). q((). 8-1. ()) 1. () (0.9- 1.1) 
Pathology NSCLC 9.0 (8.1-9.9) 0.001 1 1 
Tý-Pc SCLC 7,9 (6.9-8.8) 1.4(l. 3-1.6) 1 (0.9-1.1) 
No pathologY 3.7 (2.7-4.6) 1.9(l. 7-2.3) 1.6 (1.4-1.9) 
Stage Localiscd 29.7 (23.0-36.3) 0.001 1 1 
Rc-gional 11.9 (10.4-13.4) 2.1(1.8-2.4) 2.2 (1.9-2.6) 
Mctastatic 4.0 (3.6-4.4) 4.8(4.2-5.5) 5.0 (4.4-5.8) 
Unknov-n 3.6 (2.5-4.7) 3.2(2.7-3.8) 2.9 (2.4-3.5) 
When income was examined as a categorical variable then there was a trend for improved 
survival for patients in the highest income group (figure 3.3 Log rank p=0.063) 
Figure3.2 Cause specific survival by income group 
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Summarv of results 
256 patients diagnosed with lung cancer in 1995 of whom 59',, 'o were male. 
0 The pathological confirmation rate was 83",, ), xvith 34% adenocarcinoma, 26" ) squarnous cancer, 
o small cell, 12"'o large cell and 12", '0 other tyPes of NSCLC. 
of patients had localised disease, 24% reggonal, 33.5"/ metastatic and 12.5"ý, 0 stage was 11 
unknown. 8",, were diagnosed either at autopsy or on day of diagnosis and so \N-crc excluded 
from treatment anah-sis. 
0 Of the remaining 2073 patients, 26% were treated with curative intent, 40% received palliative 
treatment and 34% received no treatment. 
0 The resection rate was 19% of the whole population, with the 438 resections performed by 25 
different surgeons 
41% of the population received rachotherapy for their lung cancer, but only 2"'ý, of the '0 
population received radical radiotherapy 
0 17.3% of d-ie population received chemotherapy, 75.5% of SCLC cases and 8.6% NSCLC 
0 Patients -, -, -crc more likely to receive treatment if they were younger, lived in a more afflucnt area 
or had loco-regional disease. The traveling time to the closest cancer centre had no influence on 
whether or not the patient received treatment. The same factors also affected the delivery of 
potentiaLly curative treatment. 
0 The median overall sunTiVal for the complete cohort was 6.2 months and for the group of 2073 
who hved more than one dav the surVival rates were 37%, 22% and 10.3"/o at 1,2 and 5 vears 
respectively. 
0 For patients undergoing a resection the median survival was 40.8 months with 39/'0 alive at five 
years, for radical radiotherapy the figures were 17.6 months and 10.6%, and following chemo- 
radiation for SCLC 15.4 months and 17.2%. 
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CHAPTER 4 
Lung Cancer in Scotland in 1995: 
treatment and survival 
89 
Methods 
The Scottish Cancer Registry was one of the first cancer registries to be setup and achieved 
national coverage in 1959. Cases are identified from a variety of sources, such as pathology 
reports, hospital discharge summaries, cancer centre databases, and death certificates. The 
case ascertainment is one of the highest in the world with more than 96.5% of cancer cases 
being identified [25]. Due to the methods of case identification it is likely that the 
ascertainment for lung cancer is actually higher than this; though no specific data exist. 
A retrospecdve audit was conducted in 1998 of all cases of lung cancer diagnosed in 1995 
identified by the Scottish Cancer Re istry. A three-month window either side was aflowed to 1 91 
ensure complete data capture. Specially employed audit staff manually examined all the 
patients' medical records. 
Though the data on general patient characteristics, treatment and outcome have been 
published [83], along With a more detailed paper on chest radiotherapy [62], the detailed data 
on chemotherapy and surgery have not been published. 
For the purposes of this study a complete re-analysis of the data has been performed using 
the following variables: 
Name 
Gender 
Date of birth 
Postcode 
90 
Date of diagnosis - defined in order of priority as date of patholo ical diagnosis, 91 
date of radiological diagnosis, date of clinical diagnosis 
Mcthod of diagnosis (pathology, cytology, autopsy, radiolo ical, chnical) 91 
P-atholoPlical type 
Sta ing investigations (CT scans, bronchoscopy) 91 Z7) 
Site of tumour 
Stage of tumour defined as locafised, regional or metastatic 
Treatment received within six- months of diagnosis (except adjuvant radiotherapy 
following chemotherapy for limited stage SCLC as this can start during the 
seventh month). 
Date of death - this was originally linked to the death re istry at the end of 1998, hut 91 . 
for the purposes of this study, a second Enkage up to the end of 2002 was 
performed. 
Derived variables 
To enable comparison with the BC data the same variables were derived. Namely: 
1) Age at diagnosis - grouped into four categories aged under 60,60-69,70-79, and 
over 80 years. 
2) Distance to cancer centre - in British Columbia a two-hour Journey is considered 
socially acceptable, but in Scotland work performed by the Scottish Executive Health 
Department suggests that a one-hour journey is preferable. Therefore, for the 
91 
comparison a further variable 'socially acceptable Journey' i. e. two hours for Canada 
and one hour for Scotland was used. 
3) Income and deprivation - the Carstairs deprivation index has been deý-eloped for 
Scotland and uses four factors (overcrowding, male unemployment, social class 4 
and 5 and car ownership) to calculate a score for each post-code, which is then 
divided into fiN-c or scN-cn categories (I = least deprived and 7= most deprived) [36] . 
The seven categories do not divide the Scottish population evenINI; 6% of Scottish 
population reside in an area in categorv 1- 14%; 2- 22%; 3 -25%; 4 -15%; 5 -11%; 6 
categorv 7- 7%. As the only index of depriVation for BC was median income, 
the Scottish population was also split into two groups, which roughly equate to half 
the Scottish population; those Carstairs index 1-3 (42%) and those Carstairs index 4- 
(D-S"'o)[128]. 
4) Summary pathology - the following groups were formed: small cell, non-small cell 
and no pathology. 
5) Sta ing - when the ori 'nal data was collected a system of localised, re ional and 91 91 91 
metastatic stage was used corresponding to localised to lung, spread to regional 
lymph node and distant metastases, respectively. However for some cases, where the 
TNTNI stage was available, this did not appear to always to concur, therefore for these 
cases the staging was amended so node negative NSCLC patients had 'Localised' 
disease, NI or N2 NSCLC patients and Limited stage SCLC 'Regional' disease, and 
N11 NSCLC and Extensive stage SCLC 'Metastatic' disease. 
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6) Potentiaflv curative therapy - this was defined as for the BC patients. 
,) Palliative treatment - this was defined as for the BC patients. 
8) Chemotherapv - the regimens were combined to form two groups; multiple 
agents or single agent /unknown regime. 
9) Sun-ival time - time from date of diagnosis to date of death or date of censorship 
(31/12/2002) 
10) Cause of death - the primary and secondary cause of death were available. Those 
patients with lung cancer as primary cause of death or with lung cancer as secondary 
cause of death but an obvious association, for example pneumonia, were defined as 
having died of lung cancer. Other causes of death were combined to form a single 
group of patients with 'other cause of death'. 
Analysis 
An analysis similar to that conducted for British Columbia was performed. 
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Results 
1) Patient and tumour characteristics 
The Scottish Cancer Registry identified 4465 people diagnosed with lung cancer. The 
following were excluded from the audit; 115 diagnosed or treated outside Scotland, 79 not 
primary lung cancer, 18 an incidental finding at autopsy, 18 other reasons. Of the 4225 
potentially e1i ible cases, 370 had to be excluded because of inadequate medical records 91 
(inclu(: bng 102 death certificate only), leaving 3855 cases in the studý T (91.2')/, ) eligible cases). 
Of these 87 had the date of diagnosed recorded as either the end of 1994, for 28 at the 
beginning of 1996. 
Of the 3855 cases, 2341 (60.7%) were men, and the median age was 70 (range 34-97). Onlý 
57 (6.7 ", 'o) lived more than one hour's journey from a cancer centre. The distribution of the 
deprivation categories is shown in Table 4.1. As one would predict, more cases occurred in 
more depnVed areas. 
Table 4.1 Disttibution of depivation in the seven catego. Hes 
Carstairs 
Index 
1 2 3 4 5 6 7 
Number 141 393 734 988 649 556 394 
i 3.7 10.2 19.0 25.6 16.8 14.4 10.2 
The diagnosis was confirmed with histology in 51.6% cytology 20.1% (ante-mortem 
pathological confirmation rate of 71.7%). In 1456 (37.8%) cases, the tumour vvas located in 
the upper lobes, 719 (18.7%) the lower lobes, 142 (3.7%) right middle lobe, 390 (10.1%) 
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main bronchus or trachea, 263 (6.9'ý"()) more than one site and in 885 (23.0%) the site , vas 
unknown. 
Of the 28556 (74.1%) patients with pathological confirmation, 557 (19.5"o) had 
adenocarcinorna, 1106 (38.7'o) squamous cell, 678 (23.7%) small-cell, 180 (6.3%) large cell, 
2-56 (9", 'o) NSCLC-NOS, and 79 (2.8%) were found to have other patholo ical tý es. The 91 Yp 
patholo ical diagnosis N-vas, not obtained in 999 patients. For the purposes of analysis three 91 
groups NSCLC, SCLC and no pathology were formed. There were some differences in the 
gender and travel times for these pathological groups ()C2 with p<0.05), but not deprivation 
index (Table 4.2) 
Table 4.2 Distribution ofgender and travel times for the three pathologicalgroups 
NSCLC SCLC No patholop- 
Gender Male 1414 (64.9%) 356 (52.2%) 571 (57.2%) 
Female 764 (35.1%) 322(47.5%) 428 (42. W"O) 
Journey < 1hour 1984 (91.1%)* 625 (92.2%) 914(91.5%) 
>I hour 161 (7.4%) 37 (5.5 /, '0) 59 (5.9 /o) 
* Remaining patients did not have post-code recorded 
Staging information was available for 89.2% of the cases, with 964 (25.2%) of whole cohort 
presenting with localised disease, 32.7% regional, and 31.4% metastases. 
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2) Treatment 
As the patients with a 'death-certificate-only' diagnosis had been excluded from the original 
audit there were only 22 cases in this cohort where the date of diagnosis was the same as the 
date of death. These were excluded from the treatment analysis, leaving 3833 cases. 
i) Any treatment 
Of the 3833 patients, 548 (14.3%) received potentially curative treatment, 1638 (42.7%) 
palfiativc and 1647 (43%) no treatment. 
ii) Surgery 
443 patients (11.6%) of patient underwent an attempted resection, for 37 patients (8.3% of 
operations or 1% population) this was an 'open-shut' thorocotomy, and for 406 (10.6%) a 
cancer resection was performed. 
The majority of operations were performed in men (63%), with a median age of 64 (range 34 
to 82), on1v 8.6% bved more than one hour from a cancer centre and 37.1% of cases hved 
more affluent areas. 
Lobectomy was the most frequently performed resection, with 224 (5.8%) patients 
undergoing this type of operation, with 160 (4.2%) having a pneurnonectomy and 22 (0.6%) 
a segmentectomy or wedge resection. Forty patients died (9.0% of operations) within a 
month of their operation, giving a 14.4% post-operative mortality rate for pneumonectomý, 
5.8% for lobectomy and 8% for 'open and shut' thoracotomy. These rates are higher than 
most other pubfished series from this period [51]. 
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The pathological subtypes , vere as follows; squarnous cell 215 cases (48.5"', "0 operations) 144 
adenocarcinoma, 28 large cell, 43 NSCLC NOS and 13 SCLC. 
The detailed pathological stage (TN-, Nl 1997) for all the cases that underwent an attempted 
resection is shown in Table 4.3. 
Table 4.3 The disttibution ofpathological staginggroups 
N=443 IA IB IIA IIB IIIA IIIB IV LI 'N 0T 
RECORDED 
-Number 58 105 16 75 42 8 6 13 120 
% 13.1 23. ý 3.6 16.9 9.5 1.8 0.7 2.9 27.1% 
Table 4.4 includes the 406 resected tumours according to the more general staging and type 
of resection performed 
Table 4.4 Disttibution ofgeneral stage by operation type 
N=406 Localised (n) Regional (n) Metastatic (n) 
Segmentectomy 18 4 0 
Lobectomy 160 63 1 
Pneumonectorny 66 92 2 
Thirty-six patients with NSCLC received post-operative radiotherapy, 31 with a dose of 
greater than 40Gy. Most of these cases had stage IIB disease (41.71"'0) or 
IIIA disease 
(30.6%). Four patients received palliative radiotherapy within six months. Forty-two patients 
who had surgery also received chemotherapy within the 
first six-months after diagnosis. of 
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the I operated SCLC cases, two received adjuvant radiotherapy and chemotherapy, and 
four received chemotherapy alone. 
ii) Radiotherapy 
1400 (36.5'ý, ý, )) of patients received radiotherapy in the first six months f6flowing diagnosis 
(includim, chemoradiation for SCLC). The first course of treatment consisted of radical 
radiotherapy with a dose of ý-ý'50Gv for 94 patients (2.5% population, 3.0% of those with 
NSCLC or no pathology), pre- or post-operative radiotherapy 36 (0.9% population), 
adjuvant thoracic treatment or prophylactic cranial irradiation (PCý for SCLC 58 (1.5% 
population, 8.6",, "0 SCLC), palliative radiotherapy to the chest 1028 (26.8% population) and 
palliative radiotherapy elsewhere 184 (4.8% population). 
Forty-four patients had a radiotherapy intent described as 'radical', but the dose delivered 
was less than 50Gy (median 40Gy range 30-45) so the treatment was defined in this study as 
palliative. For the patients receiving radical radiotherapy the median dose was 52.5Gy (range 
50-60Gv), using a median of 20 fractions (range 20-30). For the 50 SCLC patients who 
received adjuvant thoracic radiotherapy, the median dose was 40Gy (range 30-50) using a 
median of 15 fractions (range 9-20). 
For the 1220 patient who underwent palliative radiotherapy, 225 (18.5%) died within a 
month of starting this treatment. 
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iii) Chemotherapy 
Chemotherapy was delivered to 621 patients, 16.2% of the population. For those with 
SCLC, 425 (63.1%) received chemotherapy (79.3% with a combination of agents) whereas 
onlN, 178 (8.4%) patients with NSCLC received chemotherapy (49% combination 
chemotherapy) and 18 (1.8%) patients with no pathology (56% cornhination chemotherapy). 
Eighty (13%) of the patients receiving chemotherapy died within a month of starting 
chemotherapy, 66 of whom had SCLC. 
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3) Treatment combinations by Pathological groups 
i) Small Cell Lung Cancer 
There were 674 patients with SCLC, of xx-hom 52", '0 had limited stage disease. However, onlý 
had a CT scan performed so there could be under detection of metastatic disease. 
The treatment combinations are shown in Table 4.5 
Table 4.5 Treatment delivered patients u4th SCLC 
Number % 
Surgery* offly 5 0. -1 
Surgerv* and chemotherapy 4 0.6 
Surgen-*, chemotherapy and post operative radiotherapy 2 0.3 
Chemotherapy and PCI (no thoracic radiotherapy) 8 1.2 
Chemotherapy and adjuvant thoracic radiotherapy 48 7.1 
Chemotherapy 312 4 6. 
Chemotherapy and palliative radiotherapy 51 7.6 
Palliative radiotherapy I1 10.0 
None 173 2 5.7 
*= Resection 
For the 351 patients with lin-lited-stage disease 59 (16.8%) received potentiaBy curative 
v, 224 therapy (surgery chemotherapy, or chemoradi 5 chemotherapy and PCI onlý 
(63.8%) palliative treatment (chemotherapy and/or radiotherapy) and 63 no treatment. 
Therefore, 252 (71.8%) of limited stage patients received chemotherapy. 
For the 286 extensive stage patients, 151 (52.8%) received chemotherapy (+/- palliative 
radiotherapy), 35 had palliative radiotherapy alone, and 100 had no record of any treatment. 
There were 37 unstaged patients of whom 22 (59.4%) were treated with chemotherapy (+/- 
radiotherapy), 5 radiotherapy alone, and 10 had no treatment. 
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As stated earlier, 32 patients with cxtensive stage SCLC who received chemotherapy, but 
died within a month of diagnosis, a 21% first cycle death rate. For the limited stage patients 
I died (12""0) within a month, and three unstaged patients. These rates are higher than other 
series from this era, when first cycle mortality rates of 10% for extensive stage disease and 
I 0, ý, 
-) 0 
for limited staged were obsenved in chrucal trials 
ii) Non-Small Cell Lung Cancer 
A total of 2168 patients were diagnosed with patholo icafly confirmed NSCLC. A CT scan 91 
, \\-, as performed in D9', 'o of this group of patients. Locatised disease was present in 36%, 32% 
regional, 261, "o metastatic, and for 6% the stage was unknown. 
The distribution of management is shown in Table 4.5. 
Ta ble 4.9 Trea tm en t delivered pa tien ts vvith NSCL C 
Number % 
Surgerv* onlv 315 14.5 
Surgery* and chemotherapy 40 1.8 
Surgery*, chemotherapy and post operativc radiotherapy 1 0.1 
Surgery*, chemotherapy and palhativc racbothcrapy 1 0.1 
Surgcry* and post operative radiothcrapy 35 1.6 
Surgcry* and radical radiotherapy 0 0 
Surgery* and palliative radiotherapý- 3 0.1 
Radical radiotherapy 77 3.6 
Radical radiotherapy and chemotherapy 2 0.1 
Palliative radiotherapy 808 37.3 
Chemotherapy 95 4.4 
Chemotherapy and palliative radiotherapy 39 1.8 
None 752 34.7 
*= Resection 
Potentially curative treatment (primary treatment surgery or radical radiotherapy) was used in 
21.9% of patients, 43.4% received palliative treatment and 34.7% no treatment. Table 4.6 
demonstrates the management intent broken down by the extent of disease. The differences 




Table 4.6 Intent of treatment broken down by extent of disease 
Localised Regional Metastatic Unknown Total 
potentially curative 298 168 7 1 474 
I 
0" 38.9 o 0 24.2,,, t) 1.2"', ) 0. " ? j. q()/' -0 
palliative 263 331 305 43 942 
30.5% 47.7% 53.5% 31.4% _ 43.5'' 
none 206 195 258 93 
26.9')/"o 28.1% 45.3% 67.9"1", ) 34.7% 
Total 797 694 1 570 137- F 2168 
)38 patients died within a month of diagnosis. Forty patients died within a month of surgery 
(37 after a resection and three after a thoracotomy), 141 within a month of starting 
palliative radiotherapy and 12 (7%) died one month after first dose of chemotherapy. 
iii) Patients without pathological confirmation 
A total of 991 patients did not have a pathological diagnosis. Localised disease was present 
in 19.9% of cases, regional in 21.1%, metastatic in 34.9% and the stage was unknown for 
24%. A CT scan was performed in 33% of this group of patients. 
The management is shown in Table 4.7. 
Table 4.7 Treatment delivered patients u4thout patholoeical confirmation 
Number % 
Radical radiotherapy 15 1.5 
Chemotherapy and palliative radiotherapy 3 0.3 
Chemotherapy 15 1.5 
Palliative radiotherapy 236 23.8 
None 722 7? .9 
A total of 337 of these patients died within a month. Fifty-nýine died within a month of 
starting palliatiVe radiotherapy and two after palliative chemotherapy. 
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4) Factors affecting use of treatment 
In order to explore which factors affected whether or not patients received treatment chi- 
squared and logistic re- ession multi-variate analyses were performed (see Table 4.8). Z-3 gr 
Patients were more likely to receive treatment if they were younger, had loco-re ional 91 
disease, had SCLC, lived in a more affluent area, or lived further than one hour's drive from 
a cancer centre. 
Table 4.8 Univaiiate and multivariate analysis offactors affecting the deKvery of 'any 
treatment-' 
ANY TREATMENT Yes No x2 Unad), usted Adjusted 
p value odds ratio odds ratio 
Gender Male 1358 (59%) 969 0.042 1 1 
Female 828 (55"/(ý) 678 0.9(0.8-0.99) 0.9 (0.8-1.07) 
Age <60 466(81%) 110 <0.001 1 1 
60-69 843(67%) 416 0.5(0.4-0.6) 0.52 (0.4-0.7) 
70-79 743(52%) 694 0.25(0.2-0.3) 0.31 (0.2-0.4) 
80+ 134(24%) 427 0.07(0.05-0.1) 0.1 (0.08-0.15) 
Distance <1 hour 1959 (56%) 1543 <0.001 1 1 
>1 hour 185 (72%) 71 2.0(1.5-2.7) 2.1 (1.5-2.9) 
Deprivation Cat 4-7 1432(56%) 1140 0.017 1 1 
Cat 1-3 754(60%) 507 1.2(l. 03-1.4) 1.3 (1.1-1.5) 
Pathology NSCLC 1416(65%) 752 <0.001 1 1 
SCLC 501(74%) 173 1.5(l. 3-1.9) 1.8 (1.4-2.2) 
No pathology 268(27%) 722 0.2(0.17-0.23) 0.3 (0.3-0.4) 
Stage Localised 614(64%) 350 <0.001 1 1 
Regional 877(70%) 377 1.3(l. 1-1.6) 1.0 (0.8-1.2) 
Metastatic 606(50%) 596 0.6(0.5-0.7) 0.5 (0.5-0.6) 
Unknown 89(22%) 324 0.15(0.1-0.2) 0.26 (0.17-0.31) 
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i) The effect of health board and region on treatment delivery 
In the previous publication by Erridge et al [62], it was noted that healthboard of diagnosis 
affected the use of treatment. Therefore an additional chi-squared additional analysis was 
conducted , -,, hich included healthboard and is shown in Table 4.9. The differences observed 
were statistically significant ()(2 p t:: ý0.001). 
Table 4.9 Proportion of patients receii4n-o, lanv treatment' bv healthboard of &aLynosis 





























No 12 135 ill 528 85 150 86 42 114 243 16 39 86 
For simplicity, and to allow comparison with current practice, the Health Boards were placed 
into three regions, which now form the three Scottish Cancer Networks; West of Scotland 
(WOSCAN), East of Scotland (SCAN) and North of Scotland (NOSCAN) (though these 
were not in existence in 1995). Patients living in Region 3 (NOSCAN) and Region 2 were 
much more likely to receive treatment than those in Re ion 1 (WOSCAN) 
(X2 P<0.001 for 91 
both comparisons) (Table 4.10) 
Ta ble 4.10 Proportion ofpa tien ts receAlbg "any trea tm en t' by 'Region -' 
Any treatment Re ion 1 (WOSCAN) 91 
(HB 2,3,4,5,6) 
Re ion 2 (SCAN) 91 
(HB 7,8,10,11) 
Re ion 3 (NOSCAN) 91 
(HB 1,9,12,13) 
Yes 1034 (50.6%) 636(62.2%) 516(67.3%) 
No 1009 387 251 
To investigate the potential reasons for this observation, the demographic characteristics for 
the three regions were examined and are shown in Table 4.11. Three-quarters of patients in 
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Region 1 lived in a deprived area compared with half the patients in Region 3. However, 
there were no differences in acre or gender. However, pathological confirmation and staging Z-7) 
-was more common in Region I than Region 3. 
Table 4, IlDisttibudon of patient and tumour related characteristics bv 'Reaion' 
RcOon I Reoion 2 RqZion 3 2 
Gender Nlale 1240 (60.7%) 603 (58.9%) 48ý (63.1%) P=0.20 
Female 80-33 (39.3"/()) 420(41.1%) 283 (36.9%) 
Age <60 305 (14.9%) 149(14.6%) 122(15.9%) P=(). 2-5 
60-69 700 (34.3', "t) 327 (32.0%) 232(30.2%) 
70-79 752 (36.8%) 401 (39.2%) 284(37.0%) 
80+ 286 (14.0%) 146(14.3% 129 (16.8"/o) 
Distance <1 hr 1952 (97.4%) 938(94.0%) 612(81.1%) P<0.001 
>1 hr 53 (20/6) 60(6.0%) 143(18.9%) 
Depnv'n Cat 4-7 1604 (78.5%) 595 (58.2%) 373(48.6%) P<0.001 
Cat 1--) 439 (21.5"ý)) 428(41.8%) 394(51.4%) 
Path NSCLC 1117 (54.7%) 603 (59.3%) 444(57.9%) P<0.001 
SCLC 370(18.1%) 183 (17.9%) 121 (15.8%) 
No pathology 556 (27.2%) 233(22.8%) 202 (26.3'/, -)) 
Stage Localised 580(28.4%) 265 (25.9%) 119 (15.5',,,, 'o) P<0.001 
Regional 654(32.0%) 346(33.8%) 254(33.1%) 
Metastatic 641 (31.4%) 296(28.9%) 265(34.6%) 
Unknown 168 (8.2%) 116(11.3%) 129 (16.8%) 
Therefore, the variable 'Region' was also inserted into the logistic regression model 
examining the factors affecting the use of treatment. Distance to cancer centre, pathology 
type, stage and Region were all significant predictors of the use of treatment, but gender and 
income were no longer statistically signIficant (see Table 4.14). This suggests that it may be 
healthcare orgamsation and resources issues, rather than social depriVation that influenced 
the use of treatment. 
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5) Use of notentiafly curative treatment 
The factors affecting the use of potentially curative treatment were exarruned in a 
multivariate analysis and are shown in Table 4.12. This demonstrated that younger patients, 
those with NSCLC or locabsed disease were more hkely to receive potentlafly curative 
therapy. 
Table 4.12 Univaiiate and multivariate analysis of factors affecting use ofpotentially 
curative treatment 
POTENTIALLY ý'es No X2 Unadjusted odds Adjusted odds ratio 
CURATIVE p value of PCT Of PCT 
Gender 'Male 344 (15', '()) 1983 0.30 1 1 
Female 204(14%) 1302 0.9(0. -, -1.1) 1.1(0.8-1.3) 
Age <60 150(26%) 426 <0.001 1 1 
60-69 257(20%) 1002 0.7(0.6-0.9) 0.7 (0.4-0.8) 
70-79 136(10%) 1301 0.3(0.2-0.4) 0.25(0.2-0.35) 
80+ 5 (1%) 556 0.03(0.01-0.06) 0.03 (0.01-0.07) 
Distance <1 hour 494(14%) 3008 0.038 1 1 
>1 hour 49(19%) 207 1.4(l. 04-2.0) 1.4(0.9-2.1) 
DepriV'n Cat 4-7 359 (14%) 2213 0.40 1 1 
Cat 1-3 189 (15%) 1072 1.1(0.9-1.3) 1.1(0.9-1.4) 
Patholop- NSCLC 474(22%) 1694 <0.001 1 1 
SCLC 59 (9%) 615 0.35(0.25-0.45) 0.6 (0.4-0.8) 
No pathology 15 (2%) 976 0.05(0.03-0-1) 0.1 (0.07-0.2) 
Stage Localised 309(32%) 655 <0.001 1 1 
Regional 229(18%) 1025 0.5(0.4-0.6) 0.4 (0.3-0.5) 
Metastatic 9 (1%) 1193 0.02(0.01-0.03) 0.02 (0.01-0.03) 
Unknown 1 (0.2%) 412 0.01(0.0-0.04) 0.01 (0.01-0.07) 
The model was then repeated to include the new variable 'Region' and age, pathology type 
and stage remained signIficant predictors as did 'Region' of residence (Odds ratios compared 
to Reglonl, Reglon 2 0.99 (NS) Reglon 3 1.66 (Cl 1.25-2.2, P=0.001)), but the differences 
seen were smaller than for the use of any treatment. 
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6) Factors affecting delivety of surgeM radiotherapy or 
chemotherapy 
i) Surgery 
On chi-squared analysis the only factors affecting use of surgery were age, pathology 
type and stage. With younger patients, those with NSCLC, or localised disease more likely to 
have had a resection (see Table 4.13). 
As discussed in the analysis of the Canadian patients, there is a potential issue that the extra 
information gained by surgery may bias the analysis, so it was performed with and without 
pathology and stage. When all the variables were used age, stage and pathology were 
significant predictors of having operation, as was deprivation with odds of undergoing 
surgery of 1.28 for the least deprived compared with the most deprived group (p=0.045). 
Hov-ever, when pathology and stage were removed from the model only age and social 
deprivation remained si ificant factors; possibly reflecting increased co-morbidity ý, "dth glu 
increasing age and poverty [128]. 
If pathology and stage were kept, and the variable 'Region' added to the model then age, 
, pe, and also 
'Region' were significant, with the odds of undergoing stage, pathology tv 
surgery 1.6 (1.2-2.2) for Re ion 3 compared with Re ion 1 (p=0.003). However, when 91 91 
Region 2 was compared with Region 1 the difference was non-significant. If the variables 
pathology and stage were then removed 'Region of diagnosis' was no longer a signIficant 
factor affecting the use of surgery With age and social depriVation the only factors affecting 
the use of surgery (Table 4.14). 
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ii) Radiotherapy 
On chi-squared analysis, patients were more likely to receive radiotherapy if they were 
vounger, had NSCLC, recional disease, if theý, were male, or thev lived further from a cancer 
centre (see Table 4.13). However, on multivariate analysis gender was no longer a significant 
factor for receiving radiotherapy, and onh, age, travefing time, pathology, and stage remained 
significant. 
Then, if the variable Region was added to the model traveling time was no longer a 
signiticant factor, but there was a significantly higher chance of receiving radiotherapy in 
Region 2 (OR 1.9 (1.6-2.3) p<0.001) and Region3 (OR 2.8 (2.7-3.4) p<0.001) when 
compared with Region I (Table 4.14). So, younger patients, those with NSCLC, those with 
mediastinal involvement and patients living out-with Re ion I were most likely to have 91 
received radiotherapy. 
iii) Chemotherapy 
On chi-squared and multi-variate analyses younger patients, those with SCLC and re ional 91 
stage disease were most likely to receive chemotherapy (see Table 4.13). The model did not 
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6) OveraU survival 
The median overall survival was 3.6 months, with sun7lval rate at one year 21.1"1/0, two years 
9.5"o and fivc years 4.9",,, ). The Kaplan Meler plot is shown in Figure 4.1. 
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Table 4.19 Factors affecting overall su^4val 
Median T Log rank Unadjusted Adjusted hazard 
survival P value hazard of death of death 
(months) 
Gender -i\ I ale 3.6 (3.3-3.9) 0.29 1 1 
Female 3.6 (3.2-4.0) 0.96(0.9-1.03) 0.9 (0.8-0.96) 
Age <60 6.1 (5.3-6.8) <0.001 1 1 
60-70 4.7 (4.1-5.2) 1.2(l. 04-1.3) 1.2 (1.1-1.3) 
70-80 3.2 (2.8-3.5) 1.6(l. 4-1.7) 1.6(l. 5-1.8) 
80+ 1.6 (1.4-1.9) 2.3(2.1-2.6) 2.3 (2.0-2.6) 
Distance to <1 hr 3.5 (3.2-3.7) <0.001 1 1 
Cancer centre >lhr 5.4 (4.1-6.7) 0.8(0.7-0.9) 0.8 (0.7-0.96) 
Deprivation Cat 4-7 3.5 (3.2-3.8) 0.008 1 1 
Cat 1-3 4.0 (3.5-4.4) 0.9(0.85-0.98) 0.9 (0.8-0.95) 
Pathology NSCLC 5.1 (4.6-5.5) <0.001 I I 
SCLC 3.7 (3.1-4.3) 1.4(l. 3-1.5) 1.1 (0.98-1.2) 
No pathology 2.0 (1.7-2.2) 1.9(l. 8-2.1) 1.4(l. 3-1.6) 
Stage Localised 8.2(7.3-9.2) <0.001 1 1 
Regional 5.4 (4.9-6.0) 1.5(l. 4-1-7) 1.6(l. 4-1.7) 
Metastatic 2.0 (1.8-2.2) 3.2(2.9-3.6) 3.4 (3.1-3.7) 
Unknown 1.5 (1.2-1.9) 3.0(2.6-3.3) 2.3(2.1-2.6) 
III 
On looý rank analysis Munger age, fiving in a less deprived area, a longer traveling distance I- Z-D 
were A associated with improved survival, along with NSC-LC patholog'y and locafised 
disease (Table 4.15 and figures 4.2a-e). In a multivariatc analysis male gender %vas associated 
with an increased risk of death, but SCLC was not. 
Figlliv 4.2a 
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There was also a difference in survival between the three Regions (figure 4.20; Region I 
median sun-ival 3.2 months (2.9-3.5) Region 2,4.1 months (3.5-4.6) and Region 3,4.2month 
(3.7-4.8) (Log rank P<0.001). 
If the variable 'Recrion' was then added to the Cox's regression model then 'ourney distance 
was no longer significant, but there was a significant reduction in the risk of death in Region 
2 (OR 0.87 (0.80-0.94)) and Region 3 (0.78 (0.71-0.86)) when compared with Region 1. 
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7) OveraR survival and treatment 
P<0.001 
A total of 548 patients in the cohort received potentiafly curative treatment and their median 
survival was 20.9 months (95% Cl 18.3-23.5), with an ovcrafl survival rate of 69.2%, 46.5% 
and 29.5ý/o at one, t-\vo and five years respecfively. For the 1638 patients who recelved 
palhative treatment the median survival was 5.0 months (4.7-5.3), with 18.8% sun-i-vinc), one (t) 
vear and 4.4% two years. For the 1647 patients who received no treatment the median 
sur-vival was 1.4 months (1.3-1.5), with a one year overall survival rate of 7.7%, and at two 
\T cars 2.4%. 
To further analyse the factors that could have had an impact on survival in each 'treatment 
intent' group, a Cox's regression model was conducted. The results are shown in Table 4.16. 
The variable 'Region' was then added to each of the models. For those patients that ZI 
received 'anv treatment' there was a significant difference in the hazard ratio of death Z-) 
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bet-, veen the regions (Region 2 0.86 (0.77-0.95) and Re 'on 3 0.84 (0.75-0.94) compared with , ý71' 91 
Region 1). 
For the patients treated with 'potenti-afly curative treatment', there was a sigrnificant reduction 
in the hazard ratio of death for Region 2 (0.71 (0.56-0.9) when compared with Realon 1, but 11 
not for Region 3 (figure 4.3). 
For the 'no treatment' g-roup there was no difference between the Regions. 
Figure 4.3 
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1) Survival after potentially curative therapy 
Resection 
For the 406 patients who underwent a resection, the median sunival was 26.2 months (21.2- 
31.2) with a one-year overall survival of 69.7%, two-vear 52.9% and five-year 35.9",,, o. The 
sun-IN-al by detailed stage (when TNNNI available) and the alternative broader groups shown in 
Table 4.1 -17 and figure 4.4. 
Table 4.17 Overall survival following surgery by stage 
number median 1 year 2 year 5 year 
Stage 1 163 64.6(45.9-83.4) 80.3", "() 7() 52.2 o 
Stage 11 91 24.1 (17.5-30.6) 68.1% 51.9% 28 . 70() 
Stage 111 48 9.4 (7.0-11. -ý 3 7.5(-), f, 12.50"() 8.3% 
Stage IV' 3 17.8 (9.9-25.7) 66% 33% - 
Unknown* 90 18 .7 (12.3-25.1) 64.4% 43.3% 31.1% 
Localised 244 45 (26.2-63.8) 75% 62% 45.9% 
Regional 159 15.5 61% 39.6% 21.4% 
Metastatic 3 17.8 (9.9-25.7) 66% 33% - 
*Remaining 11 limited stage SCLC 
Tatients with solitary brain metastases or found to have a nodule in different lobe of lung at pneumonectomy 
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To investigate further the difference bctwccn the Regions in the sunival of patients 
follo-wing potentially curative therapy (Figure 4.3), a log rank test ý, vas performed for the 406 
patients A, -ho had undergone a resection and results are shown in Table 4.18 and figure 4.5. 
Patients from Region 2 who had their cancer resected had signific-antly longer survival 
(p=0.018) than the combined group from Region 1 and Re 'on 3. In a Cox's regression 91 
model increasing age and stage were associated with an increased hazard of death, as was 
Region of diagnosis (Region 2 0.7 (0-5-0-9) and Region 3 0.8 (0.6-1.1) compared with Region 
1). 
Table 4.18 Overall surv4val oftesectedpatients by Region 
NLlccb-, -In surviv-'d 
(months) 
I month I vear 5 vc-ar 
Rcgion 1 (n=216) 21.9 (16.4-27.5) 93.9,, o o 65.3,0 3 1.8'-, 
Region 2 (n= 103) 42.6 (19.4-65-9) 99.30, "0 66.0'1,,,, 42.7",, 
Region 3 (n=87) 2-5.3 (19.8-30.7) 96.5(ý o 72.4" 0 ') --). 6 (1 , 
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The post-operativc mortafity rate (37 post-resection and 3 post-thorocotomy) was 14.7"//o' in 
Recrion 1 compared with 5.7% in Re 'on 3 and 3% in Region 2 (Chi-squared p=0.02, Log 91 
rank comparing survival p=0.002) which could have had a major impact on the numbcr of 
long term survivors. Though the difference in post-operarn-c mortality might be partly 
explained by the fact there were fewer pneumonectomies performed in Region 2 (34%), 
compared with Re *on 1 (40%) and Region 3 (4401/0). The mortafity following 91 ZI-) 
pncumonectomy in Re ion 2 at 6% was also lower when compared with 20% in Re ion 1, 91 91 
and 10% in Region 3. 
When -a multivariate analysis was performed examininc, the factors that could be associated 
with increased post-operative mortality (including age, gender) deprivation (as either 
dichotomous or categorical variable) and Re ion), only 'Region' and age over 70 years lwcrc 
associated with higher risk of death within one month of surgen-. ý7) , 
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If the 37 patients who died within a month of resection were excluded from the analys's then 
the survival was not statistically different between the Regions (median survival Region 2 
42.7 (14.7-70.6) Region 1+3 28.5) (22.9-34.1) log rank P=0.11) (figure 4.6) and in a Cox's ý7) 
recyression model only pathological stage was associated with an increased hazard of death. ý7) 
Therefore it appears that the high post-operative mortafity was one of the most significant 
tactors in the IoNver survival in patients undergoing potent-laRy curative therapy in Region 1. 
Fig-Lire 4.6 OveraH survival following surgery after exclusion of patients dying with a month 
of surgery 
Overall survival excluding 
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2) Radical Radiotherapy 
There were 94 patients who received radical radiotherapy. This group had a median survival 
of 16.6 months (12.6-20.4) and an overaU surVival of 66% at one year, 29.8"/", ) two years and 
10.6% five years (figure 4.6). If the survival by LRM stage was examined, the 65 patients 
with localised disease had a median survival of 19.7 months (18.1-21.3), the 22 with regional 
disease 8.8 months (6.4-11.02), and the six patients with metastatic disease 6.6 months (0.1- 
13.8). For the 59 cases with limited stage SCLC treated with curative intent, the median 
survival was 15.3 months (13.8-16.8) with a one-year overall survival rate of 67.8% and at 
five years 10.1%. 
For those patients who received radical radiotherapy for NSCLC, only living in a less 
depnVed area (median survival 28.2months (10.9-45.5) v 16.1months (12.7-19.39) log rank 
p=0.02) and presenting With localised disease (median surviVal 21.6months (16.8-26.4) v. 
regional 9.5months (6.7-12.2) log rank p<0.001) predicted for improved survival on uni- 
variate analysis. On Cox's regression analysis without the variahle 'Region' the hazard for 
death was reduced for women (HR 0.46 (0.3-0.8), those fiving in more affluent areas (0.4 
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2) Survival by treatment modality 
Table 4.19 shows the factors affecting survival for each of the three treatment modalities. 
For patients v, -ith SCLC who received chemotherapy the median survival was 6.4months 
(5.6-7.2months), with 3-')"'', ) of the limited stage patients alive at one year, 8% at two-years 
and ')', ) at five years. For the -NSCLC patients who received paUiative chemotherapy the 
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Summary of results 
422-5 lung cancer cases were identified, of whom 3855 cases (91.20/0) had sufficient data 
to conduct the audit. 
o Of the 3855 cases 60.7% were male and the median age was 70. 
The pathological confirmation rate was 72%, N-,, -lth 20% adenocarcinoma, 39"'() squamous 
cancer, 24', ýO small cell, 60, /0 large cell and 11% other types of NSCLC. 
25"o of patients had localised disease, 33% regional, 31% metastatic, and in 11% the 
stage Nvas unknown. 
0 Of the remaitung 3833 patients, 14% were treated with curative intent, 430, /o received 
palb-ative treatment and 43% received no treatment. 
e The resection rate was 11 %. 
* 37% of the population received radiotherapy during the first sl-.,, months following 
diagnosis, but only 3% of the population received radical radiotherapy 
* 16% of the population received chemotherapy, 63% of SCLC cases and S",, () NSCLC 
9 Patients were more likely to receive treatment if they were younger, had loco-regional 
disease, had SCLC, or lived more than one hour's drive from a cancer centre. There were 
significant variations in the use of treatment between healthboards areas with an adjusted 
odds ratio of 3.0 for receiving any treatment for patients in North of Scotland compared 
with those hving in the West of Scotland 
Younger patients, those with NSCLC, and those with localised disease were most likely 
to be treated with curative intent. There were also significant differences between the 
Regions with an adjusted odds ratio of 1.6 for patients from North of Scotland 
compared with those living in West of Scotland. 
126 
* Surgerý T was more commotAy used in younger patients and those living in more affluent 
areas. There were no Re ional variations in use of surgery. 91 1 
Radiotherapy -was more likely to be given to younger patients, those xith re ional 91 
disease, NSCLC, and between the Regions. Patients from North of Scotland had an odds 
ratio of 2.8 for receiving radiotherapy compared with those from the West of Scotland. 
Chemotherapy was more hkely to be dehvered to younger patients and those with SCLC. 
There vvere no Regional differences in the use of chemotherapy. 
* The median overall survival was 3.6 months with the survival rates of 21%, 9.5% and 
4.9% at 1,2 and 5 years, respectively. 
* Younger age, being female, living in more affluent area and having the diagnosis 
patholo ically confirmed were all associated with longer surVival. 91 
0 There also appeared to be improved survival for those patients living in North and 
South-East of Scotland when compared with the West of Scotland. 
0 For patients undergoing a resection for their lung cancer the median survival was 26.2 
months, with 36% alive at five years. Patient in the West and North of Scotland had 
lower odds of sunival after surgery than those in South-East Scotland, but this appeared 
to be primarily due to a high rate of post-operative mortality, particularly in the West of 
Scodand 
0 Following radical radiotherapy for NSCLC the median surviVal was 16.6 months with 
10.6% alive at five years, and following cherno-radiation for SCLC the figures were 15.3 
months and 10.1%. 
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CHAPTER 5 
Comparison of patient and tumour 
characteristics, treatment and survival for 




The two datasets described in the previous two chapters were combined to enable 
comparison of patient and tumour related features, treatment and sunival in Canada and 
Scotland. This file included 3833 Scots and 20-173 Canadian patients. In order to make the 
populations as comparable as possible neither cohort contains any 'death-certificate-ordy' 
patients, and those who died the day they were diagnosed were also excluded. 
Data on patient and tumour characteristics were compared using chi-square tests. Factors 
attecting treatment delivery were compared with chi-squared tests and logistic regression 
analvses, and survival using log rank tests and Cox's proportional hazards regression model. 
As discussed in the previous chapters any p-values between 0.05 and 0.01 should be treated 
with caution due to the number of analyses performed. 
Results 
1) Characteristics 
The patient characteristics are shown in Table 5.1. The patients diagnosed in BC were 
younger than those in Scotland, a result that remained statistically significant when age Nvas 
examined as a continuous variable and compared using ANOVA (p<0.001). However, as 
demonstrated in figure 5.1, the differences are subtle. 
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Table . 5. lComparison ofpatient and tumourrelated factors in BC and Scotland 
BC Scotland Cl-ii-squared 
Malc Gender T 1215 (58.6(), () 2 _3 )77 
(6 0.7 P=(). 12 
Female 858 1506 
A(re <60 424 (20.5%) 576 (15.0('/, )) P<0.001 
60-69 626 (-')0.2"//()) 1259 (32.8%) 
-70-79 735 (3 5'. 5 (Vo) 1437 (37.5%) 
80+ 288 (13.9%) 561 (14.6", 4)) 
Travel acceptable 1477 (71.3()//0) 3502 (9 3.2')/", )) P<0.001 
not acceptable 594 256 
Least deprived 906 (43.7"/', )) 1261 (39//o) P<0.001 
Most deprived 1165 2572 
Pathology NSCLC 1540 (74.30, /"0) 2168 (56. W/o) P<0.001 
SCLC 306 (14.80/0) 674(17.6%) 
No pathology 227 (11.0%) 991 (26.9%) 
Stage Localiscd 498 (24.00/, )) 964(25.2%) P<0.001 
Reglona. 1 538 (26.0"/(, ) 1254 (32.7()/ý)) 
Metastatic 756 (36.5()/o) 0" 1202 (31.4,, o) 
Unk-no-wri 281 (13.6%) 694 (11.8%) 













22 34 38 42 46 bU b4 bb UZ 00 IU /4 to 0, -- ov - I- 
age at diagnosis 
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As one , vould expect vith the geography of BC, more patients hvcd a si 'ficantly longer I gnI 
distance from a cancer centre in BC (28.3% >2 hours) than in Scotland (6.8% >1 hours). 
Fewer patients underwent pathological confirmation in Scotland (74%) than in BC (89",, "0). In 
Scotland 647 patients (18%) had SCLC compared with 306 (15%) in BC. There were also 
&fferences in the subtypes of NSCLC, with 51% of Scots having squamous ceR carcinoma 
and -')5", ) adet-iocarcinoma compared with 31% and 41% of British Columbians, respectively 
(X' P<0.001). 
In BC 7 4% of patients had a CT scan performed, but in Scotland only 48% had this 
procedure. Therefore it is probable that the apparently smaller proportion of patients with 
Stage IV disease in Scotland (31 v. 37/ "1 0) was simply due to under-detection of metastases. 
HoNvever, as shown in Table 5.2 the differences in the stage for the patients who had had a 
CT scan was also significantly different ()(' p<0.001), but in both countries fewer patients 
with clinically obvious stage IV disease underwent a CT scan, so this cannot be the onlý, 
explanation. 
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Table 9.2 Disttibution of stage by CT scanning, country andpathological type 
BC Scotland BC Scotland 
no scan no scan with scan with scan 
NSCLC Locallsed 70(20%) 299(34%) 375 (31%) 468 (377 ' 
', 
,) 
Regional 50 (15%) 178(20%) 359 (3( 
- 
5016(40%) 
'Metastatic 138(41%) 301(34%) 316(31%) 269 (2l'),,, /(, ) 
L'nknov, -n 83(24%) 113(13%) 1 94 (8(Yo) 24(2%) 
SCLC Limited 0" 15 (20. o) 212(49%) 96(41%) 139 (51 
Extensive 51 (70%) 188 (43%) 117 (50 )) 98(41%) 
Unknown 7 (10%) 33 (8%) 20(9%) 4(2%) 
No Locahsed 30(23%) 132(20%) 23(24%) 65(20%) 
patholoo, - Regional 10(7%) 95 (14%) 13(14%) 114(35%) 
Metastatic 45(34%) 225 (34%) 29(31%) 121 (37%) 
Unknown 48(36%) 210(32%) 29(31%) 29(9%) 
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2) Treatment 
There -was significantly greater use of treatment in BC than Scotland. Most importanth-, 
more patients -\vere treated with curative intent; 6D",, "(, of British Columbians with early stage 
lung cancer received potentially curative therapy compared with 32% of Scots 
(X2<0.001) 
(see Table 5.3). 
Table 5.3 Proportion of patients underevin-a treatment in BC and Scotland 
BC Scotland Chi-squared 
Treatment 1372 (66.2%) 2186 (57%) P<0.001 
No treatment 701 1647 
Potentia1lý- curative 546(26.3%) 548 (14.3%) P<0.001 
None/Palliative 1 1527 3285 
Surgery 438(21.1%) 406(10.6/o) P<0.001 
No surgery 1635 3227 
Radiotherapy 836(40.3%) 1400 (36.5()'o) P=0.004 
No radiotherapy 1237 2433 
Chemotherapy 368 (11.8%) 621 (16.2%) P=0.13 
No chemotherapy 11105 3212 
The use of the three treatment modahties in the two countries for each patholog 1 groUP is '71Y 
shown in Tables 5.4a-c. The difference in the use of potentially curative treatment for 
NSCLC was due to a much higher proportion of patients undergoing resection. The radical 
radiotherapy rates were siMilar; 2.1% in BC and 2.5% Scotland. 
Table. 5.4a Proportion of use of treatment for NSCLC in BC and Scotland 
BC Scotland Chi-squared 
NSCLC 
Surgery 425 (27.6%) 395(18.2%) P<0.001 
No surgery 1115 1773 
Radiotherapy 649(42.1%) 966(44.6%) P=O. 1 -5 
No radiotherapy 891 1202 
Chemotherapy 133 (8.6%) 178 (8.2%) P=0.67 
No chemotheraýp_y 1407 1990 
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Table 9.4b Proportion of use of treatment for SCLC in BC and Scotland 
BC Scotland Chi-squared 
SCLC 
Surgery 8 (2.6()0) 11 (1.6%) P=0. ')') 
170 
surgery 298 663 
Radiotherapy 160 (52. o 180 (26. 7 P<0.001 
. \o radiotherapy 160 494 
Chemotherapy 231 (75.5'), /0) 425 (63.1%) P<0.001 
No chemotherapy 75 249 
Table 9.4cPropo-ttion of use of treatment for 'no pathology'in BC and Scotland 
BC Scotland Chi-squared 
No pathology 
Surgery N/A N/A N /A 
No surgen- 
Radiotherapy -7 -, (11.9%) 254(25.6%) P<0.001 
No radiotherapy 200 737 
Chemotherapy 4 18(l. 8%) P=1.0 
No chemotherapy 223 1196 
To investigate if the differences in patient and tumour characteristics could explain the 
increased use of treatment in BC a multi-variate logistic regression analysis was performed 
(see Table 5.5). This demonstrated that even when differences in age, staging and pathology .L 
were taken into account, patients in BC were sign1ficantly more hkely to receive 'any 
treatment' or 'potentially curative treatment'. The results changed little if just the CT staged 
patients were entered into the model. 
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Table 9.9 Multivaiiate analysis of factors affecting the use of 'any treatment' and 
potentially curative treatment' 
Unadjusted odds Adjusted odds Unadjusted odds Ad), usted odds 
ratio of any ratio of ratio of PCT ratio of 
treatment anN, treatment PCT 
BC 1 1 1 
Scotland 0.7(0.6-0.8) 0.7(0.62-0.82) 0.47(0.41-0.53) 0.4 (0.3-0-5) 
'N tale 1 
Female 1.0(0.8-1.1) 1.0(0.9-1.1) 1.0(0.9-1.2) 
<60 1 1 1 1 
60-69 0.5 (0.4-0.6) 0.6(0.5-0.7) 0.8(0.7-0-9) 0.7(0.6-0.9) 
70-79 0.28 (0.23-0.33) 0.35(0.3-0.4) 0.5(0.4-0.6) 0.4(0.3-0.5) 
80+ 0.09 (0.07-0-11) 0.13(0.1-0.2) 0.09(0.06-0.13) 0.08(0.05-0.13) 
Travel acceptable 1 1 1 1 
not acceptable 1.3(l. 1-1.5) 1.1(1.0-1.4) 1.6(l. 4-1.9) 1.2(0.9-1.5) 
Most deprived 1 1 1 1 
Least deprived 1.3 (1.1-1.4) 1.3 (1.2-1.5) 1.3(l. 1-1.5) 1.3 (1.1-1.5) 
NSCLC 1 1 1 1 
SCLC 1.6 (0.4-1.9) 2.0 (1.6-2.3) 0.5(0.4-0.6) 1.0 (0.8-1.3) 
No pathology 0.16 (0.1-0.2) 0.3 (0.2-0.3) 0.06 (0.03-0.08) 0.1 (0.1-0.2) 
Local-ised 1 1 1 1 
Regional 1.2(0.05-1.4) 0.9 (0.8-1.1) 0.45(0.4-0.5) 0.35 (0.3-0.4) 
Metastatic 0.6 (0.5-0.7) 0.4 (0.4-0.5) 0.01 (0.0-0.02) 0.0 
Unknown 0.12(0.1-0.16) 0.1 (0.1-0.2) 0.0 (80-0.1) 0.08 (0.06-0.13) 
VvIen individual treatment modalities were examined in a logistic regression model the use 
of surgery and chemotherapy was sigiuficandy higher in BC than Scotland, but the use of 
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The median survival for the Scottish patients was 3.6months (3.4-3.9), and in BC 7.3months 
(6.8-8.0) Oog rank p<0.001 figure 5.2). 
Figure 9.2 Overall survival 









12 24 36 48 60 
P<0.001 
As previously demonstrated in the analyses of the indl'\Tldual counties, shorter survival was 
obsen, ed for older patients, male patients, those living in more deprived areas or closer to a 
cancer centre, patients with no pathology, or with more advanced-stagc disease Oog rank 
P</= 0.001 for all, see Table 5.7). 
In the Cox's regression model these factors, except distance to cancer centre, remained 
statistically significant (p values </=0.001 see Table 5.7). The hazard of death for lung 
cancer patients hving in Scotland in 1995' was 1.6 times that of the BC patients even when 




Table 5.7 Univariate and multivariate analysis of factors affecting survival 
5906 Nfe cha n Log rank Unadjusted hazard Adjusted hazard 
(months) P value ratio of death ratio of death 
BC 7.4 (6.8-8.0) <0.001 1 1 
Scotland 3.6 (3.4-3.9) 1.5(l. 4-1.6) 1.6 (1.5-1.7) 
N fale 4.6 (4. 
-' )-5.0) 0.001 1 1 Female 4.9 (4.5-5.3) 0.91(0.86-0.96) 0.9 (0.8-0-9) 
<60 7.6 (6.8-8.4) <0.001 1 1 
60-69 5.9 (5.4-6.4) 1.15(l. 1-1.2) 1.2 (1.1-1.3) 
70-79 4.0 (3.6-4.4) 1.5(l. 4-1.6) 1.5 (1.4-1.7) 
80+ 2.2 (1.9-2.5) 2.1(1.9-2.3) 2.0(1.8-2.2) 
Travel acceptable 4.4 (4.1-4.6) <0.001 1 1 
not acceptable 7.1 (6.3-8.0) 0.77(0.71-0.83) 0.9 (0.8-1.0) 
Most deprived 4.4 (4.0-4.6) <0.001 1 1 
Least deprived 5.4 (4.9-5.9) 0.89(0.84-0.94) 0.9 (0.86-0.96) 
NSCLC 6.2 (5.8-6.5) <0.001 
SCLC 4.8 (4.2 - 5. ' )) 1.4(l. 3-1.5) 1.1(0.98-1.2) 
No patholog 2.1(1.8-2.3) 2.1(2.0-2.3) 1.5 (1.4-1.6) 
Localised 11.8 (10.6-13.1) <0.001 
Regional 6.9(6.5-7.4) 1.6(l. 5-1.7) 1.7 (1.6-1.8) 
Mctasta6c 2.5(2.4-2.7) 3.3(3.0-3.6) 3.7 (3.4-4-0) 
Unknov-n 2.0(1.7-2.3) 2.8(2.6-3.1) 2.5 (2.3-2.8) 
To ensure that difference in the proportion of CT-staged patients between the two countries 
had no impact, the Cox's regression model was then repeated including just the 1847 Scots 
and 1526 Canadians who had been CT-staged. Even for this completely staged group of 
patients, the hazard ratio of death was increased in Scotland (1.4 (1.3-15) P<0.001), as it was 
for all the other variables, except travel times. 
If the model was repeated for just the CT staged patients with NSCLC (n=2476) there were 
no differences in the adjusted hazard of death between the pathological subtypes 
(adeno carcinoma, squamous cell, large cell v NSCLC NOS) but the adjusted hazard of death 
for Scotland was 1.37(l. 2-1.5). 
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Cause svecific survival 
A total of 1869 (90.21',, )) of the British Columbian patients died within five years of diagnosis, 
1667 (89' o) of lung cancer and 202 (11%) of other causes, whereas 3370 (96%) of the 
Scottish patients died, 3067 (91%) of lung cancer. 
The hazard of death from lung cancer within five years of diagnosis was 1.6 times greater in 
Scotland than in BC (Table 5.11) 
Table 9.11 Cox's regression model of cause specific survival 
N= 5906 Unadjusted hazard ratio of Adjusted hazard ratio of 
lung cancer death lung cancer death 
BC 1 1 
Scotland 1.55(l. 45-1.64) 1.62 (1.52-1.73) 
NHC 1 1 
Female 0.93(0.88-0.98) 0.90 (0.85-0.96) 
<60 1 1 
60-69 1.1(1.02-1.2) 1.13 (1.04-1.23) 
70-79 1.4(l. 3-1.6) 1.49 (1.37-1.62) 
80+ 2.0(1.8-2.2) 1.98 (1.78-2.20) 
acceptable 1 1 
not accept able 0.75(0.69-0.81) 0.89 (0.82-0.97) 
Most deprived 1 1 
Least deprived 0.88(0.83-0.93) 0.90 (0.85-0.95) 
NSCLC 1 1 
SCLC 1.5(l. 5-1.6) 1.04 (0.96-1.12) 
No pathology 2.1(1.9-2.2) 1.44 (1.33-1.55) 
Localised 1 1 
Regional 1.7(l. 6-1.9) 1.82 (1.68-1.98) 
I-Metastatic 3.6(3.3-3.9) 4.05 (3.73-4.41) 
Unknown 2.8(2.5-3.1) 2.53 (2.27-2.82) 
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Relative Survival 
One of the potential explanations for a variation in survival observed between two countries 
is different profiles of disease. Cox's proportional hazard regression analysis adjusts for 
different age profiles witlýn populations, but does not account for age-specific differences in 
all cause mortality between countries. For example in 1995, a sixty-five vear old male in BC 
had a life expectancy of 16.9 years compared with 13.8 years for a Scottish man of the same 
age. 
In order to adjust for tl-iis the relative survival, which calculates the excess mortality in a 
group of patients compared with the whole population, was calculated using the technique 
described by Dickman et al[521'. The life-Tables for British Columbia and Scotland covering 
the period of the study were obtained and used to calculate the expected survival of each 
group taking into account the gender and age distribution within each cohort. The survival in 
the two populations was then compared. 
The one, two and five-year survival figures are shown in Table 5.8a and figure 5.3. It can be 
seen that patients With lung cancer in Scotland had a markedly inferior survival even when 
differences in general all cause mortality in BC and Scotland were taken into account. 
Table 5.8b shows the five-year survival broken down by age and gender. The survival rates 
were superior in BC for all groups except women over the age of 80. 
Tcrformcd bv Dr Linda Williams, --, \fcdical -Statistics Unit, Urýversitv of Edinburgh 
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Table 9.8a Relative suri4val rates for Scotland and BC 
1 
-year 2- vear five-vear 
Scotland 
(n =38 ') -'» 
22 0 (21-24 0) 10 "/o (9 - 11 0/o) 6% (5 -7 
Brlüsl-i 
Columbla (2 1-2 12% (10-14'ýý) 
/n= 2070) 
Table 5.8b Five-year relative sun4val rates bygender andage group 
Five-year relative survival Scotland BC 
Male <60 10.2% 13.3% 
60-69 7.6"//i) 11.6% 
70-79 4.0% 8.5% 
80+ 0.7% 6.6% 
Female <60 8.6% 16.9% 
60-69 9.4% 20.1% 
70-79 3.0% 11.3% 
80+ 3.1% 2.4()//o 














To explore the data further, a relative survival model -,, N, -as estimated using four different 
methods as described by Dickman et al[52]. They differ in the manner in which the data are 
entered and the assumptions about the data used. The results are shown in Table 5.9. 
Table 9.9 Risks of death using the four models described by Dickman et a] 
Grouped Exact times 
Binary Poisson Individual data Collapsed times 
Deviance 88.7 72.1 116.7 
Residual df 70 70 70 
EstillIated evcess ha. Zard ratios (p-mbe) 
Follow up 1/51 9.58 (<0.0001) 8.64 (<0.0001) 10.52 (<0.0001) 10.58 (<0.0001) 
Follow up 2/5 4.99 (<0.0001) 4.96 (<0.0001) 5.11 (<0.0001) 5.14 (<0.0001) 
Follow up 3/5 2.33 (<0.0001) 2.38 (<0.0001) 2.35 (<0.0001) 2.37 (<0.0001) 
Follow up 4/5 1.66 (0.0089) 1.68 (0.0093) 1.68 (0.0068) 1.70 (0.0060) 
Female/-', \Iale 0.93 (0.0220) 0.96 (0.1344) 0.93 (0.0304) 0.93 (0.0150) 
60-69/<602 1.03 (0.4479) 1.02 (0.6580) 1.09 (0.0447) 1.09 (0.0441) 
70-79/<60 1.31 (<0.0001) 1.20 (<0.0001) 1.44 (<0.0001) 1.45 (<0.0001) 
80+/<60 1.72 (<0.0001) 1.34 (<0.0001) 2.11 (<0.0001) 2.12 (<0.0001) 
BC/Scotland 0.67 (<0.0001) 0.74 (<0.0001) 0.62 (<0.0001) 0.62 (<0.0001) 
IRatio of risk of death in first to fifth ycar following diagnosis 
2Ratio of risk of death compared to patients aged <60 
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These models demonstrated: - 
a) The excess risk of death was much greater in the first two years foHowing 
diagnosis. 
b) The main excess risk was observed in the oldest group of patients; those 
over 80 had an excess lung cancer mortality was around twice that of the 
youngest group of patients. 
c) When the increased life expectancy of women in the general population was 
taken into account women stiR had a reduced hazard of death compared with 
men. 
d) When differences in overall life-expectancy were taken into account, the 
hazard of mortality in BC was about two-thirds that of the Scottish patients. 
143 
4) Possible explanations for the inferior overaH survival in Scotland 
The question is therefore, was the inferior survival of the Scottish patients simply due to 
under-use of treatment? In order to take account for the lower use of treatment an additional 
\-, ariable, 'treatment intent' (none, potentially curative, palliative), was added to the Cox's 
regression model examining factors influencing hazard of death from all causes (overall 
surNTIVal). This had no impact (hazard ratio death Scotland v BC (1.5 (1.4-1-6)). The 
difference in the hazard ratio of death hetween the two countries also remained significant 
when only the CT staged patients were included in the model. 
The sunTiNI-al for patients in Scotland was significantly worse on univariate and multivariate 
analyses regardless of treatment intent; potentiaflý- curative therapy hazard ratio death 1.3 
(1.13-1.51) (figure 5.4a log rank p=0.001), palbative treatment hazard ratio death 1.42 (1.3- 
1.56) (figure 5.4b p<0.001), and no treatment hazard ratio of death was 1.48 (1.34-1.64) 
(figure 5.4c p<0.001). The median, one, two and five year survIval rates are shown In Table 
5.12. 
Table 9.12 Surv4val rates in BC and Scotland by treatment intent 
Median (months) 1 year 2 vear 5 year 
Potentially curative BC 34.0 (29.4-38.5) 77',,, 0 60% 34% 
Therapy Scotland 20.9 (18.3-23.5) 68% 46% 29% 
Palliative treatment BC 6.3 (5.8-6.8) 23% 8% 2% 
Scotland 5.0 (4.7-5.3) 19% 4% 1% 
No treatment BC 2.5 (2.1-2.8) 21% 9% 2% 
Scotland 1.4 (1.3-1.5) 8% 2% 0.1% 
The treatment modality used had no impact; patients in Scotland had an increased hazard of 
death for all treatment types (surgery HR death 1.3 (1-1-1.6), radiotherapy 1.5 (1.4-1.6), 
chemotherapy 1.5 (1.3-1-8)). 
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So if it was not just the increased use of treatment in BC that accounted for the superior 
survival Nvere there any other patient or turnour related factors that could have contributed? 
Unfortunately data on some important factors, -,, vhich are L-no-\N-n to predict for overall 
sunlival in lung cancer, such as performance status and co-morbid diseases [190,205], x-vere 
not recorded -with sufficient frequency and accuracy to be used in this analysis. 
However, patients who undergo surgery for lung cancer generally have a better performance 
status and less co-morbidity so by e--,, amining the survival for this group the variability of 
these factors should be mirlimised. Therefore, further logistic regression and Co-x's 
regression analyses were performed including 'lust the 844 patients who had had surcrerv t()r C, , 
their lung cancer (Table 5.13). 
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Comparison of surgical patients 
In order to ensure as accurate as possible staging a more detailed staging system was used for 
this analysis. Of the 844 surgical cases, detailed staging (patholo ical TN-Nf) was available for 91 
719 patients. For the remaining 129 cases, the 84 labeUed as having localised disease' were 
reclassified as 'Stage F, and the 9 with 'regional' disease as Stage III, leaving just 36 (4%) with 
unknown staging. In the Scottish audit the definition of local-ised and regional disease 
depended on nodal status, so a T4NOMO tumour mav have been recorded as locabsed, but in 
the process above would be inadvertently called this Stage I rather than Stage III. 
Ta ble 9.13 - Univaiia te an dm ultivaiia te an alysis of s urt4val of th e pa den ts un der 
, Zoin, Z a -resection Median (months) Log rank Unadjusted Adjusted hazard 
N=844 P value hazard of death ratio of death 
BC 40.9 (35.1-46-6) 0.018 1 1 
Scotland 20.1 (20.0-28-5) 1.2(l. 04-1.4) 1.3 (1.1-1.6) 
Male 30.1 (25.2-35-1)) 0.003 
Female 41.9 (32.1-51.9) 0.8(0.7-0.9) 0.9(0.7-1.02) 
<60 39.3 (27.3-51.5) 0.002 1 1 
60-69 38.2 (28.2-48.1) 1.0(0.8-1.3) 1.1 (0.8-1.4) 
70-79 31.6 (25.5-37.7)) 1.4(l. 2-1.8) 1.5 (1.2-2.0) 
80+ 27.3 (14.5-40.0) 1.4(0.8-2.5) 1.7 (0.9-3.1) 
Travel acceptable 32.4 (27.8-37-0) 0.50 1 1 
not acceptable 41.3 (30.9-51.6) 0.9(0.8-1.1) 1.0(0.8-1.3) 
Most deprived 36.7 (30.8-42.5) 0.46 1 1 
Least deprived 32.2 (25.2-39.2) 1.1(0.9-1.3) 1.1(0.9-1.3) 
NSCLC 35.5 (30.8-40-2) 0.24 1 1 
SCLC 29.7 (6.4-52.9) 1.0(0.6-1.7) 1.3(0.7-2.2) 
No pathology 22.2 (0-55.5) 2.1(0.9-5.0) 2.1(0.9-5.3) 
1 53.2 (42-62.0) 0.001 1 1 
11 24.0 (17.4-30-6) 1.7(l. 4-2.1) 1.7(l. 4-2.1) 
111 14.1 (9-1-19-1) 2.5(2.0-3.2) 2.7(2.1-3.3) 
IV 13.7 (4.6-22.8) 2.8(l. 6-4.9) 2.9(l. 6-5.1) 
Limit 29.7 (6.4-53.0) 1.3(0.7-2.2) 
Unknown 44.1(22.6-65.5) 1.3(0.8-1.9) 1.3(0.9-1.3) 
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Even for this sub-group of 844 patients, the hazard ratio of death was 1.3 (1.1-1.6) for 
Scotland compared with BC. The median sun-ival in BC was 41months, whereas in Scotland 
it was 26months (see figurcD-. 5 and Table 5.10, log rank P-: 0.018) The 1-year, 2-vear and 
five-ycar survival , vas 8 1%, 66%, 391VO (Cl 44-34%) in BC, and 7()%, 53%, 36% (95(ý/o Cl 41 - 
31"/o) ln Scotland, respec6velý. 














However, as the rate of post-operative death was much higher in Scotland than BC and ý7) 
could have been a contributory factor to the inferior early survival in Scotland. Therefore the 
analyscs were repeated after having removed the 49 patients who died with-in a month of 
surgen,. For the remaining 795 sur ical patients the difference in the survival in au 91 ni 
analysis was no longer statisticafly sig ificant (median sunival 42months BC v 32months Z-) gni II 
Scotland, log rank p::::::: 0.19, HR death 1.1(0.9-1.2)), hut the multivariate analysis 
demonstrated that patients in Scotland still had an increased hazard of death (HR 1.23(1.02- 
1.49)). 
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Tumour pathology 
In some surgical series, patients with adenocarcinoma have been noted to have improved 
survival compared with other pathological subtypes. In BC 205 (47%) of the resected 
tumours were adenocarcinomas compared xvith 138 (34%) in Scotland. If the outcome 
foHowing a resection for the patients with adenocarcinoma was compared with the 333 with 
squamous cell turnours in a Cox' regression model then the hazard ratio of death was not 
significantly different for patients with adenocarcinoma (HR 1.1(0.9-1.3)) when compared 
Nvith those with squamous cell tumours. 
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Summary of results 
0 The patients in Scotland were sfightly older. 
0 Around 40"',, of cases occurred in women in botb countries. 
More cases in Scotland did not have pathological confirmation (26% v 11%). There 
appeared to be more patients with adenocarcinomas in BC, but this could be artefact from 
fewer patients in Scotland having -a pathological diagnosis. 
0 The proportion of patients w1th local stage disease was similar, but there were more patients 
with regional disease in Scotland (33% v 26% BC) and more patients with metastatic disease 
in BC (31% v 37% BC). However, this may be due to greater use of CT staging in Canada 
(74% CT in BC v 48% Scodand). 
0 Even when differences of age, stage or pathology were taken into account the adJusted odds 
of a patient receiving any sort of treatment in Scotland was 0.7 compared with BC and 0.4 
for under going potentiaUy curative treatment. 
0 The resection rate for patients with NSCLC was 28 % in BC and 18% in Scotland 
0 The median survival was twice as long in BC as Scotland 
0 The differences in survival could not be accounted for by differences in patient age, gender, 
turnour stage, or turnour qpe. 
9 The relative survival at one, two and five years were 38%, 24%, 12 % in BC and 22%, 10%, 
6% in Scotland, respectively. 
0 For all treatment intent groups (potentially curative, palliative and no treatment) and 
treatment modahties (surgery, radiotherapy or chemotherapy) patients in Scotland had 
inferior survival. 
0 The shorter survival following surgery could not be completely explained by the higher post- 
in Scotland or difference in pathological subtypes. operative mortahtý- 11 
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CHAPTER 6 
Have treatment and survival improved in 
South-East Scotland since 1995? 
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Introduction 
Since the 1995 audit was conducted there havc been a number of changes to healthcare 
organisation and the staff treating lung cancer in South-East Scotland. 
These changes have included: 
1. The introduction of managed clinical networks (South-East Scotland Cancer 
Network or SCAN) to ensure smoother referral path,, vays and better patient 
management. 
2. The introduction of national patient management guidelines through the Scottish 
Intercollegiate Guidelines Network (SIGN). The first lung cancer guidelines were 
pubfished in 1998 and re'vised in 2005. 
3. The introduction of multi-disciplinary team meetings in all the main hospitals, at 
which all newly diagnosed patients are discussed. 
4. Appointment of more oncologists specialising in lung cancer; the number increased 
from two in 1995 to four in 2002 (a fifth (SCE) was appointed third-quarter 2002). 
So, all patients should have the opportunity to benefit from the opinion of a 
speciahst respiratory oncologist. 
Other changes in clinical practice have also occurred, primarily: 
1. Greater access to CT scanning and the development of scanners with improved 
image quahty 
2. Increasing evidence supporting the use of palliative chemotherapy in NSCLC 
3. Increasing evidence on the use of cherno-radiation in limited stage SCLC 
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4. More experience with 3D-conformal radiotherapy, so patients with large turnours or 
poor pulmonary funcfion who would have been previous declined are no,, N- offered 
this treatment. 
Therefore, the question is have these changes resulted in an improvement in treatment and 
surviVal of lung cancer patients in South-East Scotland? 
The aims of this study were therefore to compare a new cohort from 2002 with the 
original 1995 cohort to assess 
1. The proportion of lung cancer patients receiving treatment 
2. The median, one and two-year sunwal of lung cancer patients 
Methods 
SCAN covers a population of 1.25 million in the four Scottish healthboard regions of 
Lothian, Borders, Fife, and Dumfries & Galloway. AR radiotherapy is delivered at the 
Edinburgh Cancer Centre (ECC), which in 2002 had five linear accelerators. The majorlty of 
chemotherapy is delivered under the supervision of an oncologist, but in 2002 respiratory 
physicians in the Royal Infirmary of Edinburgh, Borders General Hospital, Victoria Hospital 
Fife, and Dumfries and Galloway Royal Infirmary administered some chemotherapy. 
Lung cancer surgery is performed in the Royal Infirmary in Edinburgh, but patients living in 
Dumfries and Galloway usually have their surgery performed in Glasgow. Therefore, for this 
study only patients fiving in Lothian, Borders and Fife were included. 
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Integral to the development of the cancer networks has been the introduction of prospective 
audit to monitor patient characteristics and management. The audit was commenced in 2001, 
and by 2002 systems were in place to identiýv most of the patients diagnosed -ý, vith lung 
cancer in the SCAN region. Cases are identified through the multi-discipfinary team 
meetings, patholop- reports, the ECC database, and Scottish Cancer Registry reports. 
Data on patient characteristics including date of birth, gender, address, and performance 
status are collected. Tumour details are recorded, including how the diagnosis was made, 
staging investigations performed, athological tý e and stage. Staging is recorded where 1-7) p Yp Cý C-) 
possible according to the TN-M sta ing, but some cases only have stage recorded as local 91 
(confined to lung), regional (involvement of hilar or mediastinal lymph nodes) or metastatic. 
Since 1995, the allocation of deprivation indices across Scotland has altered and it is 
recommended that the Carstairs index based on the 2001 census be used [98]. Therefore, 
each patient post-code was linked to the 2001 Carstairs Index. 
SMce 1974, the Edinburgh Cancer Centre (ECC) has had a computerised database that 
includes data on all referred patients and includes details of all radiotherapy and 
chemotherapy treatments delivered under the supervision of the oncologists and tracks 
patients I survival until death. 
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Firstly, patients diagnosed with lung cancer in 2002 that resided in Lothian, Borders and Fife 
healthboard areas were identified from the SCAN and the ECC databases. Then pharmacy 
records from all the hospitals were cross-checked with the database to ensure all 
chemotherapy episodes had been identified. The hard-copy records of A thoracic operations 
were hand-searched and details of all lung cancer resections recorded. 
Once a final list of patients who had received treatment under the care of the SCAN lung 
cancer team had been prepared, the database was then Oqven to the Scottish Cancer Registn 
to identiýv any missing cases. Details on the patients who had not been identified by the 
audit, but had died were supplied to the research staff to check the medical records. For the 
patients who were not identified by the audit and who were still alive, only name, date of 
birth and contact details of their general practitioner (GP) were supplied. A condition of the 
ethical approval for this study was that these patients were required to give consent before 
the release of more detailed information. 
The medical records of the additional cases were then scrutinized to assess if thev were 
eligible for entry into the audit and patient, tumour and management details recorded. For 
those patients whose notes could not be identified additional letters were sent to their 
general practitioners to ask for further details (see Appendix 2). 
The details of all cancer therapies delivered within six months of diagnosis were recorded. 
An exception was made for consolidation radiotherapy after chemotherapy in limited stage 
SCLC as this is part of the 'initial treatment package', but can commence during the seventh 
month. 
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Treatment intent was defined as for the 1995 audit, xN-ith potentially curative therapy defined 
as either surgery, radical radiotherapy with a dose of : ')OGy or more, or cherno-radiation with 
thoracic radiotherapy with a dose of 30Gv or more for limited stage small-cell lung cancer 
(L-SCLC) 
In order to obtain up-to-date surviVal, the records of the General Register Office of Scotland 
were searched for notification of any patient deaths. 
Once the database for 2002 patients was finalised comparison was then made with the 1995 
audit patients from Lothian, Borders and Fife. 
The 
-Vulti-Centre 
Ethics Research Committee for Scotland granted ethical approval for this 
study. 
An 
Patient, tumour and management characteristics were analysed using descriptive statistics 
and compared using either chi-squared for categorical or ANOVA for continuous variables. 
Factors affecting the probability of use of treatment were examined using logistic regression 
models. Due to the different lengths of follow-up between the 1995 and 2002 cohorts, 
sunival was censored at two years and estimated using the Kaplan Meier method and 
compared using log-rank tests and Cox's regression model. 
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Results 
A total of 877 patients living in the three health board areas were first diagnosed with lung 
cancer during 2002 and had been identified bv the SCAN audit. The Scottish Cancer 
Registry identified a possible additional 347 cases. However, of these 32 were first diagnosed 
in another vear (1999-2003), 156 were already on the 2002 database, but with slightly 
different spellings of name or date of birth, 5 had a different primary (mesotheboma, 
prostate cancer or carcinoma of unknown primary) and were felt by an oncolo ist (SCE) not 91 
to definitely have lung cancer, and 4 lived outside the healthhoard areas. Therefore, an 
additional 107 cases were confirmed by either the hospital or general practitioner (GP) 
medical records and were added to the database. For 43 cases neither the hospital nor GP 
medical records could be located (unverified cases). 
Only two patients with possible lung cancer were still alive, but had not been under the care 
of a SCAN lung cancer physician. One was known to have dementia and the second had 
moved outside the region so neither patient could be contacted for permission to access 
their records. These cases were therefore excluded. 
Therefore a total 984 confirmed cases and 43 unconfirmed cases were identified. 
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1) Patient characteristics 
The patient characteristics are shown in Table 6.1. There were no significant differences in 
the characteristics of the verified and unverified patents. The diagnosis was confirmed with 
patholog in 716 (73%) of the verified cases, 8 were confirmed at post-mortem and 260 were 
diagnosed on radiology alone. In 86 (33%) of the radiolo -ical only diagnosis cases biopsies 91 
were performed, but were negative. 
For the 43 cases in whom the medical records could not be located, according to the registry 
data, 11 (26%) were histologically confirmed; 5 adenocarcinoma, 2 squamous cell and 4 non- 
small cell not otherwise specified (NSCLC NOS). 
Table 6.1 Patient and turnour characteristics of all the patients diagnosed in 2002 
Verified Cases Unverified Whole cohort 
Number 984 43 102 -17 
Gender Male 543 (55%) 24(56%) 
Age Median 72.5 77.8 73.0 
Range 37-94 65-93 37-94 
Carstairs 1 152(15%) 4(9%) 156 (15%) 
2 178 (18%) 9(21%) 187 (18%) 
3 222(23%) 11 (26%) 233(23%) 
4 318(32%) 14(33%) 332(32%) 
5 114(12%) 5 (12%) 119(12%) 
Healthboard Lothian 611 (62%) 27(63%) 638 (62%) 
Borders 92(9%) 4(9%) 96 (9%) 
Fife 281 (29%) 12(28%) 293(29%) 
Performance Status 0-1 396(41%) 
2 221(22%) Not known 
3-4 235 (24%) 
Not known 132(13%) 
x' - No significant differences between verified and unverified cases 
The variations in the patient characteristics between patients from the health board areas and these 
are shown in Table 6.2. Patients from Fife live in more deprived areas than those in Lothian or 
Borders. 
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Table 6.2 Patient and turnour characteristics in the three Healthboard areas 
N= 982 Lothian Borders Fife Chi squared 
N=611 N=92 N=281 
Gender Male 326 (53(), /0) 46(50%) 11/1(61%) P=0.07 
Age Xledian 72.9N-rs 71.9 72.1 P=0.9 
Range 3-93 44-90 45-93 (ANOVA) 
Carstairs 1 113 (19%) 13(14%) 26 (9(YO) P<0.001 
2 105 (17%) 38(41%) 35 (13%) 
3 131 (21%) 32 (35%) 59 (21%) 
4 179 (29%) 9(10%) 130 (46')/o) 
5 83 (14(),,, 0) 0 31 (11%) 
Performance Status 0-1 242 (400/0) 45(49%) 109 (39%) P=0.3 
2 147(24%) 13(14%) 61(22%) 
3-4 145 (24%) 23(25%) 67(24%) 
Not known 77 11 (12%) 44(16%) 
2) Management 
No record could be found of any of the unverified cases receiving any treatment for their 
lung cancer within the SCAN region, or on the Scottish Cancer Registry database, so it was 
unlikely that these patients received any type of treatment. 
On review of the medical records of the 107 patients identified only by the Cancer Registry 
but not the SCAN audit, none were felt to have been sultable for potentially curative 
therapy. This group constituted mainly elderly patients admitted under the care of Medicine 
for the Elderly and who died within a few days of entering hospital. 
Of the verified cases, thirteen were either confirmed at autopsy or died on the day they were 
diagnosed (3 SCLC, 8 NSCLC and 2 radiological), and as these patients would have been 
unable to receive anv treatment they have been excluded 
from the analysis of management. 
Of the thirteen excluded cases six lived in LotHian, four in Fife and three in the Borders. 
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Of the remaining 971 cases, 586 (60%) underwent a bronchoscopy and 822 (85', "()) a CT 
scan. More patients living in Fife underwent a bronchoscopy; (77%) compared Nvith those in 
the Borders (58"//0) and in Lothian (53%) (Chi-squared P<0.001), but similar numbers of 
patients had a CT scan (86% Fife, 90% Borders and 83% Lothian). 
The method used to obtain the pathological specimen is shown in Table 6.3, along , vith the 
distribution of pathological subtypes and stage distribution at presentation. In Fife 22% of 
patients did not have pathological confirmation compared with 34% in Borders and 28% in 
Lothian, but this difference was non-sigpificant (Chi-squared P=0.09). 
In Fife, 48% of patients presented with metastatic disease, 32% regional disease, 10% 
localised disease and the stage was unknown for 10%. The stage distribution at presentation 
for Lothian was 41%, 35%, 15% and 10%, and for Borders 36%, 42%) 9% and 14%, 
respectiveh% However, these differences are not statisticalIN- significant (Chi-squared P=0.1). 
(see also Appendix 4) 
Details of the treatment delivered to patients with the different pathological types of cancer 
are shown in Table 6.4. 
Totentiafly curative therapy' was delivered to 229 (23.6%) patients; 102 underwent a 
resection, 101 radical radiotherapy, and 26 cherno-radiation for limited stage SCLC. Palliative 
treatment was delivered to 39% of patients (236 palliative radiotherapy only, 91 
chemotherapy only and 49 both), and 366 (38%) received no treatment. 
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T,, N-o patients died xvithin a month of surgery (2"'o post-operative mortality), eight within a 
month of starting chemotherapy (5 NSCLC (5.6%) and 3 SCLC (3.4', 1'())) and 60 (28", 0) within 
a month of palliative radiotherapy. 
Table 63 Management and tumour charactefistics 
(N=971) 
Procedure for pathology Bronchoscopy 350 (36%) 
Needle blopsy of primary 173 (18%) 
Lymph node 13 (1%) 
Pleural aspiration/ biopsy 28 (3%) 
Sputum 11 (1%) 
Surgical procedure 28(3%) 
Other 48(5%) 
Unknown 62(6%) 
Radiology only 258(27%) 
Pathological type Squamous 223 (23%) 
Adenocarcinoma 174(18%) 
NSCLC NOS 148(16%) 
Other NSCLC 27(3%) 
SCLC 141 (15%) 
No pathology 258 (26%) 
NSCLC / No pathology' Stage IA 37(4%) 
N=830 IB 87(10%) 
11A 8(1%) 
1IB 55 (7%) 
111A 96 (11%) 
TIM Ill (13%) 
IV 332(40%) 
Localised 8 (1%) 
Regional 16(2%) 
Unknown 80(10%) 
SCLC Stage Limited 53 (38%) 
N=141 Extensive 79 (56%) 
Unknown 9 (6%) 
I Pathological stage if surgery performed, otbenvise clinical staging 
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Table 6.4 Management broken down bypathological tjpe 
NSCLC 
-Sur, 
(;, ený only 78(14% 
Surgery and post-operative radiotherapy 19 (3%) 
N, -'= 572 Surgený and chemotherapy 2(0.3%) 
Sur(-), en- and valhative radiotheram, 2(0.3%) 
Radical radiotherapy 50(9%) 
Radical radiotherapy and chemotherapy 27 (5%) 
Palbativc radiotherapy 174(30%) 
Palliative radiotherapy and chemotherapy 32(6%) 
Chemotherapy 39 (7%) 
None 149(26%) 
SCLC Surgery and chemotherapy 1 (10/0) 
Chemotherapy and adjuvant radiotherapy 26(18%) 
N=141 Palliative radiotherapy 10(7%) 
Palliative radiotherapy and chemotherapy 17(12%) 
Chemotherapy 52(36%) 
None 38 (26%) 
No pathology Radical radiotherapy 24(9%) 
Palliative radiotherapy 52 (20%) 
N8 =2D None 184(71%) 
Three SCLC cases (2%) and 20 (3.5%) NSCLC cases entered therapeutic clinical trials. 
There was a sign. 1ficantly lower use of 'any treatment', and of 'potentialIN T curative treatment' 
in patients from Fife when compared with those from Lothian and Borders healthboard 
areas (see Table 6.5). The difference in the use of 'potentially curative treatment' was 
primarily due to more use of radical radiotherapy; Lothian 91 patients (15%), 
Borders 16 
(18%) and Fife 20 (7%). 
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Ta ble 6.5 Trea tm en t in ten t broken do " by h ealthboardarea 
Lothian Borders Fife Chi-squared 
(n=605) 
Any treatment 393 (66'zo) 58 (65%) 151 (55%) P=0.007 
Potentially 61 (27%) 24(27%) 44(16%) P=0.002 
curative treatment 
Surgery 
70 (12%) 8(9%) 24(9%) P=0.38 
Radiotherapy 278(46%) 48 (54%) 107 (39%) P=0.002 
Chemotherapy 133(22%) 17 (19%) 46(17%) P=0.12 
In a logistic regression model the adjusted odds of patients in Fife receiving any treatment 
was 0.5 (0.3-0.7) that of Lothian patients and potentiaRy curative treatment 0.3(0.2-0.7) (see 
Table 6.6). Poor performance status, age over 80, lack of histological confirmation, and more 
advanced stage were also associated with reduced odds of receiving 'any treatment'. 
Similar factors were also associated with reduced odds of receiving 'potentially curative 
treatment', with those aged over 70 also less likely to undergo this type of treatment. I 
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For the -ýN-hole cohort of 1027 patients the median overall survival was 4.6 months (4.1-5.2), 
with 27.41', 0 Ave at one-year and 14.0% at two-years. For those patients -, N-ho had 
patholo ical confirmation the median survival was 5.6 months, with 30.8% alive at one-year 91 
and 16.9', /'o at two-years. 
For the 97/1 patients whose notes could be located and who survived more than one day 
(similar cohort to 1995 cohort), the median survival was 5.1 months (4.5-5.7), With 28.9% 
abve at one year and 14.8% at two-years. 
The median survival in Fife was 4.1 months(3.8-5.1) compared with 4.8months (2.4-7.3) in 
Borders and 5.7months (4.9-6.6) in Lothian (figure 6.1 and Table 6.7), but this was non- 
significant on log rank testing (P=0.07). On Cox's regression model healthboard of residence 
was not associated with increased hazard of death, only age over 70 (p=0.01), performance 
status of 2 or more (P<0.001), more advanced stage (P<0.001) were associated with 
increased hazard ratio of death. 
Table 6.7 Sunival ofpa tien ts Rithin the three healthboard areas 
N Median sul-Vival (months) 1 -year 2-year 
Lothian 605 5.7 (4.9-6.6) 30% 16% 
Borders 89 4.8 (2.4-7.3) 31% 18% 
Fife 277 4.1 (3.1-5.1) 26% 12% 
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Comparison with 1995 cohort 
Of the 383' ) patients in the 1995 Scottish lung cancer audit, 927 were diagnosed in a hospital 
in Lothian, Borders or Fife. In the 1995 audit the case ascertainment was lower than in -)(-)()2, 
therefore to ensure the cohorts Nverc as simiýlar as possible, only the 971 patients in 2002 
whose notes could be located and lived longer than a day were included in this comparison. 
Table 6.8 shows the number of cases identified by the audits compared with the number of 
cases on the Cancer Registry JSD) website. It clearly demonstrates that case-ascertainment 
in Lothian exceeds 95% for both audits, but for the Borders was 65% in 1995 and 92% 
2002, and Fife 63% in 1995 and 88% in 2002. The improved case ascertairtment may have 
diluted the impact of sen-ice changes as the additional cases identified were more likely to be 
older patients With more advanced disease and were less likely to have received any 
treatment. 






Audit ISD Audit ISD Audit ISD Audit ISD 
Lothian 386 400 296 298 323 337 282 283 
Borders 34 55 19 26 44 46 45 51 
1 fe [ Fi T1-l 8 172 74 131 170 195 107 118 I 
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1) Patient and tumor characteristics 
Patient and turnour characteristics are shown in Table 6.9. Due to changes in allocation of 
Carstairs' Index it is recommended that data from the 2001 census are used for longitudinal 
assessments of deprivation [98], so the up-dated Carstairs' Indices, grouped in quintiles, were 
applied to the 1995 cohort. Data on performance status was not available for the 1995 
cohort. In 1995 only 6% of patient in these three healthboard areas lived more than one- 
hour's journey from Edinburgh Cancer Centre so this variable was also not included in this 
analysis. 




538 (58%) 537 (55%) P=0.25 
Age <60 135 (15% 131 (14%) P=0.002 
60-69 298(32%) 246 (25%) 
70-79 359 (39%) 411 (42%) 
80+ 135 (15) 183 (19%) 
Carstairs 1 131 (14%) 149(15%) P=0.13 
2 155 (17%) 175 (18"/o) 
3 240(26%) 217 (22%) 
4 258(28%) 316 (33%) 
5 120(13%)' 114(12%) 
Lothian 682(74%) 605 (62%) P<0.001 
Borders 53 (6%) 89 (9%) 
Fi fe 192(21%) 277 (29%) 
Pathology NSCLC 543(59%) 572 (59%) P=0.055 
SCLC 166(18%) 141 (15'),,,, )) 
No pathology 216(23%) 258 (2 7'ý'o) 
Localised 229(25%) 132(14%) P<0.001 
Regional 314(34%) 339 (35%) 
Metastatic 275 (30%) 411 (42%) 
Unknown 109(12%) 89 (9%) 
CT scan performed , 430(46%) 
822 (85%) P<0.001 
I For 23 data missing 
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The increasing age of patients over the seven years reflects the ageing of the high-risk heav-\- 
smoking birth-cohorts and this trend is likely to continue over the next decade. The number 
of cases in Lothian reduced, but increased in Fife. This mav reflect better case ascertairiment 
in Fife as the incidence recorded by the Scottish Cancer Re istry did not change in these 91 
regions over this period [98]. There was also a non-significant increase in the proportion of 
patients 'without a tissue diagnosis identified by the audit, reflecting the higher case 
ascertainment. 
The apparent increase in the proportion of patients who presented with more advanced 
disease maybe have been an artifact of the increased use of CT scanning and better case 
ascertainment. However, if just CT-staged patients were selected there was still a significant 
difference; 25", of patients in 1995, and in 2002 41% presenting With metastatic disease. 
This could be due an increased proportion of patients with clinically obvious stage IV 
disease having CT scan performed for evaluation of disease prior to commencing palliative 
chemotherapy, or technical improvements and more experienced radiologists has resulted in 
higher detection of metastatic deposits. 
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2) Treatment 
The overall proportion of patients receiving treatment did not increase in the se\-en ý-ears 
1995 to 2002 (Table 6.10). How-ever, though this proportion remained unchanged this \v, ý-ts 
despite higher case ascertainment and an aging population. 
The proportion of patients treated with curative intent increased from 14', 'o to 24"(), 
primarily due to a trebling of the number of people treated with radical radiotherapy. The 
proportion of patients treated with radiotherapy overafl did not change, )ust that those 
treated -\-, -ere more likely to have received a curative dose. 
Disappointingly there was no increase in the proportion of patients under-going resection 
for their lung cancer. This may simply reflect the marked co-morbidity in Scottish lung 
cancer patients, which precludes many lung cancer patients from having surgery. 
The number of patients receiving chemotherapy increased, mainh- due to doubling of the use 
of chemotherapy in NSCLC (7.1% 1995 v 17.5% 2002). Evidence demonstrating the benefit 
of palliative chemotherapýT in this group was published in the rrud 1990s [6,441. The 
proportion of SCLC patients receiVing chemotherapy did not change, and was 65% in 1995, 
and 68% in 2002. 
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Table 6 10 Compan'son of treatment intent -in 
1995, and 2002 
1995 2002 F 
An\- treatment 582 (63%) 605 (62%) P=0.85 
Potential-IN, curative 131 (14%) 229 (24"/o) P<0.001 
Palliative 451(49%) 376 (39%) 
Surgery 95 (10.2%) -J -102 (10.5% ) P=0.88 
Radiotherapy 400(43%) 433 (45%) P=0.55 
Radical' 44(4.7%) 146(15%) P<0.001 
Palliative 356 (38%) 296 (31%) 1 
Chemotherapy 151 (16%) 1 196 (20%) 1 P=0.03 
'Includes radical, PORT and cherno-radiation for L-SCLC 
The changes in management by patholo ical. subtype are shown in Table 6.11. 91 
Table 6.11 Management for each pathological type in 1995 and 2002 
1995 2002 
NSCLC Surgery only 82(15%) 78(14%) 
Surgery and post-operative radiotherapy 7(1%) 19 (3%) 
Surgery and chemotherapy 1 (0.2%) 2(0.3) 
Surgery and palliative radiotherapy 2(0.4%) 2(0.3%) 
Radical radiotherapy 18 (3.3%) 0 (8.7/6) 
Radical radiotherapy and chemotherapy 1 (0.2%) 27(4.7%) 
Palliative radiotherapy 219(40.5%) 174(30.4%) 
Palliative radiotherapy and chemotherapy 20(4%) 32(5.6%) 
T-h-emotherapy 17 (3%) 39 (6.8%) 
None 176(32.4%) 149(26%) 
SCLC Surgery and chemotherapy +/-RT 1 (0.5%) 
1 (0.5%) 
Chemotherapy and adjuvant radiotherapy 12(7%) 26 (18%) 
Palliative radiotherapy 17(10%) 
10(7%) 
Palliative radiotherapy and chemotherapy 19 (11.5%) 17(12%) 
Chemotherapy 78 (46%) 52(37%) 
K-o-ne 39 (23%) 35 (25%) 
No pathology Radical radiotherapy 
5 (2%) 24(9%) 
Palliative radiotherapy 79 (38%) 52(20%) 
-Ko--ne 130(60%) 182(71% 
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To investigate further the factors that affected the use treatment and potentiaNy curative 
treatment a multivariate analysis was performed and is shown in Table 6.12. 
Table 6.12 Factors affecting the use of 'any treatment' and 'potentially curative treatment' 
Unadjusted odds Adjusted Unadjusted odds Adjusted odds 
of treatment odds of of PCT of PCT 
treatment 
fale 
Female 0.9(0.8-1.1) (). 9(0.7-1.1) 1.0(0.8-1.2) 0.90.7-1.2) 
Age <60 1 1 1 1 
60-69 0.6(0.4-0.8) 0.8 (0.4-0.99) 0.7(0.5-0.99) 0.6 (0.4-0.9) 
70-79 0.3(0.2-0.4) 0.4(0.4-0.5) 0.4(0.3-0.5) 0.3 (02-0.4) 
80+ 0.1(0.06-0.13) 0.1 (0.08-0.2) 0.1(0.08-0.2) 0.1 (0.03-0.1) 
Carstairs 1 1 1 1 1 
2 1.9(0.8-1.5) 1.0(0.7-1.5) 0. " (0.5 - 1.1) 0.7(0.4-1.1) 
3 1.0 (0. /- 1.4) 0.9(0.6-1.3) 0.7(0.5-1.1) 0.7(0.4-1.1) 
4 0.9(0.7-1.2) 0.9(0.6-1.3) 0.7(0.5-1.0) 0.6(0.4-1.4) 
5 1.1(0.7-1.5) 1.0(0.6-1.5) 0.8(0.5-1.2) 0.6(03-1. ()4) 
Lothian 1 1 1 1 
Borders 1.10.8-1.6) 1.3 (0.8-2.0) 0.8(0.5-1.3) 0.6 (0.4-1.1) 
Fife 0.7(0.6-0.8) 0.7 (0.5-0.9) 0.6(0.4-0.8) 0.5 (0.3-0.7) 
NSCLC 1 1 1 1 
SCLC 1.3(l. 0-1.7) 1.8 (1.3-2.5) 0.5(0.3-0.4) 1.3(0.8-2.0) 
No patholop- 0.2(0.1-0.3) 0.3 (0.2-0.4) 0.2(0.1-0.3) 0.2(0.1-0.4) 
Localised 1 
Regional 0.9(0.7-1.3) 0.7 (0.5-1.0) 0.590.4-0.6) 0.6 (0.4-0.9) 
Metastatic 0.5(0.3-0.6) 0.3 (0.2-0.5) 0.01(0-0.03) 0.004(0) 
Unknown 0.07(0-0.1) 0.08 (0-0.13) 0 0 
1995 1 1 1 1 
2002 1.0(0.8-1.2) 1.3 (1.1-1.7) 1.8(l. 5-2.4) 6.0 (4.3-8.4) 
Even after adjusting for other factors, patients diagnosed in 2002 were sigmficantly more 
likely to receive 'any treatment' and 'potentiaUy curative treatment' than those diagnosed in 
1995. Older patients, those without patholoo-ical confirmation, metastatic disease and In 




The median overall sur-vival for lung cancer in Lothian, Borders and Fife increased from 4.1 
months to 5.1 months in the seven years from 1995 to 2002 (see Table 6.13 and figure 6.2). 
Table 6 13 Simival in South East Scotland 1995 v 2002 
Median 1 \-r 2 vr Log rank 
1995 4.1 (3.5 - 4.6) 23.40, /, (20.7-26.1) 1 1.40ZIO (9.3-13.5) 
(n=92-/) 0029 P=0 
2002 
-5.1 (4.5-5.8) 
28.9", ", ) (26.1-31.8) 14. W, 'o (12.5-17.1) . 
(n=9-/'I) 














To Investigate the impact of the improved case asccrtainment, the Cancer Re . stn- also 91 , 
provided data on the eligible cases from the 199-) audit that had been excluded because the 
medical records could not be found. There ý, vcre 61 patients including 355 men and the 
median age , N-, as 5 (range 34-92). Over half this group (54%) died on the day they were 
diagnosed. Though of the remainder, eight hved more than six months. 
The sunival of the whole population cohort of 994 patients diagnosed in 1995 and 10-1- 
patients from 2002 was then calculated. The improved survival remained significant. (Table 
6.14) 
Table 6.14 Overall survival for all lung cancer patients from South East Scotland in 
the Scottish Cancer registry 
Median 1 vr 2 yr Log rank 
1995 3.6 (3.1-4.1) 22.4% 10.8% 
(n=994) P=0 003 




Reasons for the improvement in survival 
To explore whether the improvement in sunival observed was not sImply due to changes in 
patient and tumour characteristics rather than the impact of increased use of treatment, a 
Cox's regression model analysis was performed (Table 6.15). This demonstrated that even 
when the differences in age and stage are taken into account patients diagnosed in 2002 had 
a hazard ratio of death 0.7 (0.6-0.8) compared with patients diagnosed in 1995. 
Table 6 19 Factors affecting hazard of death 
Unadjusted hazard of death Adjusted hazard of death 
Male 1 1 
Female 0.9(0.8-1.0) 0.9(0.8-1.02) 
Age <60 1 1 
60-69 1.2(l. 0-1.4) 1.2 (1.04-1.5) 
70-79 1.6(l. 3-1.8) 1.6 (1.3-1.8) 
80+ 1.9(l. 6-2.2) 1.8 (1.5-2.2) 
Carstairs 1 1 1 
2 1.2(l. 0-1.4) 1.2(l. 0-1.42) 
3 1.1(0.9-1.3) 1.1(1.0-1.3) 
4 1.2(l. 0-1.4) 1.2(l. 04-1.4) 
1.1(0.9-1.3) 1.2(l. 0-1.4) 
Lothian 1 1 
Borders 1.0(0.8-1.2) 1.0(0.8-1.2) 
Fife 1.2(l. 1-1.3) 1.1(0.9-1.2) 
NSCLC 1 1 
SCLC 1.4(l. 2-1.5) 1.0 (0.8-1.1) 
No patholop, 1.8(l. 6-2.0) 1.4(l. 2-1.6) 
Localised 1 1 
Regional 1.7(l. 5-2.0) 1.9 (1.6-2.3) 
Metastatic 3.7(3.2-4.3) 4.2 (3.6-4.8) 
Unknown 4.3(3.5-5.2) 3.6 (2.9-4.4) 
1995 1 1 
2002 0.9(0.8-0.95) 0.7 (0.6-0.8) 
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, 7% 
There Nvas no change in the overall sur-vival following surgery (2 year overall sunival 7 II 
1995 v 81% 2002 log rank p=0.99), radical radiotherapy (2-year overall survival 7()"1/(, v 67//0 
log rank p=0.97) or palliative chemotherapy (I-N-ear overall survIval 25% \- 24% log rank 
p=0.42). The latter two were reassuring because despite more patients receiving these 
treatments, a similar proportion benefited. 
There was a slight decline in the median sunlval of patients undergoing palliative 
radiotherapy (5.2 to 4.4months log rank p=0.03), probablý, due to changes in patient 
selection. In 2002 palliative radiotherapy was only used for patients unsuitable for either 
radical radiotherapy or palliative chemotherapy. 
If the Cox' proportional hazards model was repeated with the addition of the variable 
4treatment intent' (PCT v palliative v none) the hazard of death was still lower in 2002 
compared with 1995 (HR 0.8 (0.7-0.9)) suggesting that it was not Just the increased use of 
potentially curative therapy that was responsible for the improved outcome. 
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SUMNLkRY OF RESULTS 
Patients diagnosed in 2()()2 Nvere older than those in 1995 
e There appeared to be more patients diagnosed with metastatic disease in 2002, but 
this could have been an artifact of higher case ascertainment and more patients 
undergoing a CT scan. 
The absolute proportion of patients treated did not change, but twice as many were 
treated -\-, -lth curative intent in 2002 than 1995. 
0 The proportion of patients treated with radical radiotherapy increased from 5% to 
15%, but the proportion undergoing surgery remained unchanged at 10% 
9 The use of chemotherapy for NSCLC increased from 7% to 17% of patients 
0 On multivariate analysis the odds ratio of receiving 'any treatment' in 2002 was 1.3 
and the odds ratio of receiving 'potentially curative treatment' was 6.0 in 2002 
compared with 1995 
9 Patients diagnosed in 2002 had significantly longer sunival with the median surviVal 
increasing from 4.1 months to 5.1 months. 
On Cox's regression model the hazard ratio of dying within two years was 0.7 in 
2002 compared with 1995. 
* The improvement in sun-ival was only partly due to increased use of radical 
radiotherapy therefore other, unidentified, factors appear to also be important. 
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CHAPTER 7 
Optimal treatment utilisation and 
resources for the treatment of lung 
cancer in South-East Scotland 
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Introduction 
As has been shown in the previous chapters, one of the reasons for poor survival of lung 
cancer patients in Scotland has been under-use of treatment. Though the number of patients 
receiving radical radiotherapy and chemotherapy for NSCLC has increased markedINI, is there 
still under utiEsation of treatment? 
The potential reasons for the under-use of treatment are complex, but include nihilism on 
the part of clinicians [185], a fatalistic attitude of some lung cancer patients, and lack of 
resources. 
Therapeutic nihilism by clinicians can be overcome by site speciahsation and multi- 
disciplinary team working, which attracts motivated clinicians with a special interest in lung 
cancer and a desire to in improve the outcomes [125]. The impact of the use of treatment 
guidelines, such as SIGN guidelines, is more difficult to establish. In the previous study 
examining the introduction of protocols in the management of SCLC in BC, the number of 
patients receiving appropriate treatment increased, but did not result in a statisticallN, 
significant improvement in survival [113] 
Patients with lung cancer tend to be more fatalistic than those with other primary turnours, 
such as breast cancer; expecting much greater surviVal benefit for to-xicities experienced 
[179]. Therefore it is not uncommon for patients to decline curative treatment with surgen 
or radical radiotherapy, or palliative chemotherapy. Though often, , vith good communication 
ni and patient education by lung cancer specialists, this patient sm and prejudice against 
treatment can be overcome. 
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HowcN-cr, it is paramount that , %-hen treatments haN-e been proven to be of cost-effective 
benefit to patients' outcome, in terms of both survival and quality of life, that sufficient 
resources are in place to meet the demand. 
Data from EUROCARE and Royal College of Radiolo ists audits have suggested that the 91 
poor outcome in the UK might be due to lack of oncologists and radiotherapy equipment 
[8]. The Roval College of Radiolo ists recommends that there are 5.0 radiotherapy machines 91 
per milhon head of population, and the ESTRO QUARTS European model suggested 6.2 
machines per million are required for England [15]. In 1995, Scotland had 4.0 machines per 
million, and in 2002 4.5 per milhon. There is an on-going program of installing new 
machines to bring the capacity up to 5.0 machines per miffion by the end of 2007, but with a 
predicted 18"'o increase in the number of cancer cases (mainly breast, colon and prostate) 
over the next decade further expansion wi-U be required to keep pace with this demand [174]. 
Not only are radiotherapy machines in short supply, but also crucial staff particularlý 
therapeutic radlographers and radiation physicists. There is an international shortage of these 
specialists, and in 2002 most Scottish radiotherapy departments had vacancies. 
Though radiotherapy is the most frequently used treatment modality in lung cancer, it is also 
important to have sufficient surgical capacity, and the resources, both financial and 
it ight be of benefit. organisational, to deliverv chemotherapy to A patients for whom 1 ml 
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In order to plan for the future it is important to know what level of resources should be in 
place to meet the demand were treatment to be optimal. Therefore a model was developed 
to: - 
a) Assess the gap between current actual and optimal delivery 
b) Provide information on current resource requirements 
Methods 
Indications for treatment 
As discussed in Chapter 1, there are clearly defined indications for surgery, radiotherapy, and 
chemotherapy in the treatment of patients with lung cancer. The principal determinants of 
treatment selection are pathological type, stage, and the performance status of the patient. 
Some patients elect not to have the treatment recommended, but the resources to be able to 
offer all patients the best treatment for their clinical situation should be available. 
Obvioush- there are some areas of clinical controversy. However, as this analysis applies to 
South-East Scotland the current interpretation of the data and re imens delivered by the 91 
Edinburgh Cancer Centre Lung Cancer Team (which are based on the SIGN and NICE 
guidelines) were used for this model, and are set out in Table 7.1. 
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Table 71 Indications for treatment usedin the models 
Treatment Scenario Details 
Surgery Stage I or 11 NSCLC Prieumonectomy or lobectomy 
PFS o-1 
Radical radiotherapy Stage 1-11 NSCLC PFS 0-1 Either 54Gy in 36 fractions 
medically unfit for surgery (FEV1 (CHARTý or _55Gy in 20 <1L) or fractions 
Stage I or 11 NSCLC PFS 2 
Stage III NSCLC PFS 0-1 Either 54Gv in 36 fractions 
encompassable within safe RT (CHART), 55Gy in 20 fractions 
volume, no cytologicallv proven or 60-66GN- in 30-33 fractions 
pleural effusion. with chemotherapy 
Adjuvant radiotherapy + L-SCLC PFSO-2 5()Gy in 20 fractions 
prophylactic cranial + 30GY in 10 fractions PCI 
radiotherapy (PCI) 
Post-operative Positive resection margin 55Gy in 20 fractions 
radiotherapy 
Palliati-ve radiotherapy Stage 1-111 NSCLC / L-SCLC PFS Either 20Gy in 5 fractions or 
3-4 with local symptoms 10Gv in 1 fraction 
Stage III NSCLC PFS 0-1 not 39Gý, in 13 fractions 
encompassable within safe 
radiotherapy volume, no effusion 
Stage 11113 (pleural effusion) or IV Either 20GY in 5 fractions or 
NSCLC/ E-SCLC with focal chest 1OGy in 1 fraction 
symptoms PFS 0-3 
Stage IV NSCLC symptomatic Either 20GY in 5 fractions or 
brain metastases PFS 0-2, ESCLC 12Gx- in 2 fractions 
brain metastases PFS 0-3 
Stage IV NSCLC / E-SCLC Either 20Gy in 5 fractions or 
symptomatic bone metastases 8GY in I fraction 
PFS 0-3 
Chemotherapy Pathological Stage 11-111 PFS 0-1 4 cycles of cisplatin -,,, inorelbine 
post-operative adjuvant 
L-SCLC PFS 0-3 4 cycles cisplatin/carboplatin & 
etoposide 
Stage III NSCLC PFS 0-1 chemo- 4 cycles of cisplatin & 
radiation vinorelbine or 3 cycles 
carboplatin & gemcitabine 
Stage 11113 (pleural effusion) or 4 cycles of gemcitabine & 
Stage IV NSCLC PFS 0-1 palliative carboplatin 
chemotherapy 
Stage IV NSCLC PFS 2 age <60 4 cycles of gemcitabine & 
palliative chemotherapy carboplatin 
E-SCLC PFS 0-2 6 cycles carboplatin and 
etoposide 
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Areas of controversy include: 
i) Definition of medically inoperable 
Not all patients are medically fit for surgery. The most frequent reasons are poor lung 
tuncfion due to chronic obstructive puli-nonary disease, and cardiovascular disease. The 
criteria for deciding whether or not a patient is unfit for surgery in the basis of their heart 
disease are fairly subjective, but it is generally accepted that patients with an FEVI of less 
than one htre are unlikely to tolerate surgery. FEV1 is a measure of the volume of air a 
patient can exhale over a second, and is usually in the re 'on of 2-3 litres. A numher of 91 
studies have investigated the association between either the percentage of predicted or 
absolute value of FEV1 and the risk of post-operative complications [126]. The percentage 
of predicted pulmonanT function is a better predictor of outcome [171, but these values were 
not recorded in the audit database with sufficient frequenCýT. Therefore a level below 
IL/second was used to define a 'medically inoperable' threshold. In a case-series of sur ical 1 91 
patients from Papworth hospital, 50 patients (45%) had an FEV1 below the standard 
thresholds of 1.5L for lobectomy and 2. OL for pneumonectomy, but none had an FEV1 of 
less than 1L [206]. 
ii) Surgery for Stage III NSCLC with single nodal group involvement. 
Though this is it routinely offered in some centres in the US the efficacy of this treatment 
remains debated, and in the UK is still considered experimental [195]. 
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iii) Post-operative radiotherapy in patients found to have mediastinal nodal 
involvement 
This has not been proven to improve survival, and may actually be detrimental in some 
patients [1') 1 unless '11, so post-operative radiotherapy is not routinely offered to patients, 
there is doubt about the resection margin. 
iv) Use of radical radiotherapy in frailer (performance status 2 (PFS 2)) NSCLC 
patients 
In South East Scotland the majority of patients in this group are offered this treatment, 
unless their performance status is declining fast as a consequence of their cancer. 
v) Use of chemotherapy in frailer (PFS 2) patients with Stage IV disease. 
Patients with borderline performance status derive less benefit from chemotherapy than fit 
patients [20]. For purposes of this analysis a cut-off of age under sixty was used to ascertain 
the proportion of patients with PFS 2 suitable for chemotherapy. Though no such dogmatic 
age bmit is applied in everyday clinical practice, if frail patients are offered chemotherapy it 
more is hkely that they will be in the youngest age category. 
The models only include treatments delivered as part of the 'initial treatment package' to 
enable comparison with the data on actual treatment delivered. 
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Establishing proportion of patients suitable for each treatment 
indication 
i) Distribution of stage and performance status in lung cancer patients from South 
East Scotland 
Once the indications for each treatment were defined, prospectively collected data on stage 
and performance status within the population were used to calculate the proportion of 
patents fitting each clinical scenario. In order to ensure up-to-date figures, data from patients 
diagnosed -with lung cancer in the SCAN region in 2004 'were used for this model. The 
introduction of electronic data capture at the multi -di s ciptinary meetings has enabled greater 
completeness of data collection. 
In 2004, the SCAN prospective audit identified 1053 patients, 615 from Lothian, 82 Borders, 
2556 Fife and 100 Dumfries and Galloway diagnosed with lung cancer; corresponding to 
91.4% case ascertainment when compared to Scottish Cancer Registry average for period 
1999-2003. 
g in The median age was ý 1.6 years with a range of 37-97 years. Detailed stagin i formation was 
available for 92', I"o patients and performance status for 82%. 
The distribution of stage and patholo ical ty e by the health boards is shown in Table 7.2, 91 ýp 
along with performance stage distribution by stage. 
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Table 72 Distribution of stape and nerformance statnm 
Lothian Borders Fifc D&G Total Performance Status bv Stage 
12 3-4 
ScI. C stagc 1-11 98 17 26 14 2' )"/o 7 "1 " 11% 3 `lo 11o J, o (n=6 0) 
g 
Stagc 111 154 19 43 15 , t, 340/1 63% 22" /, ) 0o, ") f) 6" Stao1c IN' 141 19 79 2 39% 44% 20% 2(w, (ý 16% L'nknown 13 1 5 10 4% 13% 7% 1 7o,,,,,, 
SCLC Limited 36 2 13 9 37,11/0 82% 12% Y/, ) Y) /o (n= 163) Extensive 50 5 29 11 59()/o 35% 26% 19% 20% 
Unknown 11 1 4 4% 0""0 14% 00"'0 86", //0 
No path Stage 1-11 24 3 8 1 17% 36% 33% 28% 3% 
(n=214) St,, t,, c 111 35 2 13 2 24% 1 () Oz/0 16% 51% 23'),, ', ') 
st. w ý-c 
IN' 38 4 32 6 37% 18% 17% 27% 
Unkno-, vn 24 9 7 6 22% 15% 6()/'ý) 0/ 19, () 60% 
These data were then used to calculate the number of patients eligible for each treatment. In 
order to include all patients, those with NSCLC and no patholop, were combined to make 
one group 'not-SCLC' and then the patients without stage or without performance status 
recorded were re-distributed according to the ratio of the known cases (Table 7.3a). 
Table 7.3a Performance status bv staLre for 2004 SCAN 
2004 PFSO-l PFS 2 PFS 3 PFS 4 
Not - 84% Stage I or 11 : 123% 74% 18% 7% 1% 
SCLC Stage 111 35% 56% 23% 14% 7% 
42% Stage IV 44% 23% 23% 10% 
SCLC 16% 1 : 39% Limited stage 82% 14% 4% 0% 
Extensive 61% 44% 33% 19% 4% 
This process was also performed on the 2002 data (after having excluded the unverified 
patients and those living <1day as these would not have been able to receive treatment). 
However, 13% of patients did not have their performance status recorded, and for 12% the 
stage was unknown or identified only as local or regional. The higher proportion of patients 
without a defined category makes the proportions less accurate (Table 7.3b), so the 
2004 
model was selected for use in the models. 
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Table 7.3b Performance status bv staLre for 2002 SCAN 
2002 PFSO-1 PFS 2 PFS 3 PFS 4 
85'. ý'() Not Stage I or 11 li 25% 68% 19% 11% 
SCLC Sta e 111 29% 47% 31% 18% 4% 
Sta e IV 46% 9 33% 26% 29% 12% 
SCLC '0"0 Limited stacre 40% ýD i 62% 27% 11% 
10% 
'60% Extensive 40% 30% 19% 110"0 
ii) Establishing other factors involved in management decisions 
a) Proportion requiring surgery 
The proportion of patients With early stage and a good performance status has been 
established by the method above, but it was also necessary to estimate the proportion of 
patients who were medically inoperable. 
Therefore, in order establish the proportion of patients with poor pulmonary function and an 
FEN'l 
below the 1L threshold, the data on pulmonary function tests from Lothian in the 2004 cohort were 
examined. These data were available for 408 of the 608 patients 
(66%). For the patients with early 
stage disease, 26% had an FEV1 of <lL so would not 
have met the threshold for surgery. TI-ds 
proportion is similar to the 30% of patients turned down 
for surgery on grounds of poor pulmonary 
function iin a hospital-based series from Northern England 
(11/37 Stage 1-11 patients), but much 
higher than in an Italian hospital-based series where 8% (4/5-3) were not operated on 
because of 
COPD[95], and 1n a Dutch population where 5% of Stage 
I and 11 patients had an FEV1 of less 
than one litre [48]. 
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b) Proportion of patients requiring radiothergpy 
i) Proportion of suitable for radical radiotherapy 
Estimating the proportion suitable for radical radiotherapy with early stage disease ý, vas fairly 
straightforward, but assessing the proportion of patients with Stage III disease more difficult. 
Stage III NSCLC encompasses a wide range of disease states; including tumours where the 
primary and involved lymph nodes are adjacent, and others where the primary may be many 
centimeters from the enlarged lymph nodes. The main acute toxicities of radical radiotherapy 
are pneumorUtis and oesophagitis, both of which are volume dependant, so the geographical 
distribution of the disease may preclude radical radiotherapy, even if there has been a good 
response to neo-adjuvant chemotherapy. The proportion of patients that do not have disease 
'encompassable within a radical radiotherapy volume' is highly subjective, depending on the 
experience of the staff that plan the radiotherapy treatment, and the risks the oncolog'st and 
patient are prepared to take. No exact figures exist on the proportion of patients in this 
group, but in 2004 in SCAN 13% of good performance status Stage III patients were treated 
with high dose palliative radiotherapy rather than radical radiotherapy, suggesting that for the 
Edinburgh Cancer Centre they met these criteria. 
Stage III also includes patients with a cytolo ically proven pleural effusion, which, regardless 91 
of the configuration of the other disease, makes the disease incurable. The proportion of 
patients presenting with a pleural effusion is not recorded separately in the SCAN audit 
database, but can be estimated. In 2004,49 of the 127 patients with Stage III disease and 
PFS 0-1 had T4 disease. If the patients treated with either radical or high dose radiotherapy 
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were excluded (as these patients would not have had an effusion) a total of 25/127 or 2()'', ) 
probably had a pleural effusion at time of presentation 
ii) Proportion needing post-operative radiotherapy for positive margins 
Two previous models of optimal radiotherapy utifisation have been developed, and both the 
Canadian [197] and the Austrahan [491 models suggested that 2% of patients undergoing a 
lung cancer surgery will have positive resection margin. However, a recent Norwegian 
population-based study of over 3211 surgical patients 6% had an involved resection margin 
[188]. In the period 1994-2003 a total of 137 patients xvere referred to the Edinhurgh Cancer 
Centre for consideration of post-operative radiotherapy, of these 51 had positive or 
uncertain resection margins. Based on an average of 110 resections per annum (100 in 
Edinburgh and 10 in Glasgow from D&G) the Norwe ian figure of 6% appears equally 91 
applicable to Scotland. 
iii) Proportion requiring paRiative radiotherapy 
a) Chest symptoms 
Though the data on symptoms at time of presentation were recorded in the SCAN audit 
database, this was not sufficient completeness to use these data for the model. In the 1995 
audit, 64% of patients had chest symptoms (20("'o haemoptysis, 25% chest pain, 48% cough) 
that could have benefited from thoracic radiotherapy [62]. In an analysis of 247 patients 
in Devon, 20% had haemoptys's, 42% chest presenting to general practice with lung cancer 11 
pain and 65% cough [85]. The Canadian model of optimal radiotherapy utilisation also used 
a figure of 64% for Stage III patients [197], 
but a lower one of 38% for Stage IV patients. In 
the Australian model of optimal radiotherapy use in lung cancer, 
DelaneN T et al used data 
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from three of the British 'chemotherapy versus best-supportive care' trials in , -, -hich _56-71", "o 
ot patients had thoracic symptoms [491. Therefore, it appeared that the 1995 rate of 64% , vas 
a reasonable proportion to use. 
Ho,, vever, therewas no indication as to the severity of these symptoms, and chemotherapy is 
also beneficial for thoracic sý T mptoms. Therefore sometimes, if the patient has widespread 
metastases or marked systemic symptoms, such as fatigue, then chemotherapy is used in 
preference to radiotherapy. It was impossible to model this subjective decision so the model 
will over-estimate the optimal use of radiotherapy for this group of patients. 
b) Brain metastases 
In a recent an analysis of the Nlaastricht Cancer Re istry 6.8% of NSCLC and 11.2% SCLC 91 
were diagnosed with brain metastases within a month of diagnosis [172]. A review of all 
patients diagnosed with cancer in the Detroit area suggested that 19.9% of lung cancer 
patients in the SEER database were found to have brain metastases [13]. It is difficult to 
ascertain in this series at which time point this diagnosis was made, so the Dutch figures 
Nverc used for the model. 
Frail patients Nvith brain metastases do not benefit from whole brain radiotherapy [116]. 
Therefore, for the model only patients with a performance status 0-2 were deemed fit for 
radiotherapy for NSCLC brain metastases, and because of the increased radio- s ensitivity the 
broader group of PFS 0-3 was used for SCLC. 
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c) Bone metastases 
There are fc, \\- data examining the number of patients presenting with symptomatic bone 
metastases. In one hospital series from the University of Michigan 36% of patients with 
Stage FV NSCLC presented with bone metastases [156]. In a similar series from the Henry 
Ford Health System tumour database 23% of patients with stage I-V disease presented with 
cc xtra- thoracic' pain [1921. Therefore an estimate of 30% of patients with Stage IV having 
symptomatic bone metastases was selected. 
iii) Proportion of patients requiring chemotherapy 
It is recommended that chemotherapy should be delivered in the following scenarios: 
i) Patients With a good performance status with pathological Stage 11 or III NSCLC at 
surgery (adjuvant post-operative chemotherapy). In the 2004 audit, 49% of the patients who 
underwent a resection were found to have pathological Stage II or III disease so should have 
been be offered this treatment. 
ii) Combined with radical radiotherapy for patients With 'dry' stage III NSCLC, the 
proportion of patients suitable for this treatment was established by the radiotherapy model 
iii) NVith palhative intent to patients with 'wet' Stage III or IV NSCLC. 
ith L-SCLC iv) For SCLC chemotherapy should be delivered to all patients, except those wi 




The model developed is shown in Table 7.4. 
1) The first column represents the proportion of all lung patients with SCLC (0.16 or 16"", )) 
and 'not SCLC' (NSCLC and no pathology) (0.84) 
2) The second column the distribution of stage calculated based on 2004 data 
3) Third the distribution of performance status for each stage based on 2004 data 
4) The proportion of patients with early stage lung cancer and a good performance but with 
lung function above the defined threshold of 1L/second based on the 2004 Lothian data 
5) The recommended use of surgery 
6) The proportion of all lung cancer patients who should according to this model undergo 
surgery (0.84xO. 23xO. 73xO. 74 = 0.104). 











PFS 2 or more (0.37) None 




TOTAL PROPORTION 0.1 
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Therefore according to the model shown in Table 7.4, the estimated optimal surgery rate for 
South East Scotland was 12.4% of 'Not-SCLC' cases, or tO. 4"'O of all lung cancer patients, 
which is not dissimilar to the rates identified by the 1995 and 2002 audits. 
However, as the model used post-operative stage, patients who were found to have 
unsuspected Stage III disease at time of surgerý T were excluded. Despite mediastinoscopy 
being part of routine pre-operative staging, in SCAN in 2004,15 of the 100 patients were 
found to have mecbastinal nodal involvement at time of resection. If this group was included 
as 'pre-operative Stage 1-11' patients then the optimal surgical rate would have increased to 
14.1 % of Not-SCLC, or 11.80,, "o of all lung cancers. 
If the 2002 figures, rather than 2004 figures, Nvere used in the model the optimal rate of 
surgen- -, vas 10.7% based on pre-operative, and 12.2% on post-operative stage of all lung 
cancers (1 .. 6-14.3% Not-SCLC). So confirm that according to current guidelines there is not 
-1 
significant under-use of surgery in South East Scotland. 
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ii) Radiotherapy 
Table 7.5 shows the model estimating the optimal radiotherapy use in South East Scotland 
Table 7.5 propo_rtion ofpatients suitable fortadiothetapy based on 2004 figures 
Not- Stag 
,C 
1-11 PFS 0-1 FEVI >1 Surgery margins clear (0.94) Nonc SCLC 
(0.84) 
(0.2-3) (0.74) (0.74) Margins involved (0.06) Post- 
operative 
0.006 
FEVI <1 (0.26) Radical 0.037 
_PFS 
2 (0.18) Radical 0.035 
PFS 3 ocal Symptoms (0.64) Pafliativc 0.009 
(0.07) No focal symptoms (0.36) None 
PFS 4 (0.1) None 
st"I"C III PFS 0-1 No Encompassable (0.87) Radical 0.115 
(0.35) (0.56) effusion 
_(0.8) 
Not encompassable (0.13) High dose 
palliativc 
0.017 
Effusion Focal Symptoms (0.64) _ Palliative 0.021 
(0.2) No focal symptoms (0.36) No none 
PFS 2-3 Focal Symptoms (0.64) Palliative 0.069 
(0.37) 
[No 
focal symptoms (0.36) None 
PFS 4 (0.0 7) None 
Stage IV 
- 
Chest sy ptOMS (0.64) Palliative 0.203 















bone mets (0.3) 
Palliative 0.033 
No bone mets 
(0.7) 
None 





PFS 0-2 (0.96) Chemo 
RT+PCI 
0.060 
(0.39) PFS 3 'o Tmptoms (0.64) F Palliative 0.002 
(0.04) No focal symptoms (0-36) None 
Extensive PFS 0-3 Chest sympt oms (0.64) Palliativ e 0.060 
stage 
(0.61) 
(0.96) No chest 
Symptoms 
Brain mets (0.07) Palliative 0.002 
(0.3 36) No brain 
mets (0.93) 
Symptomatic 
bone mets (0.3) 
Palliative 0.009 







The model therefore suggested that 68", ", ) of patients in South East Scotland should receive 
radiotherapy, 66", "o of patients with 'not SCLC' and 86% of patients with SCLC. The optimal 
use of radical radiotherapy 'was 19% of all lung cancer patients. 
Repeating the model with the 2002 data suggested that 6-17", '() of patients should receive 
radiotherapy, 68", ", ) not-SCLC and 81% SCLC. 
These estimates far exceed the proportion of patients actuafly treated in either 1995 or 2002. 
This is either due to under-use of radiotherapy, an over-estimate by the model, or a 
combination of the two. The latter is the most likely. 
iii) Chemotherapy 











11 or greater (0.49) 
Chemotherapy 0.051 
No surgery (0.46) None 
Stage III PFS 0-1 (0.56) Chemotherapy 0.165 
(0.35) PFS 2-4 (0.43) None 
Stage TV PFS 0-1 (0.44) Chemotherapy 0.155 
(0.42) PFS 2 
(0.23) 
Age <60 (0.14) Chemotherapy 0.011 
Age >60 (0.86) None 





PFS 0-3 (1.0) Chemotherapy 0.062 
Extensive 
stage (0.61) 
PFS 0-2 (0.77) Chemotherapy 0.075 
PFS 3-4 (0.23) None 
TOTAL PROPORTIO'. \ 
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The model is shown in Table 7.6 and suggested that chemotherapy should be defivered to 
)2", '() of all lung cancers, 4D of cases of Not-SCLC, and 86% of cases with SCLC. 
Post-operative adjuvant chemotherapy was not routine climcal practice in either 1995 or 
2002, so if this scenario Nvas excluded then the optimal use of chemotherapy would have 
been 4" "''0 of -all lung cancer cases and 39%of NSCLC cases. 
The model was then repeated using 2002 data and suggested that 43% of all patients should 
receive chemotherapy, 36% of patients with NSCLC (31% excluding post-operative 
treatment) and 82% With SCLC. 
This rate is obviously much higher than the observed use of chemotherapy in 1995 and 
2002. The model does not take into account the age of the patient (other than for the PFS 2 
patients) and chemotherapy is rarely delivered to the very elderly because of concerns of 
tolerance, and frequently patient choice. If the over 80's were excluded from the model, the revised 
estimate was 41% of patients including post-operative chemotherapy, and 37% Without. 
Costs of optimal treatment 
The potential costs of delivering optimal treatment are shown in Appendix 4. A detailed 
health economic analysis is out with the scope of this thesis, but the estimate suggests that, 
based on 2005 figures, the cost to the NHS of optimally mana ing lung cancer would be 91 
between C5.3 and (6-3 miflion per 1000 cases. 
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The grap between optimal and actual treatment 
Table 7.7 sho-, x, s the difference between the models and the actual treatment delivered in South Fast 
Scotland in 1995 and 2002, whole of SCAN in 2004, and for comparison BC in 1995. 
Table 7.7 Gap between optimal and actual treatment 
Model 
2004 













(n 0 73) 
N ot- 
SCLC 
Surgery (based on 
pre-op staging) 
140, ý) 14"o 12% 12% 12()/, ) ? 1% 
Radical radiotherapy 
(excl post-op) 
22% IT/O 4') 13')'/o* 11 
Palliative radiotherapy 4 ') 0,, o 4--)', /'o 42"'0 3 2) "'0 24", ý 34% 
Chemotherapy 
(excl post-op) 
'90 34% 5(", () 12% 0"') 19 W/"O 
SCLC Chemoradiation 38% 35% 0'/ 8,0 18% 20 21% 
Chemotherapy 86% 82,, 'o 66% 68% 1-111% 7, Vo 
Palliative radiotherapy 43% 460,, "o 21% 22% 1DO'n 3()",, ) 
- dropped due to higher case ascertainment in 2004 and also includes patients from Dumfries and Galloway. 
The gap between the modelled o timal treatment and actual treatment delivered has Z: -) p 
narrowed over the last decade, but there still appears under-use of chemotherapy, 
particularly for NSCLC, and in use radical and palliative radiotherapy. 
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The model developed obviously has a number of weaknesses 
1) Data -, vas missing on performance status and stage in up to a fifth of patients and 
necessitated the extrapolation of data to the , N-hole group. This was likely to have under- 
estimated the proportion of patients with metastatic disease, or very poor performance status 
who were less hkelý, to be presented at the multi -di sciphnan- meeting- 
2) Lack of data on co-morbid diseases particularly cardiovascular and cerebrovascular disease 
which can have a major impact on management decisions, particularIv sultabilin- for surgen. 
3) Lack of published population-based data of severity of symptoms and distribution of 
metastases at time ot presentation. 
4) It was impossible to model patient choice as decisions ,,, -hether or not to have treatment 
can be based on a myriad of physical, psvCholo ical and social factors. 91 
Further prospective data coRection on severity of symptoms at presentation, co-morbid 
diseases and reasons behind patient and clinician decision making is required to improve the 
accuracy of the models. 
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Summary of results 
The optimal use of surgery in South-East Scotland was not dissimilar to that 
observed over the last decade. 
* Though the use of radical radiotherapy increased to 11.4% of the population in 2004, 
the model suggested that up to 19% of the population might be suitable for this 
treatment. 
0 There maybe under-use of palliative radiotherapy, but it is possible that clinicians are 
using chemotherapy instead to palliate patients who also have systemic symptoms 
and to prolong sunival. 
0 Though the use of chemotherapy has increased markedly in the last decade, there 
appeared to still be under-use in patients with Stage IV NSCLC, though this may 
reflect patient choice or other co-morbid conditions, such as, ischernic heart disease 
Nx-, hich make the use of chemotherapy more hazardous. 
* If optimal treatment were delivered then around 35% of patients would be treated 
with curative intent. 
199 
CHAPTER 8 
Discussion and Conclusions 
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Discussion 
The work in this thesis demonstrates conclusively that in 1995, the survival of lung cancer 
patients in Scotland was inferior to that observed in British Columbia. This conclusion was 
reached by comparing two cohorts of patients using simAar data collection and analysis 
techniques. 
The potential reasons for poorer lung cancer survival in Scotland can be summarised as 
follows: 
1) turnour related factors, 
ii) patient related factors and 
iii) availability and use of treatment. 
1) Tumour related factors 
i) Tumour pathology 
The proportion of patients with different patholo ical sub-types was statistically significantly 91 1 
different between BC and Scotland. Primarily, this was due to fewer patients in Scotland 
having a tissue diagnosis (74% N- 89%). In both populations approximately 15% of patients 
had small cell lung cancer. However, within the patholo ically confirmed NSCLC patients 91 
there were fewer cases of adenocarcinorna in Scotland than BC (19.5% v 34"/ý'(), respectively), 
although this could have been due to the lower rate of pathological confirmation. In some 
series patients with adenocarcinoma had improved survival, particularIN' if they had 
undergone surgery. However, this was not observed in either the BC or Scottish cohort. 
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Consequently, it would appear that difference in pathological subtypes was not a significant 
factor in the inferior sunival in Scotland. 
ii) Tumour biology 
Over the last decade a considerable amount of research effort has been spent on examining 
the different biolo, 7qcal profiles of lung cancer. Techniques such as, immuno-histochernistry, 
proteomics, and genomics have been used to attempt to correlate any changes in biology 
with both tumour behaviour and outcome. 
A large number of studies have been conducted to search for improved prognostic markers 
to use in routine immunohistochernical examination of pathological specimens. However, to 
date only I-, 7-i-67 (a marker of proliferating cells), p53 and Bcl-2 (both associated with 
programmed cell death) appear finked (albeit weakly) to prognosis. Other markers which are 
associated with changes in prognosis in other turnours, namehl EGFR and HER2 (both 
regulate cell proliferation), have not however demonstrated consistent results in lung cancer 
patients. Other cellular changes which might prove predictive of prognosis include VEGF 
(regulates new vessel formation), E-cadherin and P-catenin (involved in the control of 
cellular adhesion), p27 and p16 (involved in cell cycle control), but these require prospective 
vabdation [213]. 
Genomics is the study of changes in the genetic make up of a cell, whereas proteornics 
examines changes in the proteins. Over the last decade, research has shown that although 
genetic changes are important in the development of cancer, so too are any alterations in the 
form or function of the regulatory cellular proteins. These changes will not be detected bv 
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gene analysis alone. Both genomic and proteorMc techniques have major advantages over 
immuno-histochemistry as they can examine multiple changes in a cancer cell, and hence 
produce profiles of clustered alterations that can predict outcome more accurately. Profiles 
which are predictive of a worse prognosis, were iri-itially identified in breast cancer [199], but 
more recently profiles predictive of inferior outcome have been identified in 
adenocarcinoma [14,75,136] and squamous cell carcinoma of the lung [96]. Studies have 
also identified profiles that might predict earlier lymph node spread [211], for inferior 
outcome following surgery [154] and for an increased risk of metastasis [161]. 
k'v'hether or not differences in the molecular profiles of lung cancer exist between BC and 
Scotland is unknown, but the different racial profiles of the two regions make this a 
possibility. One study examined variations in EGFR gene mutations in specimens from 
Japan, Taiwan, USA and Austraba, and demonstrated that ethnicity, but not geography, was 
linked to EGFR mutations. However, these changes were not prognostic [1771. 
To date no studies have been performed to investigate whether there are variations in the 
genomic or proteomic profiles in turnours from lung cancer patients around the world. 
Prospective studies would be required to exarnine if such biological differences indeed e-.,,. ist, 
and xvhether or not they could be a contributory factor to the inferior survival in Scotland. 
iii) Stage at presentation 
Table 2.2 demonstrates that the proportion of patients presenting with metastatic lung 
cancer varies from 28 to 45% around the world. Though undoubtedly some of this variation I 
will be real, some will be due to the varying number of investigations performed; the more 
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investigations performed the more likely it is that metastases are found. As a result, the more 
recent publications will generally report higher rates of metastatic disease. 
The allocation of cancer stage in every-day clinical practice is difficult and often judgments 
have to be made on relatively few investigations. ConsequentIN,, the accuracy of staging in 
population-based series will be far less robust than is observed, for example, in clinical trials 
where multiple investigations are performed to ensure accurate staging. Although when ever 
possible the more precise TNM staging was used wherever possible in this thesis, for many 
patients, particularly in the 1995 cohorts, these data were not avaflable and therefore the 
alternate systern of local, re ional and distant stage was used. However, this latter system is 91 
ven- open to interpretation, for example in the classification of intra-pulmonary lymph 
nodes. In the TNM staging involvement of these lymph nodes indicates N1 or Stage II, but 
in the SEER svstern the disease is classified as Tocabsed'. Some inconsistencies were also 
present in the previously collected Scottish 1995 data between pathological TN-Nf stagling and 
the 'local, re ional, metastatic' system. This required amendment to ensure a consistent 91 
approach between the BC and Scottish cohorts. The patients in the 2002 and 2004 SCAN 
cohorts were mainly allocated a TNM stage at the multidisciplinary meeting by lung cancer 
oncologists and therefore staging would have been much more accurate. 
In 1995 in Scotland, 31% of patients presented with distant disease compared with 
37% in 
BC, but in 2002 in South East Scotland 42% had metastases at presentation. 
It seems 
s is probabh an artefact unlikel)T that patients presented with more advanced 
disease so thi 
due to i) higher case ascertainment (92% 1995' v 96% in 2002), and 
fi) increased use of CT 
scanning and improved image quahty. 
In 2004, the proportion of stage IV patients in South 
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East Scotland was 41"'o, sugggesting that 40'), "0 is a more accurate estimate for Scotland, than 
the 1995 figure of 31",, "o. 
In 2002 35", "o of patients presented with regional disease, 14% locabsed and 9% unknown 
and in 2004 380, `0 had regional disease, 12') locafised and 9% unknown stage. 
In recent publications reporting 'whole -population' data from the USA [33,127], around 21- Z: ) 
22' 0 patients presented with localised, 26% regional, and 41-43% with distant disease. These 
figures are similar to those obsen, -ed in the BC cohort. Therefore, though the proportion of 
patients presenting with metastases in Scotland was possibly similar to that in North 
America, there appears to be fewer patients presenting With localised disease; the stage that is 
most amenable to curative therapy. 
In order to have long-term survivors, it is important that as many patients as possible receive 
potentially curative therapy; the higher the proportion of patients with early stage disease, the 
better the population-base outcome. For example, with a five-year survival rate of around 
50% after surgery, a population with 15% sur ical candidates will have a five-year survival 91 
rate of 2.5% less than a population with 20% of patients suitable for this treatment. 
Therefore, strategies are required to optimise the number of patients presenting with earlý 
stage disease. 
The whole premise of cancer screening, and healthcare 
pofiC)T to reduce waiting times, is 
driven by the belief that earlier detection will automatically result in improved survival. 
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Ho-\N-e%-cr, it is important to determine whether there are data to support this supposition, or 
whether the biological behaviour of the tumour is the primary determinant of outcome. 
Currently, in the absence of an effective screening test, the majority of lung cancer patients 
are diagnosed with symptomatic disease. If the inten;, al from symptoms to diagnosis has an 
impact on stage at presentation, then patients need to be aware of the potential signIficance 
of any new symptoms[182]. They then have to have access to medical practitioners who 
recognise the sign-ificance of these symptoms and instigate further investigations. However 
in lung cancer patients, the higher rates of co-morbid disease may disguise cancer symptoms, 
for example, a chronic cough from chronic obstructive pulmonary disease [128]. In a series 
of in-depth interviews with twenty-two patients recently diagnosed with lung cancer, Corner 
et al noted that patients frequently tried to manage their own symptoms, often not 
recognising them as serious and warranting medical attention. Patients often only presented 
to their GP when it reached a severity with which they could no longer cope [42,43]. Only 
haernoptysis prompted an early visit to the doctor. Overall, a general decline in health had 
occurred over a median period of seven months prior to diagnosis, with the presenting 
symptom only present for a median of two months. There was no difference in the nature of 
the symptoms in patients who presented with operable disease, and in those patients who 
did not. 
Table 8.1 shows the studies, written in English, published between 1990 and September 
2006, which examined the impact of delays in presentation, diagnosis and treatment for lung 
cancer patients (search strategy: Pubmed using terms 'lung cancer' and 'delav,, all reference 
lists searched to identified missed publications). The median time from first symptom to 
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treatment ranged from 70 to 112 davs, and from presentation to a doctor, to commencing 
treatment, it was 48 to 109 davs. 
A number of the studies also examined the impact of delays on stage at presentation and/or 
sunival. In an analysis of a database of a large Italian hospital, Buchern and colleagues noted 
that although the surviVal of patients whose symptoms had been present for more than t-\x-o 
months appeared to be inferior, on multivariate analysis only the presence of dyspnoea, chest 
pain or systen-uc symptoms were associated with increased hazard of death. Whereas, 
asymptornatic patients had a reduced hazard of death (0.76 (0.62-0.94)) [30]. In a study from 
the Hospital del Mar, Barcelona including 566 lung cancer patients, the interaction between 
first symptoms and diagnosis (SDI) for patients with lung turnours was complex; patients 
with a verv short, or ven- long SDI, had a reduced hazard of death compared to those with a 
medium SDI [119]. 
Only one small surgical series of 172 patients demonstrated a negative impact of delays; 
fewer patients presented with operable disease when the delay was longer [39]. However, 
eight other studies have either found no impact, or that those patients With a loqer delay 
have an iVroved outcome. Tl-ýs is likely to be because patients \,, -ith rapidly progressive 
sym toms have biolo icaNy more aggressive tumours and therefore present with more IP 91 
advanced disease. 
A similar result has been noted in South East Scotland. In 2005,539 patients were referred 
to the three hospitals in Lothian healthboard. The median survival for the 336 patients 
treated in under 62 days was 51 months (3.9-6.2) compared xvith 21.4 (24.4-28-3) for the 1 DO 
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patients with a delay of more than 62 clays (remaining 53 date referral unknown). The hazard 
of death ad'usted for age, gender, performance status, deprivation, stage and pathology was 
1.9 (1.4-2.6) for those treated after 62 days compared with those treated more quickly 
(Fergusson and Erridge unpublished data). Z-) 
Consequently, although delays in diagnosis undoubtedly cause psycholo ical distress to 91 
patients and their carers, it appears that for patients with symptomatic lung cancer, it is the 
biolo ical behaviour of the turnour and not delays in presentation which is likely to be the 91 
main determinant of sun-l-val. 
Over the last thirty years a number of lung cancer screening trials have been conducted to 
investigate the use of chest radiographs, sputum cytoloo-y and latterly spiral CT scan ing and bý )I ni 
biolo ical markers. At present none of these have been proven to reduce mortahty rates. 91 
Advocates of screening assert that the discm-cry of small lesions must improve outcome by 
detecting the lesion at a time when surgenl is possible [89]. In the large US CT screening 
trial, 90% of patients With turnours < 15mm had no evidence of nodal or distant metastases 
compared with 555% for turnours >36mm [91]. The estimated ten year overall survival of the 
412 Stage I tumours which underwent resection was 88%, which the authors concluded was 
superior to SEER data [90]. 
However, screening may cause an apparent improvement in five-year survival rates bý-: 
i) detecting tumours earlier, but not impacting on time of death (lead time bias) 
detecting lesions that would not have become clinically apparent during the patient's 
fifetime (over diamosis) [148]. 
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Until there has been a demonstrable reduction in mortality, the positive impact of screening 
for lung cancer cannot be confirmed [1241. 
In conclusion, there appeared to be a higher proportion of patients in Scotland presenting 
Nvith regional stage disease. Therefore less patients were suitable for surgery, and 
consequently there were fewer long term survivors. Based on current evidence it does not 
appear that patient education on symptoms would result in an earlier diagnosis and the 
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2) Patient related factors 
i) Gender 
In almost all population-based lung cancer series women have longer survival than men. The 
reasons for this and whether or not women truly are at greater risk for developing lung 
cancer than men, has been the subject of much debate [1471. 
Women may be more susceptible to lung cancer for two reasons. FirstIv, due to different 
polymorphisms of the enzymes that help break down the carcinogenic polý T cyclic aromatic 
hydrocarbons in smoke (CYPIAl [135] and GSTM1 [193]). SecondIv, differences in the 
genes that control the re-proliferation of bronchial epithelium following damage 
(GRPR)[178]. However, categorical proof that women are at greater risk is difficult to 
establish as it is impossible to account completely for other variables such as, type of 
cigarette and duration of smoking. 
The impact of oestrogen on lung cancer has also been heavily investigated. Case-control 
studies have demonstrated that hormone replacement therapy appears to decrease the risk of 
lung cancer, particularly in female smokers [59,108,169]. 
The improved population-based survival for women [72,127] is particularIN T marked 
following surgery. In the Norwe *an sur 'cal series the five-year relative sun-Wal xvas 56% 91 91 1 
for women, compared with 41 % for men [188]. A similar result has also been observed in an 
American cohort of patients [10]. These studies could reflect lower rates of co-morbid 
disease in women, particularly cardio-vascular disease [203], or possibly different tumour 
behaviour. 
212 
Relative sun-ival should adjust for the difference in fife-expectancy between the sexes, but 
higher rates of smoking-related diseases in lung cancer patients compared to the normal 
population may make this adjustment inadequate [102]. The relative sun-ival model of the 
combined 1995 populations demonstrated that women had a reduced hazard of death (HR 
0.93-0.96). In British Columbia, the improved survival in women was most marked for 
patients undergoing surgery (median sunival 37months men v 49 months women, log rank (D . 
p::::::: 0.02), but the adjusted hazard of death was non-significant (HR 0.8 (0.6-1.05). In 
Scotland, the adjusted hazard of death for women was 0.9 (0.8-0.96) compared to men, but 
there Nvas not a difference following surgerý 7' . Although this may simply reflect a smaller 
proportion of patients having this treatment; when the whole group receiving 'potentiallý 
curative therapy' x-, -as examined the hazard ratio of death was 0.81 (0.7-0.99) for women. 
lf a lung cancer population has a higher proportion of women the difference in survival 
might contribute to the improved surviVal. However, this was not the case in Canada and CC 
Scotland where around 40% of patients were women in both populations ()(' p=0.12). 
ii) Age 
The age profile of a population will impact on the observed overall survival. As was 
obsen, ed in the 1995 and 2002 comparison, the median age of lung cancer patients in 
Scotland is increasing. This is because the birth-cohorts from the 1920s to 1940s, with the 
highest risk of lung cancer, make up the bulk of the current patients. This trend Nvill continue 
over the next decade, which might result in inferior lung cancer survival rates 
despite the use 
of more treatment. The data presented in Table 2.2 
demonstrates that the median age of 
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patients diagnosed in late 1980s to early 1990s was between 60 and 65, Nvhereas in more 
recent case-series the median age was 65 to 70 years. 
A population with a large number of younger patients will always have better survival as 1) 
the patients will be more suitable for aggressive curative therapies, and ii) patients are less 
hkelv to succumb to other causes of death.. 
The age profiles of the two 1995 populations were similar with median age of 70 years in 
both the BC and Scottish patients, although BC had a slightly higher proportion of patients 
under the age of 60 years (figure 5.1). The relative survival models (Table 5.9) demonstrated 
that the hazard of death in Scotland was still markedly increased even when differences in 
the age profiles were taken into account 
iii) Performance status and weight loss 
Performance status, or the abilitv to function in everyday tasks, is a strong predictor of 
survival following a diagnosis of lung cancer. However, there are little published data 
population-based data on performance status in lung cancer patients. In neither of the 1995 
cohorts were these data cotlected, but in 2002 in South East Scotland 41% of patients had a 
PFS 0-1) 22% PFS2) 24% 3-4, and it was not recorded for 13% of patients. The median 
survival was 10.1 months, 4.5 months, 1.7 months and 2.6 months, respectively. In a 
population-based cohort of 309 patients diagnosed in BC in May and June 2002,90% had a 
PFS 0-2 recorded by their GP, with a median survival of 14.7 months for those with PFS 0, 
7.8 months if PFS 1,5.7 months PFS 2 and 2.1 months PFS 3-4 (unpubhshed data TvIdeslev, 
Roques and Erridge). De Rijke and colleagues report data from the Netherlands with 64% of 
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patients having a PFS 0-1,19"'o PFS 2,12(), ', o PFS3-4 and 5",, "o unknown. Howe\-er this paper 
does not report surv, ival data. 
Weight loss is also associated with a worse outcome, primarily as it is a predictor of more 
advanced stage disease. In a hospital based senes Tammemagi et al showed that 40% of 
patients with Stage 1 disease had weight loss compared Nvith 20% with Stage IN' disease [192]. 
iv) Ethnicity/Race 
Several series from the USA have demonstrated lower survival in black patients with lung 
cancer when compared with white patients. This appeared to be due to more black patients 
presenting With advanced disease [74], and lower use of lower use of surgery [10]. 
In Scotland only 4% of the population are of non-British or Irish origin (2001 census) 
compared Nvith BC where 42% (of single ethnic group responses) are of British origin, 28% 
from other European countries, 19% Asian and 5% First Nations and the remaining 4% 
from other ethnic groups (1996 census). 
Unfortunately data on ethnic origin was not coflected in either country in 1995 and therefore 
the impact of race coLýd not be examined in this thesis. 
v) Social deprivation 
As has been alluded to earlier, social deprivation has in some studies been shown to have an 
i al i lung cancer pa 'ents [209]. Social depri impact on both use of treatment and surviv in ti 1 ivation 
can either result in inferior access to healthcare [23,33,78,127], less treatment delivered 
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[t0j, or increased rate of death from co-morbid disease [128]. The lower use of treatment 
may be a result of higher levels of co-morbid disease [128], but does not appear to be due to 
more advanced dise, ýisc at presentation [27,173]. 
For the BC patients only the data on household income were available. It should be noted 
that the use of post-code to determine median income is a crude estimate of the social 
deprivation of any particular individual [21,1181. However, it appears that patients who 
resided in wealthy areas with a household income of $CDN60000 or more per annum were 
more likely to undergo surgery or chemotherapy, but use of radiotherapy was not increased. 
The overall survival was not affected bv income. 
In Scotland, data on a broader range of factors (overcrowding, male unemployment, social 
class and car ownership) are used to estimate deprivation and have been shown to be 
superior to using income alone. The group of patients hVing in more deprived areas were less 
likely to undergo surgery (radiotherapy and chemotherapy not statistically different), and the 
surviVal was inferior (median 3.5 v 4. Omonths). 
The apparently higher proportion of patients living in a deprived area in Scotland may be an 
artifact due to the different methods of defining deprivation between the two countries. In 
Scotland, Carstairs' index groups 4 to 7 represent around 58 % of the population of 
Scotland, whereas for BC the median household income was used to split the population 
into two groups. Also how comparable these measures are of true deprivation is unknown. 
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Both Canada and Scotland have state-run healthcare systems which endeavour to offer 
equitable access to healthcare for all citizens. A number of American and Canadian 
comparisons [11,21,781 have demonstrated that impoverished patients fared better in the 
Canadian healthcare system than in the USA. Why Scots do not similarly benefit from state- 
run health care is unknown, but could reflect increased co-morbidity in people hVing in 
deprived areas [128], which make treatment more difficult to deliver and results in deaths 
from other causes. Though the impact of deprivation was less marked than for other factors, 
the adjusted hazard of cause-specific death in the less deprived areas was 0.9 (0.85-0.99 
p-0.03) compared with the more depnVed areas, whereas the other significant factors such 
as age, stage, no pathology and region all had p values </= 0.01. 
In summary, the possible increased social deprivation in Scotland could be a contributory 
factor to the inferior survival of Scottish pafients, but this effect is hkelv to be minor in 
comparison to other factors. 
vi) Life-style 
a) Smoking 
Unfortunately data on smoking was not reliably recorded in any of the three cohorts, but 
smoking is obviously the primary life-style factor that could potentially impact on the b 
survival of lung cancer patients. Not only is smoking the prime aetiolo 
ical factor, 91 
accounting for 90-95% of lung cancers, it is also the main causative agent 
for many of the 
co-morbid diseases (COPD, cardiovascular, peripheral vascular and cerebrovascular 
disease). 
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In a recent analysis of the Eindhoven Cancer Registry more than half the lung cancer 
patients bemveen the ages of 50 and 64 years had one or more serious co-morbiditA,, 
compared with around a third of patients with colorectal, prostate, breast and lymphoma in 
the same age group [203]. This difference was particularly marked for COPD, which \vas 
present in around 20% of the lung cancer patients, and 5%of patients with other malignant 
diagnoses. The rates of co-morbidity increased with age, with 72% of men and 61% of 
women over the age of 80 years having at least one serious co-morbid disease. These high 
levels of co-morbid diseases will impact on overall survival. 
For more than 25 years, researchers from the University of Glasgow have been following a 
large prospective cohort of residents in two regions of Strathclyde (Renfrew and Paisley) 
In a recent public examining a range of public health ation they noted a positive 
correlation between high levels of carboxyhaemoglobin (a biochemical marker for level of 
smoking) and deaths from lung cancer, cardiovascular, cerebrovascular disease and COPD 
[88]. 
In Scotland currently around 30% of Scots smoke, compared with 16% of British 
Columbians. This lower rate of smoking will result in less co-morbid disease and could 
therefore explain some of the difference in 
sunival observ, ed between the two cohorts. 
b) Diet 
A number of prospective cohort studies have demonstrated that a 
diet rich in fruit and 
vegetables may mitigate some of the risk associated with smoking 
[168,1801, and improve 
the prognosis of lung cancer patients [1811. The diet In Scotland Is notorlous 
for belng low In 
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fruit and vegetables. In 1996, only 18"/'(ý of people in Scotland ate five portions of these foods 
each day (13')ýýO in the most deprived group), and only 19% knew of the recommended 
guidelines. Fortunately the health education message appears to be hitting home, and in 2004 
33% ate five portions a day and 63% knew of the recommendafions, although onIN- 49% 
came from the most depri-,, -ed group [1231. 
The population of British Columbia is almost all immigrants who have moved there from all 
over the world during the last 150 years. Though citizens with British ethnic origin constitute 
a sizeable minority, many come from the Mediterranean area, Balkan states, Indian 
subcontinent, and South East Asia. This has resulted in one of the healthiest and varied diets 
in the world, With low consumption of fast-foods. In addition, a high proportion of the 
population also take regular exercise. For the period 1995-7 the age-standardised mortality 
rate for ischaernic heart disease was 113 per 100,000 for BC [66] compared with 158 per 
100,000 in Scotland in 1996 [174]. This clearly demonstrates that the lower smoking rates, 
healthier lifestyle and different ethnic mix in BC may have improved the outcome of lung 
cancer patients. 
In conclusion, the life-style of Scottish patients with higher rates of smoking and a diet with 
less fruit and vegetables may be a contributory factor to the inferior survival when compared 
with BC. 
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3) Use of treatment 
i) Surgery 
In lung cancer the proportion of individuals undergoing surgery is the strongest determinant Z--) 
of the five-year survival rate of a population. With good patient selection, around 4(-)-5()(', ) 
should be ali, \-c five N-ears after this treatment, compared with 15"'o, after conventionalh, 
fractionated radical radiotherapy. Due to the different methods of reporting the data (whole 
population -, - patholo ical subt) es) it is difficult to give exact figures to demonstrate the 91 q) 111 
correlation between surgical rate and survival, However, in populations where more than 
20", 0 of patients undergo resection (SEER series [72,1601, Bas Rhin, France (TNSCLC only) 
[68], Victoria, Austraha [163]) the observed fivc-year survival rates exceed 10%, whereas in 
populations With a resection rate of around 10", "() jreland [120], Yorkshire [3-1) the five-year 
survival rates are below 10%. In BC, 21.1% of the population underwent a resection (29.2"o 
NSCLC) and the five-year relative sun-l-val rate was 12%, compared with 10.6% of Scottish 
patients undergoing surgery (18.2% NSCLC), with an overaH five-year relative-surVival rate 
of 6%. 
In both BC and Scotland in 1995, age and social deprivation were associated with reduced 
odds of having surgery, but in 2002 in South East Scotland advanced age was the only 
patient-related factor associated with lower use of surgery. In the seven years between 199D 
and 2002 there was no increase in the use of surgery in South East Scotland; the rate in 1995' 
was 10.2", ý', ) and in 2002 was 10.5", "o (though the median age of the population increased from 
70 to -72.5years). However, the optimal treatment model (Table 7.4) suggested that this was 
due to, 1) only 23% of patients presenting with Stage 1-11 disease, ii) a high proportion have 
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severe COPD, and iii) many had a poor performance status, only between 10.4 and 11.8% of 
patients from South East Scotland appear to be suitable for surgerý - 
Therefore, it may be that unless more patients present with carly stage disease and co- 
morbid diseases can be managed more successfufly, the surgical rate in Scotland mav have 
reached a plateau. Without this change survival rates could onli T be improved by increasin Z-) 9 
the proportion of patients receiving radical radiotherapy. 
Of the patients , N-ho underwent a resection in BC, 2.7% died within a month of surgery 
(post-operative death) compared with 9.2% in Scotland (but lower in South East Scotland 
(31"o ln 1995 and 2`0 -)02)). 
The 1995 Scottish su ical mortality was much higher than most '? ( rgl 
su ical series published in the last twenty years. rg, 
In a population-based series of 132 patients operated in Western Australia, 6% died of post- 
operative compfications (30,, "0 lobectomy and 12% pneumonectomy), and another 47% had a 
serious, but non-fatal complications (primarily infection or persistent air leak-) [134]. 
In a random sample of 2118 patients over the age of 65 from the SEER database operated 
on between 1986 and 1996, the 30 dav mortality rate was 6% for patients in hospitals which 
operated on less than eight patients per year. This was compared with 3% in centres which 
operated on more than 66 patients per annum [9]. There was also an impact on overall 
-e-year survival rate of 33% in the smaller hospitals and 44% in the larger. sunwal; Nx-Ith a fiv 
11 
After adjustment for other factors, such as age, gender, stages of cancer, operation, income, 
and co-morbid disease the odds of death from lung cancer by five years was 0.8 in the larger 
hospitals when compared -with the smaller hospitals. 
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In a Spanish series of 2994 cases operated on between 1993-7 around 7% of patients died 
within 30 days of their operation. Factors which were associated with increased risk of death 
, xere older age, poor performance status, incomplete resection, exploratorv thorocotomv, 
and peripheral vascular disease. There was no effect of hospital size on the post-operative 
mortabtv rate [691. 
In the large Nonve ian series of 3211 patients operated on 1993-6, the 30 dav mortality -, vas 91 1 
4.8"0, but there was no impact on the five-year survival rate, of the number of patients 
operated on each year in each hospital [188]. 
The reason for the lack of impact of hospital size on patient outcome in the 'Norwegian and 
Spanish patients may either be because these patients were operated on more recently and 
information on best practice had, by then, filtered down to smaller centres, or the public 
healthcare system in the European countries ensures better equity of quality standards. No 
impact of case-load could be seen in the Canadian patients. 
It therefore appears that the post-operative mortality rate in BC was lower than most 
reported series, but in Scotland it was higher. The cause of the higher post-operative 
mortality in Scotland is unknown. There was no statistical association with social deprivation, 
but the mortality rate varied markedly between regions; 14% in Re ion 1,5% in Re ion 3 1 
91 91 
and 3% in Region 2 (Chi squared p=0.002). This could in part be explained by the fact there 
were fewer pneumonectornies performed in Region 2 (34%), compared with Region 1 (40%) 
and Region 3 (44%), but the mortality following pneumonectomy in 
Re ion 2 (6%) -, N-, as 91 
under half that observed in Region 1 (19.5%). 
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The higher rate of post-operative deaths contributed to the inferior survival in Scotland but 
on multivanate analysis of patients surviving more than one month following sunlVal still 
demonstrated an increased hazard of death for Scots. 
Table 8.1 shows the five-year sunTival rates in a number recently published surgical series. 
The effect of stage at presentation on sunival, is clearly demonstrated. In the Japanese series 
other factors that verc associated with improved survival included female gender, vounger 
age and adenocarcinoma F9]. 
In a subgroup of Stage IA resected cases of the large SEER series, improved survival was 
noted in patients under the age of 70 years, with well differentiated turnours, lesions less than 
10mm in size and bronchoalveolar pathological subtype [158]. In the BC and Scottish series 
bronchoalveolar carcinomas were included Within the adenocarcinoma group, but ail analysis 
of the sunlival of the patients from BC (where separate data were available) did not 
demonstrate a d-ifference in sunival following surgery between bronchoalveolar and 
adenocarcinoma (median sunTiVal 63 v 59 months). 
The overall survival rate in Scodand was around 50% at five Vears of patients with stage I 
disease, and 30% with Stage 11 disease, which was not dissimilar to the rates seen in Norway 
and Australia. Though the SEER results appear superior, the series report cause-jpe, ýific not 
overall sun)l*val, and the data from Japan may 
be biased as it is based on retrospective 
questionnaires reported by surgeons. However, the survival 
for the stage III resected patients 
in Scotland does appear to be inferior at 
8% compared with 15-30% in most other series. 
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The reasons for this -area uncertain but may be due to under-detection of metastases (real 
stage IN' not stage 111). Other explanations, such as different tumour behaviour, are I 
speculatAve. 
In conclusion, the use of surgery in Scotland is lower than in many countries, but this may 
be appropriate as medically fit patients with early stage disease constitute a lower proportion 
ot patients than in BC and reported in other series. The survival foHowing surgery was worse 
in Scotland than BC, partly due to more post-operative deaths. However, compared to other 
series Scottish patients , vith early stage disease appear to have similar surviVal, but those with 
stage III disease fared less well. 
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Table 8.1 Outcome follou4ng surgery in population-based series 
Author/Year Population Distribution of stage Survival 
Strand (2006)[1881 Norway 1993-6 650,0 Stage I five-ycar RSR 46.4" 
3211 pts Norwegian 23% Stage 11 (5(-)(',, OS) Stage 1, 
Cancer Registry 10()., (, Stage 111 28 %(2: -)'',, ) Stage 11 
2% Stage IN' 18"'n (16'-/o) Stage III 
Frei'Xinet (2006)[69] Spain 1993-7 49% Stage I five-year OS -38",, 
2994 pts reported to 17% stage 11 
surgical register 34% Stage III 
Goya (2005)[791 Japan 1994 52% Stage I five-year OS 
retrospective audit of 15% Stage 11 IA 80%, IB 60%, 
surgical cases 20% Stage III IIA 6W, 'o, IIB 42"o, 
3% Stage IV IIIA 30",,, IIIB 19% 
IV 20" u, 
Bach (2001)[9] SEER random sample 69% Stage I ffi-e-vear OS 
of 2118 patients 20% Stage 11 38'), o 
>65vrs 11 % Stage III 
operated 1986-96 
Radvin (2006)[1581 SEER 1988-97 68% Stage I five-year CS 
17,310 patients 22% Stage 11 IA 77%, IB 62(1, "o, 
10% Stage III IIA 49%, IIB 36' 
IIIA 36-230, 'o 
Mina (2004) [134] Western Australia 57% Stage I five-year OS 
Cancer Registry 1996 15% Stage 11 51 % Stage 1, 
132 patients 28% Stage 111 45% Stage 11 
15% Stage IIIA 
BC 1995- tl-ýs study 438 54% Stage I Five-year OS 38.6% 
19% Stage 11 48% Stage 1, 
13% Stage III -) 7 0,, ' /, 0 Stage 11 
2% Stage IýT 17(), ) Stage III 
12% unknown/SCLC 
Scotland 1995 - this 406 40% Stage I 
Five-year OS 35.9% 
studv 22% Stage 11 52"o Stage 1, Z-) 
12% Stage 111 29()//() Stage 11 




Radiotherapy is the most frequently used treatment modality in lung cancer. In BC, 
received radiotherapy compared with 36.5% in Scotland (Chi-squared p=0.004), though the 
adjusted odds ratio -was 0.9(0.8-1.04). 
In either country, very few patients received radical radiotherapy (2.2% in BC and 2.5""o in 
Scotland), though more patients received adjuvant thoracic radiotherapy for L-SCLC in BC 
(5-0, ) in BC v. 14% in Scotland). The fractionation schedules used were fairly similar 
reflecting the fact that many of the BC Radiation Oncologists NNere trained in the UK-. 
In BC, radiotherapy was more frequently used in younger patients, those with replional or 
metastatic disease, or with a tissue diagnosis. In addition, patients hVing closer to a cancer 
centre Nvere more likely to receive radiotherapy, whereas in Scotland those fivingfin-ther from 
a cancer centre were more likely to receiVe radiotherapy. The other factors, including 
younger age and more advanced stage disease were also important in Scotland, but patients 
with SCLC were less likely to receive radiotherapy than those with NNSCLC. The reason for 
the increased use of radiotherapy in Scots who had further to travel is unknown, but in the 
mild 1990s in Glasgow (where the majority of the patients With short travelling times resided) ) 1. 
the cancer centre had particularly long waits of more than six weeks for radiotherapy and 
this may have influenced treatment recommendations. Barbera and coHeagues obsened a 
sirmlar effect in Ontario in the lung cancer patients treated between 1994-1996 when 
radjographer shortages resulted in long waits for treatment 
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The use of radiotherapy in BC and Scodand, was similar to that reported in most other series 
that included patients without pathological confirmation [37,48,120,163], though was a 
little lower than was observed in New South Wales, where 56% of patients received 
radiotherapy [2011. In the large SEER series of patients diagnosed 1975-1999 (all of whom 
had pathological confirmation), 51% of men underwent radiotherapy and 47% of women 
[72]. In BC 43.8% of patholo ically confirmed cases received radiotherapýT, whereas in 91 
Scotland this -, -, -as a little lower at 40.3%. 
The Scottish model described in chapter 7 (Table 7.5) estimated that 66% of patients could 
benefit from radiotherapy as part of initial therapy. In Canada, Tyldeslev et al estimated that 
44.6'. 1"() of patients (+/-3.6%) would need radiotherapy during the initial treatment and 16.5% 
(+/-1.5%) later (lifetime use of 61%)[197]. The Australian model estimated that 76% of 
patients would require radiotherapy during the course of their illness [49]. 
Obviously the optimal rate of use of radiotherapy will vary between countries according to 
the distribution of the stage of presentation, pathological subtypes and differences in 
patient's suitability for treatment. In addition, the indications for radiotherapy differ, either 
because of new data (Canadian model was produced in the late 1990s) or different 
interpretation of the evidence. For example, in the Canadian model radiotherapy was only 
administered to patients With L-SCLC who were responding to chemotherapy. Evidence 
now suggests that thoracic radiotherapy should be given as early as possible with 
chemotherapy before the response can be assessed [61]. Also, in the Canadian model, 
radiotherapy was only given to patients with E-SCLC if they failed to achieve a complete 
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response to chemotherapv. However, if such an approach was adopted in the Scottish model 
the optimal radiotherapy rate would only change by 1% as it is the first three decision steps 
(patholo ical t-, pe, stage distribution and performance status) that have the most impact. 91 Y 
The rates observed in BC and Scotland were lower than the models predicted, but discussed 
in chapter 7, one of the main unknown factors is the severity of the thoracic symptoms and 
whether or not they require palhation with radiotherapy. The dechne in use of palbative 
radiotherapy over the period 1995 to 2004 (see appendix 3) has been matched with an 
increase in the use of chemotherapy. This suggests that chnicians are opting for the latter 
treatment, N',, -hich has been demonstrated to improve median survival and one-year survival 
rates In patients With metastatic disease, unlike low-dose palliative radiotherapy [44]. 
An alternative, benchmarking approach was adopted by the team from Kingston, Ontario. 
This technique assumes that areas with no resource restrictions and no fee incentives should 
have optimal use of radiotherapy. In the regions that they felt met the above criteria, the use 
of radiotherapy was 41.3% (49.3% NSCLC and 47% SCLC), but the rate vaned from 23% to 
43% in Canada, to over 60% in some SEER regions. The lower rate of use in Canada 
correlated with longer waiting times for radiotherapy [12]. This approach, developed by the 
business community, is useful but it is not possible to ensure, even with Ontario's practice 
guidelines and multi-disciplinary working, that everv patient who might have benefited from 
radiotherapy was discussed with such a lung cancer specialist. 
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Although the rate of use of radiotherapy in South-East Scotland did not increase over the 
period 1995 to 2002, the trebling of the use of radical radiotherapy over tl-iis period is 
probably the reason for the improvement in overafl survival. This demonstrates the 
importance of multi-disciplinary discussion to ensure that all patients who could benefit 
from this treatment are seen bya specialist radiation oncologist. 
It appears that in South East Scotland, the rate of surgen, mav have reached a plateau, but if 
the use of radical radiotherapy was that predicted by the model the number of long term 
survivors could potentially be increased. Around a 15-20% patients are alive five years after 
both radical radiotherapy for NSCLC and cherno-radiation for L-SCLC [113], therefore an 
increase in the use of high dose radiotherapy from 3.7%(1995 actual) to 24.7% (model 
optimal) would increase the five ycar survival rate by around 3.1-4.2%. Though this appears 
a tiny increase, it represents more than 50% increase in the number of patients alive at five 
vears. Whether or not this could be realistically achieved, particularly in light of the ageing 
lung cancer population, is unknown. 
In conclusion, the overall use of radiotherapNý was lower in Scotland than BC, but this could 
be accounted for by differences in patient and turnour characteristics. The use of radical 
radiotherapy in 1995 was low in both countries, but fewer Scots received potentially curativc 
chemoradiation for L-SCLC which might have affected the number of long term survivors. 
The use fo radiotherapy in both countries was lower than models of optimal use predict and 
increased use of radical radiotherapy might improve five-year survival rates 
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iii) Chemotherapy 
Until recently the majority of chemotherapy was delivered with palliative intent. Ot-Ay a few 
patients xvith L-SCLC can be cured by chemotherapy alone, with around 5"1") alive at five 
vears, but -\N-lien combined with thoracic and cranial radiotherapy the cure rate increases to 
around 15-20' 0 [76]. 
RecentINI, data has been published which demonstrated that the delivery of post-operative 
chemotherapy can improve the five-year overall survival rate of patients , N-ith patholo ical 91 
Stage 11 and III NSCLC by around [56,207]. However, the impact of chemotherapy on 
long term lung cancer sunival is minimal; patients with L-SCLC represent 6% and those 
with resected Stage 11 and III NSCLC 5% of all lung cancer patients. In addition, within each 
group only a minority of patients actuafly benefit and therefore at five years only around 
1.5"o of all lung cancer patients are alive due to the use of chemotherapy. 
The majority of lung cancer chemotherapy is given to prolong survival and palliate 
symptoms. For patients with extensive SCLC the sur-, -IN-al is increased from a few weeks to 
several months with the use of chemotherapy, but the improvement is less marked for 
NSCLC xvith the median survival increasing by around two months[44]. However, though 
the improvement in median survival is small the number of patient alive at one year trebles 
from 5% to 15% [6]. 
Recent trials have compared a variety of combinations of newer chemotherapy agents, but to 
date no particular combination appears greatly superior to the others in terms of either 
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response or survl\-, al, though the toxicity profiles vaty [171]. Newer biolo ical agents have yet 91 
to ha\ýe a maJor impact on sun-n-al in lung cancer with the majority of trials failing to show 
survival benefit. To date only erlotinib (an epidermal growth factor receptor inhibitor) has 
been demonstrated in Phase III randomized controlled trials to improve survival, and this 
effect -, vas primarily observ, ed in non-smokers with a good performance status [67,176]. 
In 1995, the use of chemotherapy in SCLC in BC was 76% compared with 63% in Scotland 
()(' p<0.001), though the use increased in South-East Scotland to 68% by 2002, and to 71% 
by 2004 (see Appendix 3). 
In Ireland (1994-1998) 60% [120], The Netherlands (1990-1994) 73% [101], France (1993- 
94) 9211"ý'o [114] and Australia (1993-96) 83% [201] of patients with SCLC received 
chemotherapy. In the USA, 69% of patients with SCLC on the National Cancer Database 
(NCD) who were diagnosed in 1995 (hospital registrations only) received chemotherapy [76]. 
Therefore the use of chemotherapy in SCLC in BC is comparable to most other series, but 
the use in Scotland, although improving, remains below most international series. 
61% of patients With L-SCLC received chemoradiation in BC compared with 14% in 
Scotland. A number of trials were published in the late 1980s and early 1990s confirming the 
benefit to sunival of adding thoracic radiotherapy in L-SCLC [104,149]. BC was at the 
forefront of introducing this treatment, and was the lead centre for one of the main trials on 
the tirning of thoracic radiotherapy [139] and therefore combined treatment was the standard 
of care even in 1990 [113]. The introduction of combined treatment appeared to haý-c been 
delayed in Scotland. 
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The data demonstrating the survival benefit of chemotherapy for patients with metastatic 
NSCLC was published in 1995 [6] (although it had been presented at a meeting the previous 
N-car), and therefore its use in 1995 was much lower than was observed in more recent series. 
In 1995, in both BC and Scotland, 8% of patients with NSCLC received chemotherapy. This 
rate increased in South East Scotland to 12% in 2002, and 19% by 2004 (excluding post- 
operative adjuvant chemotherapy). 
In Ireland (1994-1998) 13%, Netherlands (1997-1998) 13% [48], Australia 10% and France 
(1994-97) 39% (excluding post-operative) of NSCLC patients received chemotherapy. 
In a group of patients in the USA over the age of 65 diagnosed between 1991 and 1996 with 
stage IV NSCLC, 26% received chemotherapy [57], and in a second series, also using SEER 
data, which included patients over 65 years with Stage TIM and IV NSCLC 31 % received 
chemotherapy. As data on the use of chemotherapy is not coHected by SEER (above studies 
used Medicare data) it is difficult to ascertain a true population-based use of chemotherapy 
in USA. In the National Cancer Database (hospital based register) 30% of all lung cancer 
patients received chemotherapy. Therefore, if around 85% of patients have NSCLC, 
approximately 23% of NSCLC patients received chemotherapy in 1995 (including some 
post-operative chemotherapy). 
In summary, the use of chemotherapy in South East-Scotland is still below that in the USA, 
but exceeds most other world series from the mid to late 1990s. 
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In both BC and Scotland younger patents, those with SCLC or %\-lth more advanced disease 
were more likell, to receive chemotherapy. However in BC, patients from an area -, vith higher 
than average income -were more likely to receive chemotherapy. This effect was not observed 
in Scotland. NX'hN- such an effect should be seen in BC but not Scotland 11 in. is difficult to explai 
The use of chemotherapy has increased over the last decade, but xvithout more detailed data 
on why patients are not offered or dechne this treatment, it is impossible to know whether or 
not this can be increased further. The chemotherapy agents currently used to treat lung are 
difficult to deliver to patients with severe ischaernic heart disease (increased risk of 
myocardial infarction xvith platinum) and lung disease (gemcitabine pulmonatý- toxicity), and 
are all verv mvelosuppressive. Around 20% of patients receiving palliative chemotherapy for 
advanced NSCLC require acute hospital adnussion for toxic side-effects, such as neutropemc 
sepsis, nausea and vomiting, and renal fallure[165]. 
In addition, manv lung cancer patients who are offered chemotherapy decline it either based 
on prejudice against chemotherapy, or after being told of the possible benefits and side- 
effects[179]. Until more efficacious and less toxic agents are available it seems unlikely that 
the use of chemotherapy, particularly in advanced NSCLC, will increase in Scotland. 
In conclusion, in 1995 the use of chemotherapy for NSCLC was low in both BC and 
Scotland, but fewer Scots than Canadians received chemotherapy for SCLC. However, this 
would only have a minor impact on long term survival rates. 
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Table 8.3 Summary of potential factors contributing to inferior survival in Scotland 
compared with BC 
Factor Cause of inferior long term survival in Scotland 
Tumour related Pathology No 
Biology Possibly 
Stage Probably 





Treatment Surgery Yes - lower use + worse outcome 
Radiotherapy Possibly - lower use in L-SCLC 
Chemotherapy Unlikely 
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Conclusions and Future research 
The aim of this thesis , vas to test the hyPothesis that the outcome of lung cancer in Scotland 
is poor, and that this could be improved by optimal use of treatment. 
It has been demonstrated that the sunival of Scottish lung cancer patients is indeed inferior 
to that observed in British Columbia, and that this appeared to be due to a greater 
proportion of patients presenting with re ional disease, less use of treatment (particularly 91 
surgery), and possibly other factors, such as life-srvIe. 
The pnman- determinant of population-based surVival for lung cancer is the proportion of 
patients undergoing surgery, and to a lesser extent radical radiotherapy. Chemotherapy has 
only a minor impact on long term survival. 
Although it may be possible for there to be a small, further increase the proportion of 
patients receiving radical radiotherapy, which would slightly increase the number of long 
term survivors, in order for the outcome in Scotland to similar to that in BC, the number 
undergoing surgery would have to double. It appears unlikelv, based on the current 
distribution of stage and frequency of co-morbid diseases, that this could be achieved. The 
proportion of patients with COPD and 1schaem1c heart disease is unlikely to reduce over the 
next decade, as the average age of lung cancer patients will actually increase. In addition, in the 
absence of effective screening the proportion of patients with early stage 
disease is unlikely I 
to change in the near future. In light of the lack of impact of 
diagnostic delavs on lung 
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cancer sunTival it may be that turnour biolop, is the principal determinant of stage at 
presentation and outcome for patients with lung cancer. 
In order to confirm or refute this prospective studies are required. It would therefore he 
informative to perform a prospective study in Lothian, Fife and Vancouver simultaneously 
exan-ýining the issues of delays in presentation and turnour biolop,. Such a study could also 
im-cstigate the reasons for the poor fife-expectancy of the Scottish population, such as life- 
stý-le and co-morbid disease. By conducting this study prospectively, many factors that could 
not be addressed in the retrospective study, such as delays in diagnosis, accurate and 
complete recording of performance status, staging and co-morbid diseases could be assessed 
formally. In addition, the reasons behind management choices could be researched. By 
recording all these prognostic factors, along with all treatment delivered, and by tracking 
sun-lval, it would then be possible to combine these data with studies of tumour genomics or 
proteornics to examine if there are different biological profiles of lung cancer in Scotland and 
BC. 
Summary 
The survival of lung cancer patients in Scotland does indeed appear to be inferior to 
that seen in British Columbia, but the reasons for this are more complex than simply 
under-use of treatment. Fewer patients in Scotland are actually suitable for surgery, 
and even if the use of radical radiotherapy were maximal, the survival will never 
match that in Canada. Other factors, such as, tumour stage at presentation, lifestyle, 
co-morbid diseases, and possibly tumor biology, appear also to be important. 
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Appendix 1: BC questionnaires 
Dear Doctor, 
\Vc are performing a study looking at the treatment and survival of all individuals diagnosed with lung cancer in British Columbia in 1995. 
Your patient ................................ date of birth ........................ date of death ............... was recorded in the British Columbia Cancer Registry as being diagnosed with lung cancer. We would be very 
gratcful you could complete the following questionnaire. 
Name 
Date of Birth (mm/ddh-v) 
Date of Death (mm/dd/\-N-) 
Postal Code 
Was the diagnosis of lung cancer patholo ically confirmed 91 






Fine needle aspirate Primary 
Lymph node 
Other mctastases 
If no how was diagnosis made? 
--III.. I 
ý History and examination 
Chest X-rav 
CT scan of chest 
Autopsy 
Other please describe 




Was this patient referred to a lung cancer spcclahst (oncologi I , ist, respiratory phN-sician, thoracic surgcon)ý 
YES NO 
If N-cs, to whom 
at 
If no, xvbv? 
Hospital. 
11 
I ICK appropriate r)ox. 
Patient dying 
Patient refused 
Co-morbid disease-please describe 
Diagnosis made at autopsy 
If possible, wc would like to try and establish the performance status of all the patients diagnosed with lung 
cancer. From your records is it possible to grade the person's daily activityrý 
YES 
_N 0 
Tick at)tDrot)riate box 
Performance 
status 
0 Full), active, able to carr\- out all their normal activities 
1 Restricted in strenuous activity but able to carry out light work 
e. g. house work, office work. 
2 Ambulatorý, but unable to carry out any work activities. Up 
and about >50"O of the day. 
3 Capable of only limited self care confined to bed/chair >500"() 
of the day 
4 Completely disabled. Cannot carry any self-care. Totally 
confined to bed/chair. 
thanks for your assistance in completing this questionnaire. 
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Appendix 2: South East Scotland 2002 study documentation 
Dear Doctor, 
Study - 'Lung cancer in Lothian, Borders and Fife: have treatment 
and survival improved since 1995T 
Re dob /. 
We are performing an audit of the management of all patients in Lothian, Borders and Fife diagnosed as having lung 
cancer in 2002, We will then compare this with a previous study performed in 1995. We shall be identifying all patients 
through the national cancer registration system, and have obtained permission from the Caldecott Guardians in the 
relevant NHS institutions to use patient identifiable data from this source for this purpose. 
As far as possible we are obtaining treatment information collected from prospective audit through SE Scotland 
Cancer Network. In this case we are relying on the implied consent given by patients when they attend hospital to use 
of their data for clinical audit. 
There are some patients recorded by Cancer Registration, however, about whose management we do not have any 
information. The above patient is recorded as being registered with your practice at the time of diagnosis and as still 
alive. 
The Multi-Centre Research Ethics Committee for Scotland has approved this study, subject to obtaining the consent of 
any patients not directly under our care, who are still alive. 
We would therefore ask if voU would first1v check your records to ensure that the diagnosis of lun-q cancer in 2002 
is correct and then, assuming the diagnosis is valid, approach this patient on behalf of the study group, to ask their 
consent to allow you to release this information to us. If the diagnosis appears to be incorrect, please let us know so 
that we can inform the cancer registry and they can amend their records. Any information which you release to us wil 
be handled by audit staff trained in the requirements of data protection and working to approved methods of data 
handling. Whilst the unique identifiers are still present on the file, all data will be kept on the SCAN audit network, with 
full security. The data file prepared for analysis will be anonymised. 
GP Permission to approach pabentVersion3 
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Therefore, assuminq that vour records indicate the diaqnosis of lunq cancer in 2002 to be correct, we would be 
grateful 
If the patient is still alive and you are in agreement, could you kindly forward to the patient the enclosed patient 
information sheet, consent form and envelope. Once the patient's consent has been returned to us, we will 
contact you again with the questionnaire for completion. 
2. If the patient is alive but you do not feel is it appropriate for us to have this information, or the patient is no 
longer looked after by your practice we would be grateful if you could complete and return to us the form 'GP 
reply Version2' 
3. If the patient has died could you kindly complete the enclosed questionnaire titled 'GP questionnaire patient 
Dead' and return it to us. 
4. 
We appreciate that this may involve you in some time and trouble, but we are anxious to ensure as complete as picture 
as possible about the outcomes for patients with this very unfortunate diagnosis. 
If you have any questions or require further information please get in touch with me at the address above. 
Many thanks for your assistance. 
Yours sincerely 
Dr Sara C. Erridge 
on behalf of the SCAN Lung Cancer Group. 
GP Permission to approach patientVersion3 
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'Lung cancer in Lothian, Borders and Fife: have treatment and survival improved since 1995T 
Sara C. Erridgel, l Jamie-Megaw, Ron Fergusson3, Allan Price' 2, Janet lronside2, Felicity Little2, William Walker", Anna Gregor 2.3 
Jillian Campbel 15, Roger Black5on behalf of the South-East Scotland Lung Cancer Network 
'University of Edinburgh, 2Edinburgh Cancer Centre, 3South East Scotland Cancer Network,, 'New Royal Infirmary Edinburgh"5 




I do not feel it is appropriate to approach my patient 
Name 
date of birth for this consent. 
Signature Date 
-/. 
F-I This patient has passed away, date of death 
(please complete enclosed questionnaire) 
Fj This patient is no longer registered at this practice 
New practice is 
F-I Cancer registration diagnosis was incorrect. 
Final diagnosis was 




I have been approached by the South East Scotland Cancer Network for information regarding your lung cancer. I 
cannot release this information to them without your permission. 




Gp I ettertopatien tVe rsi on 1 
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Study -Lung cancer in Lothian, Borders and Fife: have treatment and survival improved since 19957 
Patient Information sheet Versionl. 
We are performing a study to look at the treatment of lung cancer in South East Scotland and how it has changed over 
the last seven years. In 1995, a large Scottish National Audit of Lung cancer was performed and we would like to see 
how the treatment and outlook changed for patients, like yourself, who were diagnosed with lung cancer in 2002. 
According to the Scottish Cancer Registry, you were recorded as being diagnosed with Lung Cancer in 2002. The 
Scottish Cancer Registry is a database run by NHS Scotland, which includes details of all patients diagnosed with 
cancer. It is used to increase our understanding of cancer in Scotland, how it is managed and to plan better services 
for cancer patients. 
We are approaching patients to ask their permission to allow their General Practitioners to release information about 
their medical care to us. We will be asking your doctor about treatment you received. Any information will be handled 
in a confidential manner by specially trained audit staff working for the South East-Scotland Cancer Network. 
If you are happy for your GIP release this information to us, we would be very grateful if you would initial the box and 
sign and date the enclosed consent form and send it back to us in the stamped addressed envelope provided. 
If you or your family would like further information on this study and/or the results we can be contracted at 
SCAN Audit Office 
Edinburgh Cancer Centre 
Western General Hospital 
Edinburgh 
EH42XU Patient Information Verslonl 
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Patient Consent for Release of information (Version2) 
'Lung cancer in Lothian, Borders and Fife: have treatment and survival improved since 1995T 
Sara C. Erridgel 2Jamie MegaW3, Ron Fergusson3, Allan Price' 2, Janet Ironside2, Felicity Little2, William Walker14, Anna Gregor 2,3 
Jillian Campbel 15, Roger Black5on behalf of the South-East Scotland Lung Cancer Network 
'University of Edinburgh, 2Edinburgh Cancer Centre, 3South East Scotland Cancer Network, 'New Royal Infirmary Edinburgh, 5 
Information Services, NHS National Services Scotland 
F7 I have read 'Patient Information sheet Version 1'and I agree that my General Practitioner can release to the SCAN 
Lung Cancer Group information on the care I have received for my lung cancer. 
F-1 I understand that my permission is voluntary and that I am free to withdraw my permission at any time. 
Name Signature Date 
-/ 
(Please initial the boxes and sign and date, and return to us in the enclosed stamped addressed envelope) 
OR 
F-1 I have read the letter 'Patient Information sheet Version 1'and I do NOT agree that my General Practitioner can 
release this information 
Name Signature Date -/ 
(Please initial the boxes and sign and date, and return to us in the enclosed stamped addressed envelope) 
Patient consent Version2 
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Dear Doctor, 
Study -'Lung cancer in Lothian, Borders and Fife: have treatment and survival improved since 1995T 
Re. 
You may remember we wrote to you previously requesting permission to approach your patient for their consent for 
release of information on their lung cancer care to us. They have now given us their consent, a copy of which is 
enclosed. 
We would therefore be very grateful if from your records you could complete the attached questionnaire. 
We appreciate that this may involve you in some time and trouble, but we are anxious to ensure as complete as picture 
as possible about the outcomes for patients with this very unfortunate diagnosis. 
If you have any questions or require further information please get in touch with us at the address above. 
Yours sincerely 
Dr Sara C. Erridge 
on behalf of SCAN Lung Cancer Group 
G pletterwithconsentve rsion 1 
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'Lung cancer in Lothian, Borders and Fife: have treatment and survival 
improved since 1995T 
GP questionnaire patient ALIVE 
Patients Name 
Address 
DOB I I. 
Date cancer diagnosed 
-/ 










Was the cancer 
Localised to the chest 
Metastatic 





f they were not referred why was this? 
Patient dying 
Severe co-morbid disease 
Patient request 
Not felt to be appropriate 





Any other relevant information 
F-1 
R 
Fý if yes where 
F-1 if yes where 






if yes where 
Fj if yes where 





Study -'Lung cancer in Lothian, Borders and Fife: have treatment and survival improved 
since 1995T 
Re. 
We are performing an audit of the management of all patients in Lothian, Borders and Fife diagnosed as having lung 
cancer in 2002. We will then compare this with a previous study performed in 1995. We shall be identifying all patients 
through the national cancer registration system, and have obtained permission from the Caldicott Guardians in the 
relevant NHS institutions to use patient identifiable data from this source for this purpose. 
There are some patients, however, about whose management we do not have any information. The above patient was 
recorded by Cancer Registry as being registered with your practice at the time of diagnosis but according to mortality 
records has subsequently died. 
We would be very grateful if, from your records, you could complete the enclosed questionnaire. 
We appreciate that this may involve you in some time and trouble, but we are anxious to ensure as complete as picture 
as possible about the outcomes for patients with this very unfortunate diagnosis. 
If you have any questions or require further information please get in touch with me at the address above. 
Many thanks. 
Yours sincerely 
Dr Sara C. Erridge 
on behalf of SCAN Lung Cancer Group 
Gpletterpatientdeadversionl 
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Study -'Lung cancer in Lothian, Borders and Fife: have treatment and 




Date cancer diagnosed 
_/ 










Was the cancer 
Localised to the chest 
Metastatic 





If they were not referred why was this? 
Patient dying 
Severe co-morbid disease Fý 
Patient request 7 
Not felt to be appropriate El 
F] 
F7 
F-I if yes where 
El if yes where 
7 if yes where 
Fý 





When did the patient die? 
and what was the cause of death 
Any other relevant information 
F-j if yes where 
F-1 if yes where 




Appendix 3: Combined stage analysis for 2002 and 2004 patients 
The 2002 analysis suggested that there might be a difference in the stage at presentation 
between Fife and the other two health boards, but this was not statistically si ificant 9111 
because of the smaller numbers in each group. Therefore a combined analysis of the 2()(-)2 
and 2004 clatasets \vas performed and is shown in the Table below. 
Distribution of stage for patients with 'Not SCLCI within Lothian and Fife in 2002 
and 2004 
Stage I Stage 11 Stage III Stage IV No detailed 
staging 
Lothian 16.5') o 7.5% 29.4% 35.7% 11.0% 
(n= 1033) 
Fife 10.8, /, /0 6.5,0 23.0% 48.9% 10.8"/o 
(n=833) 
I 
BC 1995 24.0% 26.0% 3 71'), o 13(Vo 
The reasons for the variation in stage at presentation are difficult to deterrmne. The 
proportion of patients undergoing bronchoscopy and pathological confirmation in 2002 was 
higher in Fife than Lotl-ýian, so the problem does not appear to be due to medical nihilism 
within the hospitals, but maybe with initial healthcare access. One study suggested that 
deprived patients with lung, breast or colorectal cancers are more likely to present as an 
emergency [150]. Though Fife has a much more socially deprived population than Lothian 
(see Table 6.2), there was no significant association With stage at presentation and 
deprivation in any of three cohorts in this thesis (Scodand 1995, BC 1995 and SCAN 2(-)(-)? ) 
so it is unlikely that deprivation is the cause of the higher proportion of patients presenting 
-\v, ith metastatic disease in Fife. The impact of social 
deprivation on stage at presentation has 
been extensively studied, with mixed results. In general, the association 
between more 
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advanced stage and social deprivation is weaker in patients with lung cancer, than has been 
obsen, ed in patients with breast and colorectal cancer [173,209]. Bradley et al noted that in 
the USA, patients who were uninsured, hut then enrofled on Medicaid when thev were 
diagnosed with cancer, were three times more likelv to have distant disease than those on 
Medicaid at time of diagnosis [23,241. 
Further prospective research is required to elicit the exact reasons for the observed 
differences in stage at presentation between the neighbouring healthboards in South East 
Scodand. 
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Appendix 4: Exploratory analysis of British Columbia 1995 and South 
East Scotland 2002 
To investigate if the difference observed between Scotland and BC was due in part to inadequate 
staging, of the Scottish patents in 1995, and to ascertain the impact of the increased use of potentially 
curative treatment a further exploratory analysis was performed comparing the BC patients diagnosed 
1995 with the more recent cohort from South East Scotland. 
The patient and tumour characteristics are shown in Table A4.1 Patients in Scotland were older and 
-\N-cre less likely to have patholo ical confirmation. In both cohorts around 90% of patients had their 91 
stage of disease at presentation documented, but there definitely appeared to be a lower proportion 
of patients with localised, and hence the most curable, stage disease in Scotland. There also appeared 
to be more patients With involvement of the mediastinal lymph nodes. 
Table A4. lCompaiison ofpatient and tu-mourcharactezistics 1995BC and 2002 Scotland 
BC 1995 SE Scotland 2002 
Number 2073 971 
Gender Male 1215 (59%) 537 (55%) NS 
Age Median 68 71 P<0.001 
Range 22-96 37-94 (ANOVA) 
Pathology NSCLC 1540(74%) 572 (59%) P<0.001 
SCLC 0 306 (15,,, 0) 141 (14.5', o) 
no pathology 227(11%) 258 (26.5%) 
Locallsed 498(24%) 132(14%) P=0.001 
Regional 538 (26%) 339 (35%) 
-Mctastatic 756(37%) 411 (42%) 
Unknown 281 (14%) 89 (9%) 
Potentially curative 546(26.3%) 229 (23 3.6%) P=0.08 
Palliative 826 (39.8%) 376 (3 8.7/6) 
No treatment 701 (33.8%) 366 (3-, 7 . 70, )) 
Resection 438(21%) 102(11%) P<0.001 
Radiotherapy 836 (40%) 433 (45'), o) P=0.02 
Chemotherapy 368 (18 196 (210", o) NS 
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The sun, vval in SE Scotland (SCAN) remained inferior to that in British Columbia (adjusted HR 
death 0.88 (0.81-0.96), median survival of 7.3 v 5.1months log rank p<0.001). On Cox's regression 
analysis including the variable 'treatment intent' the hazard of death was reduced for patients in BC, 
women, patients aoed under -10 ycars, with loco-re ional disease, and with NSCLC patholop-. 1ý7) 91 
Patients treated -with potentially curative therapy (PCT) also fared less well in SCAN (median not 
reached by 2 years in BC v 22 months SCAN log rank p=0.015). However, in BC in 1995 radical 
radiotherapy constituted only 20% of the PCT delivered, compared with 56"/'(, In Scotland in 2002 
and radical radiotherapy even when combined with chemotherapy is a less effective treatment than 
surgery (figure A4.1). Of the patients with localised disease 56% underwent a resection in BC 
compared with 4W, ",, in Scodand ()(2 p=0.006) When patients in Soutb East Scotland xN-crc treated 
-with the -, ame modality of treatment they do not have inferior survival compared with patients in 
British Columbia (figure A4.1). Based on 40% five-year survival following surgery and 2()", ) following 
radical radiotherapy for locabsed disease (based on actual 1995 BC and Scottish data) if the surgical 
rate in Scotland increased by 16% to 56% of localised cases and radical radiotherapy rate dropped 
from 32", "0 to 16% then the percentage of patients with localised disease alive at five years could 
theoreticaUy increase from 22% to 26%. 
The difference seen in survival for patients treated with palliative treatment (median 6.3 in BC -, - 
5. Omonths SCAN log rank p=0.001) was not associated with an increased adjusted hazard of death 
so the difference in age, pathology and stage were the main contributory factors for fl-i=is group. 
However, for those patients receiving no treatment (med'an 2.6 v 1.5months log rank p<0.001) the 
difference remained (adjusted hazard of death 0.8 (0.7-0.9)). 
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This therefore suggests that the difference in sur-\, l-, --. d seen bevveen the m-o countries appeared to be 
due to 
1) the older age 
2) fe,, Ner patients xvith locallsed disease at presentation 
3) less use of surgery for pa6ents with loc-aliscd disease 
4) inferior survival of untreated patients. 
FifrUre A4.1 Overafl surv4val by treatment modaKty andyear/country of diagnosis Z70 
Overall survival 

















12 18 24 
Appendix 5: Summary of treatment delivered in South East 
Scotland in 2004 
NSCLC N=676 
Surgery onlý_ 
Surgervand chemo 2% 16 
Surgery, chemo and post-op radiotherapy 0.5% 2 
Surgery and post-operative radiothcrapy 1% 7 
Surgery and palliative radiotherapy 1% 4 
Radical radiotherapy 8% 56 
Radical radiotherapy and chemo 7% 48 
Palliative radiotherapy 23 "/, "o 153 
Palliative radiotherapy and chemo 4% 28 
Chemotherapy 11% 75 
None 31% 210 
SCLC N=163 
Surgery only 1% 2 
Surgery and chemo 1 (ý, /o 1 
Chemotherapy 41% 67 
Chemotherapy and adjuvant radiotherapy 20",, 'o 33 
Chemotherapy and palliative radiotherapy 9% 14 
Palliative radiotherapy 6% 10 
None 22% 36 
No pathology N=214 
Radical Radiotherapy 71), 14 
Chemotherapy 1% 2 
Palliative radiotherapy 14'ý"() 30 
None 76% 168 
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Appendix 6: Estimate of resources required for optimal 
treatment of lung cancer 
Based on the lower estimates of the models a rough calculation of the potential costs of initial 
treatment for every 1000 lung cancer patients was performed using NHS costs for 2005 taken from 
the English Department of Health website (Table A6.1). 
Table A6.1 Potential costs of optimal treatmentper 1000patients 
Cost according to 2005 Number Total cost Number Total cost 
NHS charging according based on according based on 
2004 data 2004 data (L) 2002 data 2002 data 
Surgery Complex ý: 6540 118 771,720 119 778,260 
thoracic 
surgery 
Radical RT CHART 37@ (238 72 639,792 78 693,108 
Stage 1-11 +, (801 
33 daily 34@ (l 42 115 564,420 81 397,548 
fractions + 001 
Stage Ill 
Post-op 20 daily 21 @ (142 6 18,372 6 18,372 
fractions +00 1 
ChemoRT 25 twice 26@ L238 60 376,080 53 332,204 
SCLC daily +, C801 
fractions 
HD palliative 13 13@L105 17 24,565 12 17,340 
chest fractions +L80 
Pall RT chest 5 fractions 6@, (105 383 241,290 400 252,000 
or brain 
Pall RT bone 1 fraction 1@ L105 37 3,885 38 3,990 
Chemotherapy 4 cycles 4@ (1072' 3823 1,638,016 3083 1,320,704 
NSCLC (1,310,413)4 (1,056,563) 4 
Chemotherapy 4 cycles 4@ L10722 62 265,856 60 257,280 
L-SCLC (245,917) (234,125) 
Chemotherapy 6 cycles 6@ k10722 753 482,400 63 405,216 
E-SCLC (393,960)4 (330,926)4 
TOTAL 5,026,396 4,476,022 
(4,590,414) (4,114,436) 
1 includes additional visit for planning and C80 for radiotherapy planning CT scan 
2 Dept of Health wcbsite has conflicting costs of either, (1072 per visit for chemotherapy for respiratory malignancy (D98) 
or L403 per visit for chemotherapy for NSCLC (X99LNS) and (141 for SCLC (X99LSC), 
but figure of C1 0-21 per cycle 
seems more appropriate for currently used agents. 
3 over-estimate as <60% of patients actually receive all 4 cycIcs of chemotherapy 
4 revised costs based on 60% 4 cycles, 10", "o 3 cyclcs, 20% 2 cycles 
10% 1 cycle (local audit results) 
5 revised costs based on 10% 1 cycle 10%, 90% 4 cycles (estimate of use in clinical practice) 
6 revised costs based on 10% 1 cycle, 30% 4 cycIcs, 
60% 6 cycles (estimate of use in clinical practice) 
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Table 7.11 Potential costs of d7agnosisand staging oflung cancer 
Estimate of use Total per 1000 Unit cost 
Diagnostic CT scan 90 900 ý160 
Bronchoscopý -011 -00 (1059 
741,300 
CT guided biopsy 20"0 [1121 2()() ; (l 60 
32,000 
PET forall potentially 31-28", 305-278 ; (884 245,752-269,620 
curative patients 
CT brain Sta, )-e III for 12-8') o It-)-81 (160 12,960-18,40() 
potentially curative 
therapy 
TOTAL 1,160,012- 1,189,320 
Other costs which have not been included arc outpatient appointments (around L175 tirst visit and LIUU thcrcattcr), 
imaging to assess response to treatment, costs of any unscheduled in-patients admissions, transport costs and costs to the 
patient. 
However, this does not include any costs of diagnostic and sta ing tests, whýich are outlined in Table 91 
1. NNIen these are included the total cost of diagnosis and initial treatment per 1000 lung patients ZI-) 
diagnosed (who lived >1 day) is between k5.3 and 6.2 n-dlion. 
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